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Abstract
Merkel cell polyomavirus (MCPyV) infection causes near-ubiquitous, asymptomatic infection in the skin,
but occasionally leads to an aggressive skin cancer called Merkel cell carcinoma (MCC). Epidemiological
evidence suggests that poorly controlled MCPyV infection may be a precursor to MCPyV-associated
MCC. Improved understanding of host responses that normally control MCPyV infection could inform
prophylactic measures in at-risk groups. Similarly, elucidating the sensitivities imbued by the presence of
MCPyV in most MCCs could yield targeted solutions for metastatic MCC cases in which therapeutic
options are limited. We performed MCPyV infections in primary human dermal fibroblasts and examined
the interface between virus and host cell via several methods including qPCR, western blotting,
immunofluorescence microscopy, qPCR, and lentiviral CRISPR knockout. We found that MCPyV infection
leads to innate inflammatory cytokine induction in response to late events in the viral infectious cycle.
This innate gene induction was mediated by the cGAS-STING and NF-κB pathways and has the potential
to restrict MCPyV replication. We also screened natural compounds for their activity against the MCPyV
promoter and for specific cytotoxicity in MCPyV-positive MCC cell lines. We determined the mechanism
of action of a lead compound using cell viability assays, a reverse-phase protein array, and western
blotting. This compound induces DNA damage and cell death specifically in MCPyV-positive MCCs.
Combined treatment with BCL-2 inhibition led to more complete killing and expanded the phenotype to a
broad set of MCPyV-positive MCC cell lines. Our findings provide foundational context to the events prior
to MCPyV-driven oncogenesis and to the susceptibility of MCPyV-associated tumors to medical
intervention. The MCPyV infection experiments illustrate the manner in which healthy cellular conditions
might allow low-level infection until highly active replication is restricted by host responses. Conversely,
pathologic conditions could result in unbridled MCPyV replication that licenses MCC tumorigenesis.
Moreover, the profound vulnerability to DNA damage and BCL-2 inhibition shared by MCPyV-positive MCC
cell lines underscores the clinical relevance of MCPyV presence in the future solutions to metastatic
MCC.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Jianxin You

Keywords
DNA damage, Innate immunity, Merkel cell carcinoma, Merkel cell polyomavirus

Subject Categories
Microbiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4614

INTERACTIONS BETWEEN HOST CELLS AND MERKEL CELL
POLYOMAVIRUS IN THE CONTEXT OF INFECTION AND IN
MERKEL CELL CARCINOMA
Nathan A. Krump
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2021

Supervisor of Dissertation

Dissertation Committee

________________________
Jianxin You, PhD
Associate Professor of Microbiology

Elizabeth White, PhD
Assistant Professor of
Otorhinolaryngology:
Head and Neck Surgery
Paul Lieberman, PhD
Wistar Institute
Professor of Microbiology

Graduate Group Chairperson
________________________
Daniel Kessler, PhD
Associate Professor of Cell and Developmental Biology

Susan Weiss, PhD
Professor of Microbiology
Matthew Weitzman, PhD
Professor of Microbiology,
Professor of Pathology and
Laboratory Medicine

INTERACTIONS BETWEEN HOST CELLS AND MERKEL CELL POLYOMAVIRUS IN THE
CONTEXT OF INFECTION AND IN MERKEL CELL CARCINOMA

COPYRIGHT
2021
Nathan Alphonse Krump

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 4.0
License
To view a copy of this license, visit
https://creativecommons.org/licenses/by-nc-sa/4.0/us/

DEDICATION
This work is dedicated to my family. To my wife, Emma, your unwavering support made this work
possible and worth the journey. To my son, Miles, I hope that you continue to take joy in being
curious and never stop learning. I am so proud of you both.

iii

iv

ACKNOWLEDGMENT
Throughout my education and training at the University of Pennsylvania, I have been
surrounded by supportive people who have made me a better scientist and more well-rounded
person. I am forever grateful for their intellectual and emotional contributions to my development
and to the work presented here. I hope that they know value of their contributions and I apologize
in advance for any omissions. I will attempt to highlight the most influential people here.
First, I want to express my deepest gratitude to my thesis mentor, Dr. Jianxin You. With
each of her trainees, she approaches her role as a mentor with the utmost gravity, and I was no
exception. She constantly sought to understand my goals and help me achieve them. When I
faced challenges, she helped orient my efforts toward long-term career fulfillment and personal
well-being. In addition, she exemplifies traits that I aim to embody in my scientific career.
Specifically, she addresses research questions with a rare capacity to adhere to the scientific
method, limit bias, and consider the benefits to patient outcomes. It has been an honor to be the
recipient of her guidance.
I owe a great deal to the members of the You Laboratory. In particular, Drs. Wei Liu and
Ranran Wang were endlessly generous with their time and knowledge. Every aspect of my thesis
work was influenced and improved upon in some way by their support, ideas, or experiments.
Even more so, my life has been enriched personally as a result of their friendship and unique
perspectives. I also want to thank the other You Laboratory trainees, especially Ms. June Yang,
for their ever-present support, intellectual discussion, and camaraderie.
I want to give special thanks to my thesis committee comprised of Drs. Elizabeth White,
Paul Lieberman, Susan Weiss, and Matthew Weitzman. Their guidance and regular input on the
progress of my research were critical to the direction of my thesis. In addition, they were a
valuable resource in my progression as a scientist and in identifying potential avenues for my
future career. Special mention must be made of the chair of my thesis committee, Dr. Elizabeth
White, who was an invested advisor who ensured that I was meeting the requirements set forth
by the graduate program and the goals I set for myself.
v

I want acknowledge all of the individuals that make up the Biomedical Graduate Studies
and Cell and Molecular Biology graduate group for providing a welcoming place to learn. The
administrators, course coordinators, and lecturers created an environment that exposed me to a
vast breadth of foundational information upon which I could expand my subject-area knowledge.
My thanks go out to Dr. Michael Betts, the chair of the Microbiology, Virology, and Parasitology
(MVP) program for the duration of my time at Penn, for his approachable guidance and
coordination of such an engaging scientific community.
The friends that I have made from my peer-group as part of the MVP program have been
a treasured part of my graduate experience. It has been immensely gratifying to have people in
which to confide and with whom I can share both successes and setbacks. I especially want to
acknowledge the scientific and personal support I received from Natasha Lopes-Fischer, Tomaz
Mansoni, Nawar Naseer, Dr. Son Nguyen, Prioty Sarwar and Elisha Segrist.
Lastly, I would like to thank my family: my parents, Anne and Paul, my sisters, Emily and
Heidi, my wife, Emma, and my son, Miles. I am grateful for the years of effort invested in raising
me that allowed me to pursue a career in science. I want to thank them for encouraging me to
follow my interests and fostering a loving environment that supported my curiosity. Any of my past
and future achievements are only possible because of them.

vi

ABSTRACT

INTERACTIONS BETWEEN HOST CELLS AND MERKEL CELL POLYOMAVIRUS IN THE
CONTEXT OF INFECTION AND IN MERKEL CELL CARCINOMA
Nathan A. Krump
Jianxin You
Merkel cell polyomavirus (MCPyV) infection causes near-ubiquitous, asymptomatic
infection in the skin, but occasionally leads to an aggressive skin cancer called Merkel cell
carcinoma (MCC). Epidemiological evidence suggests that poorly controlled MCPyV infection
may be a precursor to MCPyV-associated MCC. Improved understanding of host responses that
normally control MCPyV infection could inform prophylactic measures in at-risk groups. Similarly,
elucidating the sensitivities imbued by the presence of MCPyV in most MCCs could yield targeted
solutions for metastatic MCC cases in which therapeutic options are limited. We performed
MCPyV infections in primary human dermal fibroblasts and examined the interface between virus
and host cell via several methods including qPCR, western blotting, immunofluorescence
microscopy, qPCR, and lentiviral CRISPR knockout. We found that MCPyV infection leads to
innate inflammatory cytokine induction in response to late events in the viral infectious cycle. This
innate gene induction was mediated by the cGAS-STING and NF-κB pathways and has the
potential to restrict MCPyV replication. We also screened natural compounds for their activity
against the MCPyV promoter and for specific cytotoxicity in MCPyV-positive MCC cell lines. We
determined the mechanism of action of a lead compound using cell viability assays, a reversephase protein array, and western blotting. This compound induces DNA damage and cell death
specifically in MCPyV-positive MCCs. Combined treatment with BCL-2 inhibition led to more
complete killing and expanded the phenotype to a broad set of MCPyV-positive MCC cell lines.
Our findings provide foundational context to the events prior to MCPyV-driven oncogenesis and
to the susceptibility of MCPyV-associated tumors to medical intervention. The MCPyV infection
experiments illustrate the manner in which healthy cellular conditions might allow low-level
vii

infection until highly active replication is restricted by host responses. Conversely, pathologic
conditions could result in unbridled MCPyV replication that licenses MCC tumorigenesis.
Moreover, the profound vulnerability to DNA damage and BCL-2 inhibition shared by MCPyVpositive MCC cell lines underscores the clinical relevance of MCPyV presence in the future
solutions to metastatic MCC.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 – Importance of Merkel cell polyomavirus and Merkel cell carcinoma research
Merkel cell polyomavirus (MCPyV) infection can be detected on the skin of most healthy
adults (Schowalter et al., 2010; Tolstov et al., 2009a), yet details of its virology and infectious
cycle remain sparse. Evidence from serological studies suggests that MCPyV infects most people
during early childhood with exposure to the virus increasing as populations age (Chen et al.,
2011; Martel-Jantin et al., 2013; Nicol et al., 2013; Viscidi et al., 2011). A vast majority of MCPyV
infections are asymptomatic (Tolstov et al., 2011), but some result in an aggressive
neuroendocrine skin cancer called Merkel cell carcinoma (MCC) (Feng et al., 2008; Gjoerup and
Chang, 2010; Harms, 2017; Schadendorf et al., 2017). The etiology of over 80% of MCC tumors
can be traced to MCPyV by the presence of integrated MCPyV genomic sequence in the cellular
DNA (Feng et al., 2008; Santos-Juanes et al., 2015).
Though MCC cases are rare, the incidence of MCC has tripled over the last two decades
and is projected to increase further in the future (Fitzgerald et al., 2015; Freeman et al., 2019;
Jacobs et al., 2020; Paulson et al., 2018a; Stang et al., 2018). MCC has a high rate of mortality
with 5-year overall survival around 51% for patients presenting with local disease at the time of
diagnosis, and worse prognoses for those with more advanced stages of disease (Harms et al.,
2016a). Primary MCC malignancies are combatted by aggressive surgical resection, sentinel
lymph node biopsy, and/or adjuvant radiation (Cassler et al., 2016). In metastatic MCC,
chemotherapies have thus far failed to produce durable responses (Cowey et al., 2017; Iyer et al.,
2016). Promisingly, a recent bourgeoning of anti-PD1 and anti-PDL1 treatments for MCC has
yielded prolonged responses in patients with advanced disease, though a significant proportion of
patients do not respond and the durability of responses varies (Becker et al., 2017b; D'Angelo et
al., 2018; Nghiem et al., 2019; Nghiem et al., 2016). The pursuit of more targeted and effective
MCC therapies necessitates a better understanding of the oncogenic underpinnings of MCC and
the role of MCPyV in tumorigenesis.
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Despite the status of MCPyV as a member of the human skin virome and its relevance to
human disease, much is unknown about its biology. For instance, while it is clear that MCPyV
integration and oncogene expression enable MCC cell growth, the conditions that lead to MCPyV
integration are not known. Neither has a consensus been reached regarding the MCC cell of
origin. Most pressingly, ways in which to limit MCPyV infection and thereby prevent MCC onset
have yet to be discovered. In recent years, however, nascent efforts have been aimed at
exploiting the presence of MCPyV oncoproteins to develop targeted therapies for virus-positive
MCC tumors (Chapuis et al., 2014; Gavvovidis et al., 2018; Longino et al., 2019; Sarma et al.,
2020). The potential for expanding on these opportunities to provide prophylactic or therapeutic
interventions for a highly lethal skin cancer should not be overlooked.
1.2 – Merkel cell carcinoma
Merkel cell carcinoma (MCC) was first described in 1972 by Cyril Toker, MD (Toker,
1972). He called the tumors trabecular carcinomas; describing their rod-like organization of tightly
packed cells with low cytoplasmic volume. Importantly, he determined that the tumors arose in
the dermis or lower subcutis layers of the skin and that they metastasized readily via the
lymphatic system. He explained that in the absence of specific markers, the neoplasms were
difficult to distinguish from anaplastic metastases from other body sites. In a subsequent study,
he and a colleague identified neurosecretory granules resembling those seen in neural crestderived cells (Tang and Toker, 1978). Because Merkel cells were the only skin cells known to
contain such granules, they reasoned that these somatosensory cells must originate the
trabecular carcinomas. With mounting evidence that the malignancies shared neuroendocrine
markers with Merkel cells, such as cytokeratin-20 (CK20) and neuron-specific enolase (NSE), the
proposal to coin the disease Merkel cell carcinoma reached a consensus (De Wolff-Peeters et al.,
1980; Gu et al., 1983; Moll et al., 1992).
The next breakthrough in characterizing MCC came in 2008 when the Chang and Moore
group identified a novel polyomavirus genome monoclonally integrated in the DNA of MCC tumor
cells (Feng et al., 2008). Previously, they had correctly predicted the viral etiology of AIDS2

associated Kaposi’s sarcoma (KS) (Chang et al., 1994), hypothesizing that the altered immune
status of these individuals engendered dysbiosis between the host and virus to trigger
oncogenesis. Following the same principle, they suspected viral involvement in MCCs given the
knowledge that MCCs were far more likely to occur in HIV-positive individuals (Engels et al.,
2002). Probing MCC primary tumors and metastases by digital transcriptome subtraction and viral
genome walking revealed the presence and sequence of the MCPyV genome respectively (Feng
et al., 2008).
As a result of their discovery, assays to determine the presence or absence of MCPyV
have provided definitive markers and more assured diagnosis for a subset of MCCs (Buck and
Lowy, 2009; DeCaprio, 2009; Duncavage et al., 2009; Haugg et al., 2014; Starrett et al., 2020).
Moreover, it is now widely acknowledged that immunocompromised individuals are more likely to
develop virus-driven cancers (Chadburn et al., 2013; Ellerbrock et al., 2000; Ponce et al., 2014;
Schadendorf et al., 2017; Weber et al., 2006). The discovery of MCPyV also opened the
opportunity to research the role of MCPyV oncogenes in MCC carcinogenesis and to inform our
understanding of human cancer.
Building upon those earlier discoveries, recent research has been aimed at comparing
MCPyV-positive and MCPyV-negative MCCs, which despite evidently different etiologies, have
similar disease presentation and prognoses (Fischer et al., 2010; Handschel et al., 2010;
Schrama et al., 2011). In virus-associated MCC, MCPyV DNA is integrated into the tumor cell
genome in a manner that preserves expression of MCPyV genes called tumor antigens (Cheng
et al., 2013; Shuda et al., 2008; Shuda et al., 2011). Expression of these viral oncoproteins drives
oncogenesis in virus-positive MCC tumors and is required for the growth of the tumor cells
(Grundhoff and Fischer, 2015; Houben et al., 2012; Houben et al., 2010; Shuda et al., 2014;
Shuda et al., 2011; Spurgeon and Lambert, 2013; Verhaegen et al., 2014a; Wendzicki et al.,
2015). MCPyV T-antigens drive MCC oncogenesis despite otherwise low chromosomal mutation
burdens in MCPyV-positive MCCs (Starrett et al., 2017). By contrast, virus-negative MCCs exhibit
a high, UV-related, mutation frequency indicating that pro-oncogenic mutations arose as a direct
3

result of chronic exposure to UV-radiation (Goh et al., 2016; Harms et al., 2015; Starrett et al.,
2017; Wong et al., 2015). MCPyV-negative MCCs also have higher levels of activation-induced
cytidine deaminase (AID) which could contribute to mutagenesis (Matsushita et al., 2017). The
gradual selection for transforming mutations may lead to shared traits among MCPyV-negative
cancers such as loss-of-function mutations in Rb, NOTCH, PRUNE2, as well as, activating
mutations in PI3KCA and HRAS (Cimino et al., 2014; Goh et al., 2016; Harms et al., 2016b;
Harms et al., 2013; Harms et al., 2015; Nardi et al., 2012; Sahi et al., 2014; Sihto et al., 2011;
Wong et al., 2015).
Disparities between the etiologies of MCPyV-positive and -negative MCCs extend to
differences in their morphology. MCPyV-containing malignances are more likely to have regularlyshaped nuclei, low cytoplasm volume, and more homogeneous cell types than those lacking
MCPyV (Iwasaki et al., 2013; Kuwamoto et al., 2011). They are also more likely to display
classical markers for MCC such as CK20 and neurofilament (Pasternak et al., 2018). Differences
in morphological phenotype between the two MCC types could be a reflection of their alternative
expression profiles in factors such as cell adhesion molecules or miRNAs (Iwasaki et al., 2016;
Xie et al., 2014).
There are also disparities between these two types of cancers that have more
immediately discernible implications. Virus associated MCCs are more likely to occur in non-sunexposed areas than MCPyV-negative MCC (Dabner et al., 2014; Leroux-Kozal et al., 2015) and
on a population scale, virus-negative MCCs occur in greater proportions in Australia, where
people with low-melanin concentrations are exposed to high levels of UV-radiation (Paik et al.,
2011). Moreover, MCC tumors in younger patients and females are more likely to be viruspositive (Wang et al., 2017a). These trends suggest that while UV-exposure and advanced age
increase the incidence risk for both cancer types, MCPyV oncogenesis is less dependent on
these exogenous factors.
Beyond differences in underlying oncogenic mechanism, morphology, and incidence,
there are an increasing number of reports that MCPyV-positive MCC patient prognosis is
4

statistically better than those with MCPyV-negative MCC (Higaki-Mori et al., 2012; Laude et al.,
2010; Leroux-Kozal et al., 2015; Moshiri et al., 2017; Sihto et al., 2009). One reason for the
improved patient survival associated with MCPyV-LT-expressing MCC tumors may be correlated
with the presence of foreign T antigens that enhance immunogenicity (Walsh et al., 2016). In
MCC patients undergoing PD-1 treatment, there is a greater degree of B- and T-cell clonality in
MCPyV-positive tumor infiltrates than MCPyV negative, reflecting the greater diversity of
neoantigens in the latter case (Miller et al., 2018). MCPyV-positive MCCs also exhibit elevated
expression of prokineticin-2, an inflammatory and angiogenic signaling molecule, resulting in
enhanced T cell infiltration (Lauttia et al., 2014). Another reason for better prognoses in MCPyVpositive MCC patient cases could be that low levels of somatic mutation allow expression of wild
type tumor suppressors like p53 to support therapeutic interventions and native immune
responses in restricting cancer progression.
The juxtaposition of these two MCC subtypes informs our understanding of both through
comparative analysis, and can guide the development of novel treatments. In MCPyV-driven
MCC, there exists the promise of truly targeted therapies towards an aggressive solid tumor.
What we learn about viral MCCs can be applied to the more complicated and divergent cases of
MCPyV-negative MCC. These lessons can, in turn, broaden our understanding of other
immunosuppressive, rapidly-metastasizing cancers.
1.3 – MCPyV biology

1.3.1 - MCPyV genome
MCPyV has a ~5.4kb circular dsDNA genome (Fig. 1.1). Like other polyomaviruses,
existing evidence suggests the MCPyV genome remains episomal throughout the infectious cycle
(Gjoerup and Chang, 2010; Liu et al., 2016b). The viral genome is divided into early and late
regions by a non-coding control region (NCCR) containing the viral origin of replication and
bidirectional promoters that drive early and late gene transcription (Harrison et al., 2011b). The
early region expresses alternatively spliced tumor antigens, termed large tumor antigen (LT) and
5

small tumor antigen (sT) that support replication, as well as, 57kT and an alternate LT open
reading frame (ALTO) with functions that are less defined (Carter et al., 2013; Kwun et al.,
2009a). Major and minor capsid proteins, VP1 and VP2 respectively, are expressed from the
MCPyV late region along with a miRNA that has been proposed to modulate early gene
expression (Schowalter et al., 2011; Seo et al., 2009).
There is some sequencing evidence of genotypic variants of the MCPyV genome
diverging across geographic boundaries and tracking with human migration (Hashida et al., 2018;
Martel-Jantin et al., 2014; Matsushita et al., 2014; Torres et al., 2018). The specific impact these
genetic variations may have on the course of disease is unclear.
In MCPyV-positive MCC, the MCPyV genome is integrated into the host DNA such that
the functions of its early promoter and partial expression of its T antigens are preserved (Feng et
al., 2008). Point mutations in other regions of the genome and truncations of the MCPyV LT Cterminal domain, however, are common in viral MCCs (Liu et al., 2016a). Expression of the viral
oncoproteins is largely driven by the preserved MCPyV promoter rather than endogenous
promoters, though there are conflicting reports as to whether MCPyV is more likely to integrate in
specific regions of chromatin (Czech-Sioli et al., 2020; Doolittle-Hall et al., 2015). Sequencing of
integration sites in multiple MCC tumors reveal that initial recombination of a linearized MCPyV
genome with the host genome could lead to transient circularization and amplification of the viral
genome and neighboring host DNA (Starrett et al., 2017). The amount of amplification and the
site of DNA repair accounts for differences in viral genome copy number and duplications of host
sequences.

1.3.2 - Large Tumor Antigen (LT)
In MCPyV infected cells, LT localizes to the nucleus where it performed functions directly
and indirectly supporting MCPyV replication (Nakamura et al., 2010). Like T antigens in other
polyomaviruses, LT contains an origin binding domain (OBD) and an ATP-dependent helicase
domain by which it unwinds MCPyV DNA for replication (Harrison et al., 2011b). LT localizes to
replication foci containing high concentrations of nascently synthesized MCPyV genomes (Liu et
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al., 2016b). In replication foci, LT binds to G(A/G)GGC-like pentanucleotide sequences on the
MCPyV genome sequence to initiate efficient replication in a manner that requires the LT DnaJ
domain and is supported by the presence of sT (Harrison et al., 2011b; Kwun et al., 2009a).
Somatic genes also localize to MCPyV replication foci and support LT-mediated
replication. Bromodomain protein-4 (BRD4) associates with LT in replication centers where it
amplifies MCPyV replication by recruiting replication factor C (RFC) (Wang et al., 2012). Ataxia
telangiectasia mutated (ATM) and Rad3-realted (ATR) DDR factors also co-localize to MCPyV
replication centers in a manner dependent on the presence of LT and the MCPyV origin (Tsang et
al., 2014). These DDR proteins support efficient viral genomic DNA synthesis, but may also be
essential in limiting the transforming potential of MCPyV T antigens. For example, ATM
phosphorylates LT in the C-terminal domain at Ser-816, leading to increased apoptosis (Li et al.,
2015). Alanine mutagenesis at this site leads to enhanced colony formation in C33A cells. This
LT-ATM interaction could both promote MCPyV replication and limit rampant cellular growth. The
delicate balance of establishing an S-phase-like environment for the production of new virions
without causing the terminal fate of cellular transformation can explain the duality of MCPyV
traits.
The necessity of MCPyV to avoid terminating its infectious cycle by transforming its host
cell is underscored by the fact that unlike other polyomavirus T antigens, LT neither binds nor
inhibits p53 (Cheng et al., 2013; Lilyestrom et al., 2006). In fact, our group found that the helicase
activity in full-length LT, in the context of MCPyV DNA synthesis, induces cell cycle arrest in a
p53-dependent manner that activates cell cycle arrest and limits cellular proliferation (Li et al.,
2013). This observation provided an evolutionary explanation as to why MCPyV may have lost
the ability to inactivate p53, in that allowing p53 to guard cell cycle progression could limit
incidental progression to cancer and abortive MCPyV infection. It also suggests why mature
MCCs invariably express a truncated variant of LT (LTT) lacking the C-terminal domain. In
support of the protective nature of the LT C-terminal domain, expression of LTT, but not fulllength LT, sensitizes cells to UV-DNA damage due to impaired cell cycle arrest and DNA damage
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responses (DDR) (Demetriou et al., 2012). Moreover, expression of LTT promotes cell growth,
while expression of the C-terminal domain alone, or full-length LT, negatively regulates cell
growth (Cheng et al., 2013).
The ability of MCPyV LTT to promote cellular proliferation has been attributed to its ability
to bind and inactivate Rb through an LXCXE domain similar to other polyomaviruses (Houben et
al., 2012). This region is present in both wild-type LT and LTT. The LT-Rb interaction results in
enhanced E2F-transcriptional activity; promoting growth in MCPyV-positive MCC cells
(Hesbacher et al., 2016; Schrama et al., 2016; Sihto et al., 2011). The impact of LT-Rb binding
was further illustrated by the fact that silencing LTT expression in a xenograft MCC mouse model
resulted in tumor regression in an Rb-binding dependent manner (Houben et al., 2012). The
LXCXE-Rb interaction also enhances entry into S-phase, cellular proliferation, and motility in
hTERT immortalized BJ human foreskin fibroblasts (BJ-hTERT) (Richards et al., 2015). The
functional significance of MCPyV LTT inactivation of Rb in human populations is supported by the
finding that MCPyV-negative MCCs frequently contain mutations in the Rb gene, whereas
MCPyV-positive tumors usually express wildtype Rb (Sihto et al., 2011).
LT-Rb binding domain could also be responsible for increasing Sox2 and subsequent
Atoh expression in MCPyV-positive MCC cells (Harold et al., 2019). This is significant because
the activity of these transcription factors can confer cells with markers of the shared phenotype
between Merkel cells and MCCs both in vitro and in vivo (Verhaegen et al., 2017). Though sT has
garnered more attention regarding cellular transformation, it may be that LT alters the
transcriptional landscape of the original cell of MCC to imbue it with its morphological
characteristics.
Recently, it has been shown that the Rb inhibitory domain of LT could indirectly activate
p53 by upregulating an inhibitor of the p53-degrading E3 ubiquitin ligase MDM2 (Park et al.,
2019). This assertion suggests that even without the helicase domain, LTT would activate p53 in
MCC cells, but the investigators propose that the sT-MYC-EP400 transcriptional complex
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counteracts p53 activity through upregulation of MDM2 and the related enzyme MDM4 (Park et
al., 2019).

1.3.3 - Small Tumor Antigen (sT)
MCPyV sT consists of 186 amino acids, including a C-terminus that is spliced out of the
other MCPyV T antigens that confers it with entirely unique functions. MCPyV sT localizes to the
nucleus and is able to support LT-mediated replication though the exact mechanism remains
unclear (Kwun et al., 2009a). The functions carried out by the C-terminal domain unique to
MCPyV sT is of critical importance because its expression is necessary for MCC survival and
appears to be the primary driver of cellular transformation (Shuda et al., 2011).
MCPyV sT expression is capable of transforming rat fibroblasts and epithelial cells in an
in vivo mouse model via a region incorporating amino acids 91-95 termed the LT stabilization
domain (LSD) (Kwun et al., 2015; Shuda et al., 2011; Verhaegen et al., 2015). As its name
implies, MCPyV sT containing wild-type LSD increases LT protein level, though the underlying
mechanism is an area of active investigation (Dye et al., 2019; Kwun et al., 2013). MCPyV sT
drives cellular transformation in rat fibroblasts by promoting hyperphosphorylation of eukaryotic
translation-initiation factor 4E-binding protein (4E-BP1) (Shuda et al., 2011; Velasquez et al.,
2016; Wu et al., 2015). The LSD domain was also linked to activation of the non-canonical NF-κB
pathway, induction of a senescence associated secretory phenotype (SASP), and enhanced
MCC cell proliferation (Zhao et al., 2020). Besides those functions attributed to the LSD domain,
numerous other oncogenic functions have been ascribed to MCPyV sT.
MCPyV sT expression may promote cellular growth by activating c-Jun downstream of
MEK/ERK factors(Wu et al., 2016). In addition, MCPyV sT expression in normal fibroblasts
elevates aerobic glycolysis via modulation of the host cell transcriptome, including upregulation of
monocarboxylate lactate transporter SLC16A1 (MCT1), likely contributing to oncogenic potential
(Berrios et al., 2016). Still another way in which sT could enhance metastatic potential is through
disruption of inter-cellular junctions via upregulation of A-disintegrase-and-metalloproteinase
(ADAM) 10 and 17, which are more highly expressed in MCPyV-positive MCCs (Nwogu et al.,
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2018). The manner in which MCPyV sT might be affecting transcriptional changes described
above is by recruiting a MYCL-MAX heterodimer to the EP400 complex (Cheng et al., 2017). This
interaction was elegantly shown to promote cell viability in MCPyV-positive cell lines, MKL-1 and
WaGa, as well as, confer a transforming phenotype in keratinocytes (Cheng et al., 2017). Two
genes that are upregulated by this transcriptional program are MDM2, which promotes p53
proteasomal degradation, and lysine-specific histone demethylase 1A (LSD1), which is necessary
for maintaining plasticity and proliferative capacity of MCC cells (Leiendecker et al., 2020; Park et
al., 2020).
MCPyV sT contains protein phosphatase 2A (PP2A) binding sites similar to other
polyomaviruses, but this binding activity is not required for transformation of rat fibroblasts (Kwun
et al., 2015). It may be that these PP2A binding sites are involved in the interaction with protein
phosphatase 4C (PP4C) (Griffiths et al., 2013; Kwun et al., 2015). In conflict with findings
mentioned earlier, one group found that sT targets NEMO through interaction with its regulatory
subunit (PP4R1) to disrupt NF-κB mediated inflammatory signaling (Abdul-Sada et al., 2017;
Griffiths et al., 2013). The sT-PP4C interaction has also been implicated in lowering microtubule
stability through altered expression of cellular proteins like stathmin, as well as, Rho GTPasemediated actin remodeling, leading to an enhanced cell motility phenotype (Knight et al., 2015;
Stakaityte et al., 2018). These broad changes resulting from the sT-PP4C interaction have been
recently ascribed to upregulated p38 MAPK signaling via MKK4 (Dobson et al., 2020). MCPyV sT
related motility may confer transformed cells with invasive and metastatic properties.
Our group found that the proposed PP2A binding sites may also serve as iron-sulfur
(Fe/S) cluster domains (Tsang et al., 2015). This discovery had significance because proteins
containing Fe/S domains often modulate helicase activity (Pugh et al., 2008; Wu and Brosh,
2012). The ability of MCPyV sT to bind Fe/S clusters was linked with its localization to LT
containing replication foci and enhanced MCPyV DNA synthesis without increased LT protein
stability. Moreover, MCPyV sT was able to sequester Fe/S much more efficiently than sT proteins
from SV40, HPyV6, and HPyV7. Another group recently found that expression of MCPyV sT in
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HEK 293 cells elevated several markers of DNA damage, and at a higher rate than HPyV6 and
HPyV7 sT proteins (Wu et al., 2019). Given these findings, the supportive role of sT in LTmediated MCPyV replication could be direct, through sT activity in replication centers, or indirect,
through activation of ATM and subsequent phosphorylation of LT Ser816.

1.3.4 - 57kT and ALTO
A third alternatively spliced T antigen is that of 57kT. 57kT does not appear to support
MCPyV replication, and its specific function in infection or in MCC oncogenesis is unclear (Kwun
et al., 2009a). Because it shares the MCPyV unique region (MUR) with LT, but lacks the helicase
and origin-binding domains, it can be hypothesized that 57kT indirectly supports MCPyV
infection, but does not directly support replication as LT does. Similar to LTT, 57kT could bolster
pro-oncogenic functions associated with Rb-binding without helicase-related cell cycle arrest or
DNA damage.
Carter and colleagues discovered an overprinting gene product expressed from the early
region that they termed alternate Large T open reading frame (ALTO) (Carter et al., 2013) (Fig
1.1). This transcript utilizes a start codon that is +1 nucleotide frame-shifted relative to the second
exon of LT. The authors of this study hypothesize that overprinting genes such as these evolve in
viruses as a strategy to maximize the coding potential of relatively small genomes (Carter et al.,
2013). As of the writing of this dissertation, no molecular functions have been attributed to ALTO.

1.3.5 - VP1, VP2, and miR-M1
The MCPyV late promoter drives expression of the capsid proteins VP1 and VP2, as well
as, a miRNA, MCPyV miR-M1 (Fig 1.1). VP1 and VP2 encapsidate MCPyV DNA during
packaging and mediate cell surface interactions that activate entry and trafficking (Neu et al.,
2012; Schowalter and Buck, 2013; Schowalter et al., 2011). Attachment to cell surfaces is
mediated through interactions between VP1 capsomeres and sulphated polysaccharides while
subsequent viral entry requires the interaction between VP1 and sialic acid (Bayer et al., 2020;
Neu et al., 2012). In A549 cells, MCPyV entry was mediated through caveolar/lipid raft
11

endocytosis (Becker et al., 2019). Subsequent MCPyV trafficking is carried out by the endosomalto-ER pathway requiring microtubule transport activity (Becker et al., 2019). By comparison, VP2
mediates post-attachment phases of MCPyV entry and is necessary for native MCPyV infection, if
not the formation of pseudo-virus particles (Schowalter and Buck, 2013).
By comparison, another late region gene product MCPyV miR-M1 likely regulates
MCPyV early gene expression. Highly expressed miR-M1 transcripts in MCPyV-transfected
neuroectodermal tumor (PFSK-1) cells down-regulated the expression of MCPyV T antigens and
MCPyV replication (Theiss et al., 2015). The function of miRNA-M1 to restrain MCPyV replication
and gene expression enabled a low level of detectable MCPyV to persist in cells for several
months. Thus, the MCPyV miRNA could drive a persistence mechanism by which MCPyV
maintains a limited infection in human hosts for prolonged periods. One group found that
expression of a synthetic MCPyV-miR-M1 in HEK293 or MCC cells targets the cellular host gene
SP100 thereby lowering CXCL8 expression and neutrophil chemotaxis (Akhbari et al., 2018). In
principle, this anti-inflammatory effect could be protective in the setting of MCPyV infection.
Unlike analogous miRNAs in animal polyomavirus tumors, however, the MCPyV miRNA is not
highly expressed in MCC tumors, suggesting that the function for which it is selected in MCPyV
infection does not, in turn, promote tumor fitness (Chen et al., 2015).
1.4 – MCPyV tropism and a model of infection
Epidemiological evidence suggests that MCPyV establishes asymptomatic, persistent
infections in most people. As many as 88% of healthy adults are positive for MCPyV-specific
antibodies (Kean et al., 2009; Pastrana et al., 2009; Tolstov et al., 2009b; Touze et al., 2011).
Serological activity against the MCPyV major capsid protein increases as populations age, from
about 10% in early childhood to about 80% in adults (Chen et al., 2011; Tolstov et al., 2011;
Viscidi et al., 2011). MCPyV-specific antibody titers positively correlate with viral load as
measured by MCPyV DNA encapsidated in viral particles shed from healthy skin, suggesting that
MCPyV positivity rates could also increase as populations age (Pastrana et al., 2012; Schowalter
et al., 2010).
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Within a given healthy individual, MCPyV antibody titers remain relatively stable over a
period of at least 15 months (Pastrana et al., 2012). By comparison, neutralizing antibody titers to
MCPyV, but not other human polyomaviruses, are significantly higher in patients with MCPyVpositive MCC despite the fact that MCC tumors do not express capsid protein (Pastrana et al.,
2009). Together, these findings suggest that MCPyV has the capacity to persist, and that MCPyV
expansion within a host correlates with disease propensity. Inadequate restriction of MCPyV may
be a critical factor in enabling MCC development. This hypothesis is supported by the fact that
chronic UV-exposure, advanced age, and HIV-related or iatrogenic immunosuppression pose
significant risk for MCC (Bertrand et al., 2013; Heath et al., 2008b; Ma and Brewer, 2014).
Direct evidence of the natural host reservoir cells that maintain latent MCPyV infection
also remains elusive. Excitingly, our group found that primary dermal fibroblasts support
productive MCPyV infection in vitro and ex vivo (Liu et al., 2016b). In the development of the in
vitro model, we found that the addition of modulatory factors present in the skin could greatly
enhance MCPyV proliferation. Specifically, MCPyV replication is boosted by priming human
dermal fibroblasts with epidermal and fibroblast growth factors and a WNT activator which induce
fibroblast proliferation and matrix metalloproteinase (MMP) expression (Liu et al., 2016b). That
these same conditions are found in the skin wounding response suggests that the MCPyV
infection cycle could be linked to damage to the skin by way of abrasions or UV-damage (Fig.
1.2).
The picture of MCPyV infection is far from complete, yet inferences can be made from
distinct sources of evidence. In ex vivo skin culture, MCPyV preferentially infects dermal
fibroblasts underlying the basal layer of the epidermis and those surrounding hair follicles (Liu et
al., 2016b). Furthermore, MCPyV virions are readily detected in eyebrow hair bulbs sampled from
healthy human volunteers (Bellaud et al., 2015; Hampras et al., 2015; Peretti et al., 2014). It is
possible that MCPyV infects the dermal cells surrounding the hair follicle and subsequently uses
the follicular space as a means to disseminate to the skin surface and access new hosts (Figure
1.2).
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MCPyV may also infect cells at body sites other than the skin to establish a reservoir
(Salakova et al., 2016). For instance, MCPyV DNA was detected in buffy coats of healthy blood
donors and inflammatory monocytes of MCC patients, indicating that the virus may establish
latent infection in peripheral blood leukocytes (Mertz et al., 2010; Pancaldi et al., 2011). In two
MCPyV-positive patients with prior history of MCC and active non-melanoma/non-MCC skin
cancers respectively, MCPyV DNA was detected in inflammatory, but not resident monocytes
(Mertz et al., 2010). Presence of MCPyV in inflammatory monocytes in patients with distinct
medical histories suggests that the virus may persist and spread in these cells throughout the
body (Mertz et al., 2010).
There is no animal model for MCPyV infection; a goal which has proven to be challenging
due to the narrow host range of the virus (Liu et al., 2018a). Lack of an animal model for MCPyV
infection presents a major obstacle for identifying potential reservoirs and elucidating the MCPyV
infectious cycle. Generation of MCPyV chimeras with mammalian polyomaviruses may provide a
solution to overcome its narrow host range in the future (Liu et al., 2018a).
1.5 – MCC cell of origin
Though named for similarities to Merkel cells, the true original cell of MCC is rigorously
debated. The proposition that MCC arises from differentiated Merkel cells is in question because
these cells are post-mitotic, and thereby have limited oncogenic potential, and because they arise
in the epidermis, while MCCs almost always occur in the dermis or subcutis layers (Toker, 1972).
In response, it has been suggested that MCCs could arise from Merkle cell progenitor cells
present at the hair follicle (Narisawa et al., 2019; Sauer et al., 2017b; Zur Hausen et al., 2013).
Similarly, progenitor cells derived from the neural crest have been pointed to since MCPyV
positive MCC cell lines cocultured with keratinocytes undergo neuronal morphological
differentiation in a manner dependent on MCPyV LT upregulation of Sox2 and Atoh1 (Harold et
al., 2019).
Some also propose that MCC could have an epithelial origin since on rare occasions,
epithelial MCCs have been reported (Narisawa et al., 2020; Navarrete-Dechent et al., 2020; Song
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et al., 2020). One group advocating for an epithelial origin of MCC points to a case of a combined
MCC and trichoblastoma tumor that shared somatic mutations(Kervarrec et al., 2019). They
submit that this mixed tumor could represent a transition from early to late MCC carcinogenesis in
cells with integrated MCPyV genome begin to predominate. The same group also found that
expressing MCPyV sT and GLI1 in keratinocytes results in an MCC-like phenotype, including
expression of CK20 (Kervarrec et al., 2020). Another group has developed a mouse model for
MCC, by expressing MCPyV sT and Atoh in keratinocytes, that results in the epidermal layer
developing several MCC markers and characteristics (Verhaegen et al., 2017).
It has also been argued that pre/pro B-cells are the source of MCC because MCC cells
consistently express a number of B-lymphoid lineage markers, like Pax5 and TdT (Sauer et al.,
2017b; Zur Hausen et al., 2013). Cell expression similarities may be coincidental however, since
it has also been proposed that epigenetic changes in the cell of origin could lead to a dramatic
transcriptional and phenotypic changes culminating in Merkel cell resemblance. It has even been
proposed that MCPyV-positive and negative carcinomas have distinct cells of origin, and that
through epigenetic reprogramming they converge on a common phenotype (Sunshine et al.,
2018). Under normal developmental conditions, loss of polycomb repressive complex 2 (PRC2)
and subsequent reduction H3K27me3 marks enables the differentiation of Merkel cells in mice
(Bardot et al., 2013; Perdigoto et al., 2016). Given this information, one group reasoned that the
development of MCC may involve a similar change in the epigenome of the unknown cell of
origin. They found that pure MCPyV-positive MCCs were more likely to have low H3K27me3 than
MCPyV-negative tumors (Busam et al., 2017). Other researchers, however found contradicting
evidence that virus-negative MCCs, especially those with combined squamous cell carcinomas,
had lower H3K27me3 marks than MCPyV-positive MCCs (Matsushita et al., 2019).
1.6 – Immune responses to MCC
Immune function is relevant to every aspect of MCC progression. Incidence of MCC is
greatly increased in immunocompromised individuals, especially in those who are HIV-positive or
recipients of organ transplants (Cook et al., 2019; Koljonen et al., 2009; Ma and Brewer, 2014).
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Loss of adaptive immune competence increases the risk of both MCPyV-positive and negative
tumors, implying that immune surveillance of nascently transformed MCC cells is protective at
early stages of the disease. There is also evidence that adequate immune responses can lessen
the severity of MCC disease progression. For example, patients with chronic inflammatory
disease had higher rates of MCC incidence, and the tumors of those that developed MCC had
higher expression of the proliferative marker Ki-67, and a greater tumor size (Sahi et al., 2017).
Furthermore, systemic immune suppression has been linked to greater incidence of MCC, as well
as, lower rates of survival in MCC patients (Paulson et al., 2013). These epidemiological data
suggest that immune restriction of MCC is critical to patient outcomes at each stage of the
disease.
Studies of the immunological interface in MCC tumors have revealed further detail
regarding the course of disease and the ability of MCC to evade destruction. For example,
circulating MCPyV T antigen-specific antibody level positively correlates with MCPyV-positive
MCC recurrence and has prognostic value (Paulson et al., 2017a; Samimi et al., 2016). In MCC
tumors, CD8 T cell and other immune cell infiltration is usually poor, and those cases with better
infiltration positively correlate with patient outcomes (Miller et al., 2017; Wheat et al., 2014)
(Feldmeyer et al., 2016; Lipson et al., 2013; Sihto et al., 2012). Moreover, the MCPyV-specific Tcells present in MCC tumors expressed markers of exhaustion like PD-1 and Tim-3 (Afanasiev et
al., 2013). The same phenomenon could be found in vitro and in a MCC xenograft mouse-model
(Dowlatshahi et al., 2013). Histopathology of MCC tumors indicate that immune cells expressing
exhaustion markers like PD-1 and CD33 congregate in the areas surrounding the tumors,
suggesting that MCC acquires traits that suppress immune cell migration (Mitteldorf et al., 2017).
Observations that tumor-experienced T cells were unable to infiltrate MCC tumors led to
recent efforts to introduce immune checkpoint therapies in metastatic cases. A 2015 case study
showed a promising response in a patient with metastatic MCC case treated with anti-PD1
antibodies (Mantripragada and Birnbaum, 2015). In the years that followed, clinical trials exploring
safety and efficacy of anti-PD1 and anti-PDL-1 infusions yielded significant response rates and
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relatively low rates of adverse events given the severity of patient prognosis (Kaufman et al.,
2016; Nghiem et al., 2019; Nghiem et al., 2016). While the durability of responses varied, they
could extend to well over a year (Kaufman et al., 2018; Nghiem et al., 2019).
Given that there are no effective chemotherapeutic treatments available for metastatic
MCC, the introduction of immune checkpoint inhibitors greatly benefitted patients (Colunga et al.,
2017; Paulson et al., 2017b). Still, a significant portion of patients do not respond or have
responses that are short-lived. Moreover, patients with immunosuppression or autoimmune
disease may not be eligible for immune-based therapy. It also became clear that loss of durability
or relapse is a problem in long term treatment for MCC, even in MCPyV-positive MCC cases
where mutagenesis is low. A longitudinal study revealed that HLA-I components were
downregulated in resistant tumor cells at the level of transcription as a result of continued
interaction with CD8 T cells (Paulson et al., 2018b). These shortcomings necessitate the
development of alternative strategies or combination of existing therapies to modulate immunity
to MCC.
One such strategy is to augment innate immunity at the primary tumor site in order to
enhance adaptive function systemically. One group was able to achieve improved responses at
distal MCC metastases by injecting a TLR-4 agonist intratumorally at the primary MCC site
followed by standard-of-care surgery and irradiation (Bhatia et al., 2019). They later delivered IL12 plasmids to MCC tumors via electroporation that led to enhanced immunogenicity at primary
and distal tumors in all patients tested; 25% of which had responses in the progression of their
disease (Bhatia et al., 2020). Still other means of activating intralesional innate inflammation
have proven effective. Administration of an oncolytic herpesvirus that stimulates granulocytemacrophage colony-stimulating factor has led to durable complete responses in multiple patients
(Nguyen et al., 2019; Westbrook et al., 2019). A recent case study involving an advanced-stage
MCC patient resulted in complete remission upon receiving a combination of radiation therapy
and anti-PD1 therapy (Bloom et al., 2019). This suggests that targeted DNA damage at
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accessible lesions combined with activation of immunity against a primary tumor could help train
immune responses against distant lesions.
In pursuit of understanding the cause of immune repression characterizing the MCC
tumor microenvironment, our group discovered that STING is dramatically silenced in MCC cell
lines and tumor cells (Liu et al., 2020a). We showed that rescuing STING expression and
activation in MCC cells led to greatly induced cytokine expression, T cell migration, and MCC cell
death. Delivery of a mutant STING vector via AAV transduction and subsequent activation with a
selective agonist could achieve the same results. Such a strategy has the potential to be highly
specific in humans without the danger of systemic inflammatory pathology because the mutantspecific STING agonist does not interact with native human STING.
Targeting distal MCC metastases is also the aim of researchers activating or genetically
engineering immune cells for autologous infusion. For example, one group showed that activation
and administration of genetically engineered T cells expressing TCRs specific to naturally
processed MCPyV T epitopes led to tumor regression in mouse MCC xenografts (Gavvovidis et
al., 2018). In one human case study, a similar infusion procedure using MCPyV T antigen-specific
T cells that were expanded ex vivo resulted in HLA upregulation, T cell recruitment, and
responses in most metastases (Chapuis et al., 2014). A recent study developed a means of
improving autologous CD8 T cell therapeutic vaccines for MCC by exposing those T cells to
cytokine-conditioned dendritic cells presenting LTT peptides on both MHC-I and II surface
receptors (Gerer et al., 2017). MCPyV-positive tumor microenvironments can also be engaged by
engineered CD4 T cells that recognize the LXCXE epitope of LTT (Longino et al., 2019).
1.7 – Immune responses to MCPyV

Given that the risk factors for developing MCC, including advanced age, UV exposure, and
compromised adaptive immunity, can each alter the immune environment in the skin, it is
possible that unmitigated proliferation of MCPyV encourages oncogenesis (Stang et al., 2018).
The possibility that uncontrolled MCPyV activity leads to MCC cases agrees with the ability of
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Chang and Moore to predict the viral etiology of MCC due to its greater incidence in immune
compromised persons (Feng et al., 2008). The transition from low-level MCPyV persistence to
rampant proliferation could promote carcinogenesis by increasing the frequency of integration
events or entry into the original host cell of MCC. Because nascently transformed cells are also
favored by loss of normal immunity, it would be easy to conflate these two factors. Interestingly
though, there is increasing evidence that alterations to systemic and skin immunity can
exacerbate MCPyV infections.
A study in Japan found that MCPyV DNA prevalence and viral load on sun-exposed skin
increased sharply in individuals over the age of 40 and remained high for the oldest groups
(Hashida et al., 2016a). Also, HIV-positive men more frequently have detectable MCPyV DNA on
their skin and in their sera, and those with poorly-controlled HIV infection have higher MCPyV
antibody titers and DNA loads than those with better-controlled infections (Fukumoto et al., 2013;
Vahabpour et al., 2017; Wieland et al., 2011). In kidney transplant recipients, MCPyV DNA was
more readily detected in the urine of those with BKPyV-DNAemia and with histologically verified
polyomavirus associated nephropathy (Signorini et al., 2014; Wang et al., 2019). MCPyV DNA
detection rates and loads were significantly lower in patients with psoriasis compared to the skin
of healthy volunteers suggesting a potential inverse relationship between chronic inflammation in
the skin and MCPyV proliferation (Hashida et al., 2019). MCPyV-positive MCC patients, however,
have higher MCPyV DNA loads shed from their skin and more frequently produce MCPyV VP1specific circulating antibodies and at higher titers (Faust et al., 2011; Hashida et al., 2016b;
Pastrana et al., 2009; Pastrana et al., 2012; Touze et al., 2011). More recently, it was found that
higher MCPyV DNA load correlates with worse survival outcomes in MCC patients (von der Grun
et al., 2019).
These findings suggest that sudden loss of normal immune functions could swing the
balance between host and virus to favor uncontrolled MCPyV proliferation (Fig. 1.3). From the
perspective of the virus, however, MCPyV must have evolved mechanisms of its own to evade
host immunity since it can persist and remain highly prevalent in the general population
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asymptomatically (Foulongne et al., 2012; Schowalter et al., 2010; Tolstov et al., 2009b). The
mechanisms by which MCPyV evades immune detection and/or destruction are not known.
Some examples of MCPyV gene products or transfected MCPyV genomes interacting
with cellular immunity have been documented. For instance, LT expression reduces TLR-9
expression via downregulation of C/EBP transcription factors in epithelial and MCC cell lines
(Shahzad et al., 2013). This observation agrees with in vivo data revealing that TLR-9 expression
was significantly lower in MCPyV-positive MCC tumors compared to MCPyV-negative tumors
(Jouhi et al., 2015). MCPyV sT expression was shown to inhibit NF-κB inflammatory signaling
through its interaction with PP4C and the adapter NEMO (Abdul-Sada et al., 2017; Griffiths et al.,
2013).
There are also examples of cells eliciting an immune response to the expression of
MCPyV genes and genomes. As mentioned previously, MCPyV LT and sT expression in BJhTERT cells led to upregulation of cellular growth and expression of genes that increase motility
(Richards et al., 2015). Accompanying this phenotype was the dramatic induction of many
inflammatory response genes including ISGs like OAS1 and ISG20; cytokines like IL-1β and IL-6;
and chemokines like CXCL1 and CXCL6 (Richards et al., 2015). Whether MCPyV T antigens
induce such a response in the context of infection remains undetermined.
Depletion of the nuclear protein SP100 enhances MCPyV replication in H1299 cells
(Neumann et al., 2016). This is especially interesting given the finding that a MCPyV-miR-M1
mimic specifically targeted SP100 for degradation (Akhbari et al., 2018). In 293 and MCC cells,
this downregulation of SP100 reduced the secretion of CXCL8 in MCC cells treated with TNF-α
(Akhbari et al., 2018).
Despite the recent progress made in examining how MCPyV interfaces with the host
immune system, all of the studies were performed using transfection or transduction of MCPyV
genes into established cancer cell lines. In order to understand how these mechanisms may
contribute to MCPyV persistence, it will be important to study them in the context of MCPyV
natural infection, and eventually in animal models with dynamic innate and adaptive immune
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responses. In Chapter 2, I discuss our discovery that MCPyV infection elicits an antiviral innate
immune response mediated by the cGAS-STING and NF-κB pathways.
1.8 – Developing targeted therapies for treating MCC
Existing chemotherapies approved for MCC treatment have failed to demonstrate durable
responses in MCC (Nghiem et al., 2017). The toxicity of such systemic treatments is also a
concern, especially when targeting critical cellular proliferation and survival pathways. Novel
chemotherapeutics must be highly specific in order to be an effective alternative to immune
checkpoint therapies and avoid deleterious effects.
That most MCPyV-positive MCCs have a low somatic mutational burden is an aspect of
their biology that could potentially be exploited chemotherapeutically, since the wild-type
functions of their cell death and tumor suppressor pathways remain intact. For example,
investigators found that targeting a specific isoform of PI3K, rather than a broadly-acting PI3K
inhibitor, was able to achieve a complete response in a patient with no adverse effects (Shiver et
al., 2015). This work has continued through identification of compounds that exploit the unique
sensitivity of MCC to particular factors in the PI3K pathway or by indirectly inhibiting PI3K/mTOR
and c-Myc expression via the BRD4 inhibitor JQ1 (Fang et al., 2020; Kannan et al., 2016). Dual
inhibition of p53-degrading E3 ubiquitin ligases MDM2 and MDM4 represents another critical cell
pathway that could be effectively exploited in p53-wild type, MCPyV-positive MCCs (Park et al.,
2019).
MCPyV-positive MCCs also exhibit the expression of MCPyV T antigens which is
required for their survival and absent in healthy human cells. Targeting MCPyV T antigens or their
impacts on the cell, therefore, could achieve tumor-specific killing. For example, inhibition of
LSD1, a histone demethylase upregulated by MCPyV sT, induces neuronal differentiation, cell
cycle arrest, and cell death (Leiendecker et al., 2020; Park et al., 2020). Another group found that
an anti-malarial drug lowered MCPyV LTT expression, leading to MCC cell death in vitro and in
xenograft mouse models (Sarma et al., 2020). Though the chemotherapies tested thus far have
had limited impact on patient outcomes, a better understanding of the weaknesses conferred by a
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dependence on MCPyV T antigen expression could provide needed alternatives to immune
checkpoint therapies. In Chapter 3, I discuss our finding that several MCPyV-positive cell lines
are uniquely susceptible to combined DNA damage and BCL-2 inhibition.
1.9 – Scope of this work
This dissertation aims to elucidate cellular factors that detect and counter MCPyV
infection, as well as, highlight potential strategies for targeting MCPyV-positive MCC tumors. In
Chapter 2, I detail the antiviral innate immune response to MCPyV infection that is mediated by
the cGAS-STING and NF-κB pathways. In Chapter 3, I identify a natural product that induces
DNA damage specifically in MCPyV-positive MCC cells, but is well-tolerated by healthy primary
cells and MCPyV-negative MCC cell lines. In this study, I showed that combination therapy of
DNA damage and BCL-2 inhibition induces robust apoptotic cell death across a wide array of
MCPyV-positive cell lines. Lastly, in Chapter 4, I analyze a mass spec dataset from MCPyVinfection and control samples to form connections between key gene sets and changes to the
cellular environment induced by MCPyV. With the results from this analysis, and with the efforts
described in previous chapters, I aspire to encourage new research directions for current and
future investigators of MCPyV and MCC.

22

1.10 – Chapter 1 Figures

Figure 1.1

Figure 1.1) Map of MCPyV genome. NCCR = Non-coding control region; Origin: Origin of
replication; LSD = LT stabilization domain; NLS = Nuclear localization signal; MUR = MCPyV
unique region; OBD = Origin binding domain.
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Figure 1.2

Figure 1.2). The proposed MCPyV infectious cycle. MCPyV infects human dermal fibroblasts,
and no other skin cell types, in ex vivo culture. MCPyV infectious particles (yellow circles) may
reach the dermal layer through deep abrasions. Fibroblasts closest to the basement membrane
and hair follicles support the greatest MCPyV infection in ex vivo culture (Liu et al., 2016b). Cells
within the hair follicle may support MCPyV infection or may be a critical route of transmission. (Not
drawn to scale).
Figure reproduced from:
Krump NA, Liu W, You J. Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol.
2018 Oct;32:71-79. doi: 10.1016/j.coviro.2018.09.002. Epub 2018 Oct 1. PMID: 30278284; PMCID:
PMC6263785.
1879-6257/© 2018 Elsevier B.V. All rights reserved.
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Figure 1.3

Figure 1.3) Hypothetical model of in vivo MCPyV persistence and dysbiosis leading to
MCPyV-positive MCC. Healthy individuals support both low and high MCPyV loads, depending on
external factors. U.V. irradiation or abrasion of the skin could cause infected dermal fibroblasts to
upregulate MCPyV gene expression and replication. Damaged and repairing skin could be a vector
by which MCPyV escapes the dermis to infect new hosts. Healthy immune responses may reduce
the MCPyV burden asymptomatically. In immunocompromised patients and those with years of
chronic U.V. damage, the microenvironment of the skin may be altered in a way that drives MCPyV
entry into the original cell of MCC and integration into the host chromatin.
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CHAPTER 2: Merkel cell polyomavirus infection induces an
antiviral innate immune response in human dermal fibroblasts
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2.1 – Abstract
Merkel cell polyomavirus (MCPyV) infects most of the human population
asymptomatically, but in rare cases leads to a highly aggressive skin cancer called Merkel cell
carcinoma (MCC). MCC incidence is much higher in aging and immunocompromised populations.
The epidemiology of MCC suggests that dysbiosis between the host immune response and the
MCPyV infectious cycle could contribute to the development of MCPyV-associated MCC.
Insufficient restriction of MCPyV by normal cellular processes, for example, could promote the
incidental oncogenic MCPyV integration events and/or entry into the original cell of MCC.
Progress towards understanding MCPyV biology has been hindered by its narrow cellular
tropism. Our discovery that primary human dermal fibroblasts (HDFs) support MCPyV infection
has made it possible to closely model cellular responses to different stages of the infectious
cycle. The present study reveals that the onset of MCPyV replication and early gene expression
induces an inflammatory cytokine and interferon stimulated gene (ISG) response. The cGASSTING pathway, in coordination with NF-B, mediates induction of this innate immune gene
expression program. Further, silencing of cGAS or NF-B pathway factors led to elevated MCPyV
replication. We also discovered that the PYHIN protein IFI16 localizes to MCPyV replication
centers, but does not contribute to the induction of ISGs. Instead, IFI16 upregulates inflammatory
cytokines in response to MCPyV infection by an alternative mechanism. The work described
herein establishes a foundation for exploring how changes to the skin microenvironment induced
by aging or immune-deficiency might alter the fate of MCPyV and its host cell to encourage
carcinogenesis.
2.2 – Importance
MCC has a high rate of mortality and an increasing incidence. Immune-checkpoint
therapies have improved the prognosis of patients with metastatic MCC. Still, a significant
proportion of the patients fail to respond to immune-checkpoint therapies or have a medical need
for iatrogenic immune-suppression. A greater understanding of MCPyV biology could inform
targeted therapies for MCPyV-associated MCC. Moreover, cellular events preceding MCC
27

oncogenesis remain largely unknown. The present study aims to explore how MCPyV interfaces
with innate immunity during its infectious cycle. We describe how MCPyV replication and/or
transcription elicit an innate immune response via cGAS-STING, NF-B, and IFI16. We also
explore the impacts of this response on MCPyV replication. Our findings illustrate how healthy
cellular conditions may allow low-level infection that evades immune destruction until highly active
replication is restricted by host responses. Conversely, pathologic conditions could result in
unbridled MCPyV replication that licenses MCC tumorigenesis.
2.3 – Introduction
Merkel cell polyomavirus (MCPyV) infection can be detected on the skin of most healthy
adults (Schowalter et al., 2010), yet details of its virology and infectious cycle remain sparse.
Evidence from serological studies suggests that MCPyV infects most people during early
childhood and prevalence of exposure to the virus increases as populations age (Chen et al.,
2011; Martel-Jantin et al., 2013; Viscidi et al., 2011). A vast majority of MCPyV infections are
asymptomatic (Tolstov et al., 2011), but some result in an aggressive skin cancer called Merkel
cell carcinoma (MCC) (Feng et al., 2008; Gjoerup and Chang, 2010; Harms, 2017; Schadendorf
et al., 2017). Over 80% of MCC tumors can be traced to a viral etiology by the presence of
integrated MCPyV genomic sequence in the cellular chromatin (Feng et al., 2008). Though MCC
cases are rare, the incidence of MCC has tripled over the last two decades (Fitzgerald et al.,
2015; Paulson et al., 2018a; Stang et al., 2018). MCC has a high rate of mortality with 5-year
overall survival around 51% for patients presenting with local disease at the time of diagnosis,
and worse prognoses for those with more advanced stages of disease (Harms et al., 2016a).
Chemotherapies have thus far failed to produce durable responses in patients with metastatic
disease (Cowey et al., 2017; Iyer et al., 2016). A recent bourgeoning of anti-PD1 and anti-PDL1
treatments for MCC has shown promise as first line therapies, though a significant proportion of
patients do not respond and the durability of responses varies (Becker et al., 2017b; D'Angelo et
al., 2018; Nghiem et al., 2019). The pursuit of more targeted MCC therapies necessitates a better
understanding of the oncogenic underpinnings of MCC and the role of MCPyV in this process.
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MCPyV has a ~5.4kb circular dsDNA genome. As a small DNA virus, MCPyV encodes an
efficient repertoire of genes. The viral genome is divided into early and late regions by a noncoding control region (NCCR) containing the viral origin of replication and bidirectional promoters
that drive early and late gene transcription (Harrison et al., 2011b). The early region expresses
large tumor antigen (LT) and small tumor antigen (sT) which support replication, as well as, 57kT
and an alternate LT open reading frame (ALTO) with functions that are less defined (Carter et al.,
2013; Kwun et al., 2009a). Major and minor capsid proteins, VP1 and VP2 respectively, are
expressed from the MCPyV late region along with a miRNA that modulates early gene expression
(Seo et al., 2009). In documented cases of virus-associated MCC, however, MCPyV DNA is
integrated into the tumor cell genome such that expression of native sT and a truncated LT (LTT)
is invariably preserved (Cheng et al., 2013; Shuda et al., 2008; Shuda et al., 2011). Expression
of these viral oncoproteins drives oncogenesis in virus positive (v+) MCC tumors and is required
for their survival (Houben et al., 2012; Houben et al., 2010; Shuda et al., 2011). The mechanism
and prerequisite conditions through which MCPyV integrates, however, are unknown.
Factors driving MCPyV integration and oncogenesis are difficult to probe in a laboratory
setting because the virus has a narrow tropism, and the original cell of MCC is still the subject of
speculation. Some evidence suggests that the absence of healthy immune surveillance and
suppression of MCPyV in the skin enable development of v+MCC. For example, several factors
that can dampen antiviral immunity such as advanced age, chronic UV exposure, and
immunosuppression increase the risk of MCC development (Heath et al., 2008a). Most MCC
patients have experienced chronic, high-levels of UV-exposure, maintain lower melanin content in
their skin, and are over the age of 60 (Stang et al., 2018). In addition, those at the greatest risk for
MCC relative to others in the same age range include persons who are immunocompromised as
a result of HIV/AIDs, chronic lymphocytic leukemia, and treatment for autoimmunity or organ
transplantation (Buell et al., 2002; Engels et al., 2002; Hemminki et al., 2012; Koljonen et al.,
2009; Penn and First, 1999).
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While immune escape of nascently transformed cells likely contributes to increased
incidence of MCC in these at-risk populations, there is additional evidence that these groups
control MCPyV infection poorly. A study in Japan found that MCPyV DNA prevalence and viral
load on sun-exposed skin increased sharply in individuals over the age of 40 and remained high
for the oldest groups (Hashida et al., 2016a). HIV-positive men more frequently have detectable
MCPyV DNA on their skin, and those with poorly-controlled HIV infection have higher MCPyV
DNA loads than those with better-controlled infections (Wieland et al., 2011). In kidney transplant
recipients, MCPyV DNA was more readily detected in the urine of those with BKPyV-DNAemia
and with histologically verified polyomavirus associated nephropathy (Wang et al., 2019). Though
it is impossible to determine whether v+MCC patients had high MCPyV titers prior to disease
onset, they more frequently produce MCPyV VP1-specific circulating antibodies and at higher
titers: markers that positively correlate with high MCPyV DNA and capsid load on the skin (Faust
et al., 2011; Pastrana et al., 2009; Pastrana et al., 2012; Touze et al., 2011). More recently, it was
also found that higher MCPyV DNA load correlates with worse survival outcomes in MCC patients
(von der Grun et al., 2019).
Collectively, these epidemiological data afford the possibility that altered immune status
in the skin enables unimpeded propagation of MCPyV and a favorable environment for
oncogenesis. Rampant MCPyV infection may promote pro-oncogenic conditions such as more
frequent replication errors that could result in MCPyV integration and mutation, and/or entry into
the original MCC cell from its reservoir. Probing the host responses that keep MCPyV infection in
check has been limited until recently due to a lack of tools and systems with which to study
infection. Using ex vivo skin sections and in vitro cultures of cells isolated from human foreskins,
we found that human dermal fibroblasts (HDFs) are uniquely capable of supporting MCPyV
infection (Liu et al., 2016b). Establishing this model infection system has made it possible to
explore cellular responses to MCPyV infection and to determine what impact those responses
have on the course of MCPyV proliferation.
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In the present study, we discovered that MCPyV induces expression of interferon
stimulated genes (ISGs) and inflammatory cytokines in primary HDFs during later stages of
infection. Using a CRISPR knockout approach, we found that this response to infection is
mediated by the cGAS-STING and NF-B pathways. While others have explored how expressed
MCPyV genes might modulate host immune factors in different cellular contexts (Abdul-Sada et
al., 2017; Akhbari et al., 2018; Griffiths et al., 2013; Shahzad et al., 2013), to our knowledge these
are the first observations of host cellular responses in the context of MCPyV infection. The
present study therefore represents an important step in broadening our understanding of this
enigmatic virus and its role in initiating human cancer.
2.4 – Results
2.4.1 – MCPyV infection induces an ISG/inflammatory cytokine response concomitant with peak
viral replication and transcription
Since discovering that HDFs support MCPyV infection, we have been able to observe
distinct stages of infection using this model system (Fig. 2.1A). We previously described that
MCPyV entry is enhanced in the absence of FBS, and that addition of FBS enables MCPyV gene
expression, replication, and transcriptional changes in cellular genes (Liu et al., 2016b). Because
further MCPyV spread is limited in the presence of FBS (Liu et al., 2016b), we are able to parse
the cellular response to a single round of the infectious cycle (Fig. 2.1A).
In this study, we infected HDFs using our established conditions as described in (Liu et
al., 2016b) to examine both viral activities and the host response to viral infection. In order to
control for the impact of non-infectious viral particles, loose nucleic acid, and other components of
the virus preparation, we heat-inactivated half of the MCPyV stock and used it in the control
experiments. By comparing total DNA extracted from MCPyV-infected HDFs and those treated
with the same volumes of heat-inactivated-MCPyV (control), we found that the rate of increase of
MCPyV replication is the greatest between 72 and 120 hours post infection (h.p.i.) (Fig. 1B).
MCPyV replication continues up to at least 168 h.p.i at a slower rate. In a similar manner, we
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performed qPCR on supernatants from MCPyV and control conditions to measure relative release
of output viral genomes into the extracellular environment (Fig. 1B). With control supernatant
containing a relatively constant level of MCPyV DNA, MCPyV-infected supernatants show the
greatest increases between 72-96 hours and 144-168 hours (Fig. 1B). These spikes in relative
MCPyV genome abundance suggest that MCPyV is being released from infected cells continually
after replication begins.
After delineating a time frame in which MCPyV replication is elevated, we sought to
determine if there was evidence of an innate immune response to MCPyV activity. We performed
RT-qPCR with a set of primers targeting ISGs and inflammatory cytokines with documented antiviral functions (Fig. 1C-D). This experiment revealed that relative to the control condition, MCPyV
infection of HDFs induced up to 1000-fold stimulation of several ISGs, including OAS1, ISG54,
Mx1, Mx2, Viperin, ISG15, and RIG-I at 144 h.p.i. (Fig. 1C). Besides the robust induction of ISGs,
MCPyV infection also caused 10-30-fold induction of inflammatory cytokines, including IL-8, IL-6,
IL-1, and TNF-, whereas the level of IFNs was not significantly stimulated by MCPyV (less than
3-fold) (Fig. 1D). We have consistently observed similar responses to MCPyV infection using low
passage primary HDFs isolated from more than 10 donors, thus ruling out donor-to-donor
variability. A time course RT-qPCR of MCPyV infection revealed that peak ISG transcriptional
activity occurred around 144 h.p.i. (Fig. 1E).
To establish whether the ISG response to MCPyV-infection was present at the proteinlevel, we harvested whole cell lysates for protein extraction from MCPyV-infected and control
conditions at 96, 120, and 144 h.p.i. (Fig. 1F). Immunoblotting for MCPyV LT and VP1, early and
late genes respectively, served as a reference for infection stage. As expected, MCPyV LT, which
directly supports MCPyV replication, declined at the protein level coinciding with slowing MCPyV
replication that occurs between 120 and 144 h.p.i (Fig. 1B and 1F). MCPyV VP1, however,
increases in abundance from 96 h.p.i and remains high by 144 h.p.i. Crucially, ISGs that were
induced at the RNA level by MCPyV infection were also upregulated at the protein level after 120
h.p.i. (Fig. 1 C and F). From these studies, it is clear that the ISGs/cytokines are induced after
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infected cells have reached peak viral replication and early transcription, suggesting that these
viral activities produce pathogen-associated molecular patterns (PAMPs) or damage-associated
molecular patterns (DAMPs) to trigger the cellular response.
2.4.2 – IFI16 localizes to MCPyV replication centers
Canonical immune responses to viral infection begin when PAMPs or DAMPs, like viral
DNA, are sensed by pattern recognition receptors (PRRs). PRR agonist binding stimulates
conserved intracellular signaling cascades that activate transcription factors belonging to the IFN
regulatory factor (IRF) and nuclear-factor kappa B (NF-B) families (Bonizzi and Karin, 2004;
Honda et al., 2006; Yarilina and Ivashkiv, 2010). These activated transcription factors can in turn
stimulate production of IFNs and cytokines that are secreted from the cell to function via autocrine
and paracrine modalities. Cytokines binding cell surface receptors activate downstream signaling,
including the Jak-STAT pathways (Bonizzi and Karin, 2004; Honda et al., 2006; Yarilina and
Ivashkiv, 2010). Cytokine-mediated signaling events can also spread and intensify ISG
expression and the antiviral status by further stimulating NF-B and IRF transcriptional activity
(Bonizzi and Karin, 2004; Honda et al., 2006; Yarilina and Ivashkiv, 2010).
Given the evidence that peak MCPyV replication and gene expression precedes a
marked ISG response, we wanted to identify the sensor responsible for detecting the putative
MCPyV-associated molecular pattern. We performed immunofluorescence microscopy (IF) on
MCPyV-infected and the control HDFs using antibodies targeting known sensors of viral nucleic
acid to determine if they are differentially localized in MCPyV-infected cells. This approach
established interferon- inducible protein 16 (IFI16), an upstream component for stimulator of
interferon genes (STING) (Dunphy et al., 2018; Kondo et al., 2013; Unterholzner et al., 2010), as
a candidate sensor for MCPyV. Immunostaining for IFI16 revealed that a small percentage of
nuclei in the MCPyV infection setting developed a distinct punctate or track-like IFI16 pattern (Fig
2). On the other hand, all cells the control condition and the vast majority of cells in MCPyV
infection exhibited diffuse, pan-nuclear IFI16 staining that was sometimes enriched in nucleoli.
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Co-staining experiments revealed that the intense punctate IFI16 signal only occurred in nuclei
that were VP1 or LT positive (Fig. 2.2A-B). When IFI16 punctate signal was present in nuclei
containing LT puncta, markers of MCPyV replication centers, the intense IFI16 and LT signals
generally overlapped (Fig. 2.2B). Replication centers, or foci, are sub-nuclear regions in which
active viral DNA synthesis takes place and where most MCPyV DNA is present in the nucleus
(Liu et al., 2016b). Because IFI16 formed puncta in a small subset of MCPyV-positive nuclei, and
that those puncta overlapped with LT-containing replication foci, we hypothesized that IFI16 was
localizing to MCPyV DNA at brief periods during the infectious cycle independently of LT.
To test whether IFI16 localizes to centers of actively synthesizing MCPyV genomes, we
performed IFI16/RPA70 co-staining (Fig. 2.2C). We have shown previously that RPA70, which
binds single-stranded DNA, forms intense puncta at MCPyV replication centers likely undergoing
DNA synthesis (Wang et al., 2012). The experiment showed that concentrations of ssDNA
represented by nuclear RPA70 foci that were unique to MCPyV infection specifically overlapped
with IFI16 foci (Fig. 2.2C) To confirm that IFI16 puncta were forming at concentrations of MCPyV
DNA we performed immuno-FISH: staining for IFI16 and probing for MCPyV-specific DNA
sequence (Fig. 2.2D). As was true with other markers of MCPyV nuclear presence, IFI16 puncta
occurred in a small population of MCPyV DNA foci containing nuclei, yet this signal was unique to
MCPyV positive cells and correlated with the pattern of MCPyV DNA-containing foci (Fig. 2.2D).
That IFI16 formed puncta in a small proportion of MCPyV positive cells lead us to suspect that
this is either a rare or temporally brief event taking place during MCPyV infection. We also
concluded that while IFI16 and MCPyV replication foci did not coincide 1:1 in the fashion of true
co-localization, the signals always overlap or are adjacent when present in the same nucleus. Because IFI16 foci are unique to MCPyV infected cells and appear to localize to sites of active
MCPyV DNA synthesis we hypothesized that IFI16 detects MCPyV genomes in the nucleus and
elicits down-stream ISG and innate inflammatory cytokine induction.
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2.4.3 – MCPyV infection activates the STING/TBK1/IRF3 and NF-B pathways
IFI16 is a DNA-binding protein reported to stimulate type-I IFN and ISG induction through
interaction with the cyclic GMP-AMP synthase (cGAS)-STING pathway in response to infection
with other DNA viruses (Diner et al., 2016; Orzalli et al., 2015; Unterholzner et al., 2010). Since
IFI16 is localized to replication centers and ISGs are upregulated during MCPyV infection, we set
out to understand whether cGAS-STING pathway factors were being activated. Again, we
performed time course western-blot analysis comparing the key downstream molecules in
MCPyV-infected and control whole cell lysates (Fig. 2.3A). Downstream effectors of STING, tankbinding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3), appear to be more abundant in their
active, phosphorylated state in infection conditions relative to control. The frequency of p-IRF3
signal in cells was also elevated in MCPyV infection as observed and quantified by IF (Fig 2.3BC). Given that cGAS-STING effector proteins were likely activated by infection, we also confirmed
that the activated form of STING was more abundant in MCPyV-infected cells by western (Fig.
2.3D).
Canonical activation of STING in response to viral pathogens involves cGAS binding
foreign DNA, which activates its catalysis of the STING agonist cyclic GMP-AMP (cGAMP) (Ni et
al., 2018). Our candidate sensor of MCPyV DNA, IFI16, has also been reported to cooperate with
cGAS in some instances to initiate STING signaling (Almine et al., 2017; Orzalli et al., 2015).
Therefore, we examined the possible involvement of cGAS in activating the STING-TBK1-IRF3
pathway. We performed an ELISA to quantify cGAMP production in whole-cell lysates from mockinfected and MCPyV-infected HDFs. T cGAMP concentration was significantly higher in MCPyVinfected samples than in control (Fig. 2.3E). Thus, the catalytic activity of cGAS is likely
upregulated in MCPyV infection and may contribute to the host cell innate response.
NF-B can also be regulated by STING and is capable of upregulating transcription of
inflammatory cytokines such as those we observed (Fig. 2.1D). Therefore, we assessed the
activation status of the NF-B pathway during MCPyV infection. When the NF-B pathway is
activated, the inhibitor of NF-B Kinase (IKK) and the p65 subunit of NF-B are phosphorylated,
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allowing p65 to be phosphorylated and translocate into the nucleus (Christian et al., 2016).
Immunoblotting for phosphorylated epitopes on IKK- and p65 revealed elevated levels in
MCPyV infection relative to control (Fig. 2.3A). IF co-staining for MCPyV LT and p65 also made
evident an increased nuclear localization of p65 in MCPyV-infected conditions (Fig. 2.3F-G).
Collectively, these data suggest that the cGAS-STING-TBK1-IRF3 and NF-B pathways are
stimulated by later events in MCPyV infection and may contribute to an antiviral response with
induced cytokine/ISG expression.
2.4.4 – CRISPR knockout of cGAS-STING-TBK1-IRF3 pathway, but not IFI16, ablates ISG
response to MCPyV infection
Next, we aimed to discern how these immune regulatory factors impact the course of the
innate response to MCPyV and its proliferation. We used a lentiviral CRISPR-Cas9 system to
knockout several regulatory genes in the cGAS-STING-TBK1-IRF3 and NF-B pathways in
primary HDFs. Since these primary cells cannot be grown from a single clone, we selected for
successful expression of the given sgRNA and validated knockout efficiency by western blotting
(Fig. 2.4A-B). We verified that each of these cell lines, along with a control cell line expressing an
sgRNA targeting the non-mammalian gene, was capable of supporting MCPyV infection by IF
(data not shown). For RT-qPCR analysis we harvested cell lysates at 144 h.p.i., which is the peak
time point for ISG induction as determined by our time course (Fig. 2.1E). We found that
individual knockout of cGAS, STING, TBK1, IRF3, IKK-, or p65 ablated normal ISG induction
during MCPyV infection (Fig. 2.4C). This result implied that each of these factors is required for
inducing ISGs in response to MCPyV. Surprisingly, knockout of IFI16 did not significantly reduce
induction of ISGs relative to control.
We then assessed the transcriptional upregulation of IL-1, IL-6, and TNF- by RT-qPCR
in each knockout setting during MCPyV infection. It is well-documented that these cytokines are
transcriptionally regulated by the NF-B pathway (Bonizzi and Karin, 2004). This fact was
substantiated with regards to MCPyV infection by the result that knockout of either IKK- or p65
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dramatically reduced IL-1, IL-6, and TNF- RNA levels (Fig. 2.4D). IFI16 knockout also
significantly reduced the expression of each of these cytokines suggesting it may influence the
cytokine response to MCPyV independently of the mechanism driving ISG induction. On the other
hand, cGAS and STING knockout does not appear to have a significant impact on cytokine
expression while knockout of TBK1 and IRF3 moderately inhibits IL-6 and TNF- induction by
MCPyV. These observations indicate that both the NF-B and IRF3 axes participate in the
transcriptional induction of IL-1, IL-6, and TNF- triggered by active MCPyV infection.
2.4.5 – ISG and inflammatory cytokine induction has a modest, direct impact on MCPyV
proliferation
After establishing that these immunological pathways participate in a host response to
MCPyV, we assayed whether the response has measurable consequences for the propagation of
MCPyV genomes in HDFs. To accomplish this, we compared MCPyV genome level in lysates
and supernatants harvested at 168 h.p.i. across the HDF knockout cell lines. Knockout of cGAS,
IKK-, or p65 significantly increased the replication of MCPyV genomes in whole cell lysates (Fig.
2.5A). However, none of the knockout cell lines showed a significantly increased level of MCPyV
genomes in the supernatant (Fig. 2.5A).
Unexpectedly, elimination of some factors, especially IFI16, resulted in substantially
lower MCPyV genomes detected in the supernatant. This finding was of particular interest
because it coincides with the observation that high titer infection of IFI16 knockout HDFs results
in apparent fragmentation of VP1-positive nuclei (Fig. 2.5B). Unlike the control cells that show the
typical pan-nuclear VP1 signal, most of the IFI16 knockout HDFs showed scattered VP1 signal
that often spreads outside of the infected cells, indicating that severe cell lysis is occurring in the
IFI16 knockout samples (Fig. 2.5B). Quantification of the IF results reveals that, compared to
other knockout cell lines, IFI16 knockout cell lines showed a markedly lower number of intact VP1
positive nuclei (Fig. 2.5B value inserts). Therefore, it is possible that disruption of MCPyVcontaining cell membranes and early cell death in IFI16 knockout cells either prevents the
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completion of MCPyV genome replication in these cells or alters the mode of egress of MCPyV
into the extracellular space. Considered together, these results imply that the presence or
absence innate immune effectors during highly active MCPyV infection could alter the rate of
MCPyV replication and, ultimately, host cell fate.
2.5 – Discussion
MCPyV maintains asymptomatic persistent infection in more than 80% of the general
population (Foulongne et al., 2012; Schowalter et al., 2010; Tolstov et al., 2009a), but tends to
cause MCC in elderly and immunocompromised individuals (Heath et al., 2008b). Epidemiological
studies have revealed a strong correlation between immunosuppression, elevated MCPyV
genome loads, and increased risk for MCC (Heath et al., 2008b; Wieland et al., 2011). These
observations suggest that the virus strikes a balance in healthy hosts where it is restricted by
immune mechanisms, but avoids eradication. Furthermore, settings where immune restriction is
reduced increase the likelihood of MCPyV-induced tumorigenesis. However, little is known about
the immune response elicited by MCPyV. By extension, neither is much understood about the
immune evasion strategies that enable MCPyV to establish persistent or poorly-controlled
infection in different settings. Such insights could explain the duality of MCPyV infection
outcomes involving either long-term asymptomatic infection or integration and rapid oncogenesis.
In the current study, we employed the MCPyV infection model established in our recent
study (Liu et al., 2019; Liu et al., 2018a; Liu et al., 2016b) to examine the host innate immune
response to MCPyV infection. We discovered that MCPyV infection of low-passage primary
normal HDFs induces robust expression of key antiviral ISGs and inflammatory cytokines at 144
h.p.i., while no significant induction of these genes was observed at the early time points (Fig.
2.1F). We found that the ISG response reliably follows peak MCPyV infection activities (Fig.
2.1F), suggesting that it is most likely induced by MCPyV DNA replication and/or transcription.
Besides the robust induction of ISGs, MCPyV infection also caused 10-30-fold induction of
inflammatory cytokines, including IL-1, IL-6, TNF-, and IL-8, (Fig. 2.1C and 2.1D).
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Our observation that MCPyV infection results in ISG induction builds upon existing
literature that examines cellular responses to other polyomaviruses. It has been demonstrated
that overexpression of SV40, JCPyV, or BKPyV T antigens in mouse embryonic fibroblasts leads
to upregulation of ISGs and an antiviral state (Giacobbi et al., 2015; Rathi et al., 2010). In
addition, JCPyV infection of human renal proximal tube epithelial cells results in IFN-secretion
and subsequent ISG induction in a manner that partially controls the extent of infection (Assetta
et al., 2016). Infection of the same cells with BKPyV, however, fails to produce the same ISG
response and protection. In microvascular endothelial cells found in the lung and bladder,
however, BKPyV infection seems to be blunted by IFN-mediated innate immune gene induction
that coincides with later stages of the infectious cycle (An et al., 2019). Intriguingly, like BKPyV,
the induction of ISGs by MCPyV occurs relatively late in the viral life cycle. Perhaps further
investigation of the cell-type specific innate immune responses to polyomaviruses may offer an
explanation as to why certain cell types are more or less permissible to MCPyV. Antiviral
mechanisms unique to the as yet unidentified cell of origin of MCC, for example, could increase
the frequency of MCPyV integration events.
We also found that IFI16 localizes to the sub-nuclear sites of MCPyV replication in a
small population of MCPyV positive cells (Fig. 2.2). The rarity of the IFI16 punctate phenotype
and its tendency to localize to MCPyV replication foci led us to conclude that it is likely enriched
at MCPyV genomes at a brief and specific part of the infectious cycle. Despite being a promising
candidate as the initiating factor of the ISG response to infection for its ability to shuttle between
nucleus and cytoplasm, we found that IFI16 was not necessary for MCPyV-associated ISG
induction (Fig. 2.4C) (Li et al., 2012). Instead, cGAS proved to be likely activated by MCPyV
infection, essential for ISG induction, and involved in repressing MCPyV replication (Fig. 2.3C,
2.4C, 2.5A). The manner in which cGAS senses MCPyV is still in question. Largely described as
a cytoplasmic sensor, it has been found to localize to the nucleus in HDFs, where it has been
suggested that cGAMP is able to diffuse through nuclear pores in order to activate STING
signaling (Gentili et al., 2019).
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Due to the role of STING signaling in mediating responses to viral DNA (Dunphy et al.,
2018; Kondo et al., 2013; Unterholzner et al., 2010), we assessed the activation status of STING
downstream effectors during MCPyV infection and their functional relevance to the antiviral status
of the host cell. We found that STING, TBK1, IRF3, IKK-, and the NF-B subunit p65 are
activated by phosphorylation during MCPyV infection (Fig. 2.3). In addition, CRISPR knockout of
these key immune mediators represses MCPyV-induced ISG and cytokine expression (Fig. 2.4),
allowing increased MCPyV replication (Fig. 2.5). Our data therefore support a model in which
MCPyV infection generates PAMPs or DAMPs that activate STING and NF-B-mediated
induction of cytokines and ISGs, which in turn negatively regulate MCPyV infection (Fig. 2.6).
The cytokines upregulated by MCPyV such as IL-1 and TNF- are capable of further
positive regulation of ISG expression via IRF1, IRF3, and NF-B (Aarreberg et al., 2019;
Aarreberg et al., 2018; Bartee et al., 2009; Mayer-Barber and Yan, 2017; Orzalli et al., 2018;
Rivieccio et al., 2005; Venkatesh et al., 2013; Wang et al., 2016; Wang et al., 2017b; Yarilina et
al., 2008). Therefore, we suspect these cytokines function in both autocrine and paracrine
manner during MCPyV infection to generate and amplify the antiviral status of infected cells and
neighboring uninfected cells alike (Fig. 2.6). Unlike the inflammatory cytokines, the change in
IFN- mRNA level did not reach the threshold of statistical significance (p = 0.0765) (Fig. 2.1D).
Whether this level of induction is biologically relevant to the cascade of events regulating ISG
expression remains to be investigated.
As this is the first study to examine innate intrinsic responses to MCPyV infection, the
findings herein pose questions that should be addressed in the future. For example, while cGAS
is likely the predominant MCPyV PRR responsible for the induction of ISGs (Fig. 2.4), the role of
IFI16 throughout MCPyV infection remains to be fully detailed. We found that IFI16 localizes to
sites of MCPyV replication and contributes to the induction of inflammatory cytokines but not
ISGs (Fig. 2.2, 2.4D). This suggests that it may support transcriptional upregulation of cytokines
by means other than the cGAS-STING and NF-B pathways.
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One mechanism by which IFI16 could induce inflammatory cytokine induction is that
MCPyV-DNA-bound IFI16 could shuttle to the cytoplasm where it may engage in inflammasome
activation and pyroptosis as has been reported in herpesvirus infection (Iqbal et al., 2016;
Johnson et al., 2013). The VP1-positive nuclei fragments found in IFI16 knockout conditions
during MCPyV infection could indicate that the absence of IFI16 disrupts typical cell death
responses to infection. If IFI16 does not promote inflammasome-related pyroptosis, it may
promote other cell fates such as senescence. For example, it has been reported that IFI16 is
accumulated in aging fibroblasts (Duan et al., 2011) and that the loss of IFI16 in fibroblasts allows
a bypass of cellular senescence (Xin et al., 2004). Recently, another group showed that MCPyV
genome transfected into HDFs causes a secretory senescence phenotype (Siebels et al., 2020).
Together these findings hint that IFI16 may promote a secretory senescence phenotype in
MCPyV-infected fibroblasts in tandem with innate signaling from cGAS-STING and NF-B.
Changes in IFI16 activity and abundance in aging skin could also alter the course of MCPyV
propagation and host cell fate.
Knockout of IKK-, p65, or cGAS led to elevated MCPyV replication as measured by
qPCR analysis of whole cell lysates (Fig. 2.5). The most significant of these changes was that of
cGAS knockout, which resulted in ~6X higher levels of MCPyV DNA in cell lysates (Fig. 2.5). One
explanation for the dramatic impact of cGAS presence on MCPyV replication compared to the
other factors is that, as a principal sensor of MCPyV DNA, cGAS impacts all downstream aspects
of the host cellular response. Another possibility is that cGAS binding to MCPyV DNA can directly
inhibit MCPyV replication in addition to initiating host signaling events. That knockout of effectors
downstream of cGAS was not sufficient to limit MCPyV replication could imply that MCPyV has
evolved strategies to antagonize the STING-mediated antiviral immune response. Alternatively,
the varied impacts of silencing the downstream components on MCPyV replication may be due to
unexpected influences outside of canonical pathways. For example, one group found that
knockout of innate immune regulators like IFI16, STING, and IRF3 had pleiotropic effects on
herpesvirus replication (Liu et al., 2018b). It is possible that other antiviral immune signaling
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pathways not explored here are involved in controlling MCPyV infection. Therefore, how MCPyV
evades the host immune responses to achieve persistent infection remains an important question
to address in the future.
Our current data suggest that ISGs and inflammatory cytokines induced by MCPyV
infection could dampen viral spread even in the absence of intervention by innate and adaptive
immune cells. The extent to which this antiviral immune response can prevent uncontrolled viral
propagation within the skin microenvironment will need to be tested in an in vivo model once one
becomes available. Until then, exploring the mechanisms by which MCPyV counteracts the innate
host cell response will yield insights regarding MCPyV persistence in healthy hosts. Such a
mechanism would clarify how the lack of antiviral pressure in at-risk populations encourages
MCC tumorigenesis.
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2.6 – Chapter 2 Figures

Figure 2.1
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Figure 2.1) ISGs and innate inflammatory cytokines are induced in coordination with MCPyV
early gene expression and viral replication. A) Schematic visualization of MCPyV infection
events in HDFs. The time frame and magnitude of each event is estimated by the data shown in
our previous studies (Liu et al., 2019; Liu et al., 2018a; Liu et al., 2016b) and the current study. B)
MCPyV genome abundance measured by qPCR of whole-cell lysates and supernatants at the
indicated time points relative to HDFs treated with heat-inactivated MCPyV. The y-axes in both
panels are on a log10-scale with a horizontal line (y=1) representing the control condition.
Supernatant genome values in MCPyV infection are initially less than that of the control condition
likely because the heat-inactivated viruses added to the control group have lower tendency to enter
the cells and therefore remained in the supernatant. For the live virus treated group, as output
MCPyV exceeds input virus in the supernatant at later time points, the values become many-fold
greater than control. C-D) RT-qPCR analysis of the transcript level of ISGs (C) and innate immune
cytokines (D) at 144 h.p.i. in HDFs infected with MCPyV relative to those treated with heatinactivated MCPyV. Error bars represent the standard error of the mean. E) RT-qPCR analysis of
select ISGs from MCPyV infection relative to heat-inactivated MCPyV-treated condition harvested
at 120, 144, and 168 h.p.i. Error bars represent the standard error of the mean. F) Western blot
time course of MCPyV early gene, LT, and late gene, VP1, as well as ISGs for 96, 120, and 144
h.p.i. Lanes loaded with samples from heat-inactivated MCPyV treated HDFs are labeled (-), and
those infected with MCPyV are labeled (+). Cellular GAPDH from all samples was blotted as a
loading control.
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Figure 2.2
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Figure 2.2) IFI16 localizes to MCPyV replication centers exclusively in nuclei that are
robustly VP1 positive. A) IF staining for IFI16 and VP1 in MCPyV-infected nuclei. MCPyV-infected
and heat-inactivated-MCPyV treated HDFs were stained using IFI16 and VP1 antibodies, and
counterstained with DAPI. B) A) IF staining for IFI16 and LT in MCPyV-infected nuclei. MCPyVinfected and mock-infected HDFs were stained using IFI16 and VP1 antibodies, and counterstained
with DAPI C) IF staining for IFI16 and RPA70 in MCPyV-infected nuclei. MCPyV-infected and heatinactivated-MCPyV treated HDFs were stained using IFI16 and VP1 antibodies, and counterstained
with DAPI. D) Immuno-FISH experiment staining for IFI16 and probing for MCPyV genomic DNA.
Mock- or MCPyV-infected HDFs were harvested at 120 hours post-infection. The cells were
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subjected to sequential immunofluorescence staining using IFI16 antibody (Sigma,
Cat.#HPA002134) and FISH with an MCPyV probe (Biosearch technologies). Bar, 10 m. Pannuclear IFI16 staining and slight enrichment in nucleoli was evident in control conditions and in
most cells in the MCPyV-infected condition. A subset of those cells with MCPyV DNA foci revealed
adjacent or overlapping signal with IFI16 puncta.
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Figure 2.3
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Figure 2.3) STING-TBK1-IRF3 and NF-B pathways are activated during MCPyV infection in
HDFs. A) Whole-cell immunoblot time course of the STING-TBK1-IRF3 pathway and the NF-B
pathway respectively for 96, 120, and 144 h.p.i. Lanes loaded with samples from heat-inactivated
MCPyV treated HDFs are labeled (-), and those infected with MCPyV are labeled (+). Cellular
GAPDH from all samples was blotted as a loading control. B) IF co-staining for p-IRF3 and LT in
HDFs infected with MCPyV or treated with heat-inactivated MCPyV 6 days post infection/treatment.
C) Quantification for B. D) HDFs were infected with active (+) or heat-inactivated (-) MCPyV. At 120
h.p.i., the whole lysates were blotted with the indicated antibodies. E) ELISA quantification of
cGAMP present in whole-cell lysates of mock-infected and MCPyV-infected cells at 120 h.p.i. One
tailed student’s t-test produced a p-value = 0.0052 (<0.01). F) IF co-staining for MCPyV LT and
NF-B p65 subunit in HDFs infected with MCPyV or treated with heat-inactivated MCPyV. All cells
were fixed at 144 h.p.i. G) Quantification for F.
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Figure 2.4
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Figure 2.4) CRISPR knockout of STING-TBK1-IRF3 and NF-B pathways ablates the ISG
response to MCPyV infection in HDFs. A) Immunoblot validation of HDF CRISPR knockout cell
lines. Cell lysates were harvested at the time of seeding for infection. Lanes are labeled with the
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genes targeted by the stably expressed sgRNA. HDFs stably expressing Cas9 and an sgRNA
targeting the non-mammalian luciferase gene were used as a negative control. A lane was cropped
out between IFI16 and STING lanes. B) Immunoblot validation of cGAS cell line used in shown
experiments was blotted separately. C-D) RT-qPCR analysis of marker ISGs (C) and inflammatory
cytokines (D) in MCPyV-infected HDF CRISPR knockout cell lines targeted by the indicated
sgRNAs. Cells were analyzed at 144 h.p.i. For each gene of interest, expression levels for each
cell line are displayed relative to the control cell line stably expressing Cas9 and a luciferasetargeted sgRNA. Error bars represent standard error of the mean.
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Figure 2.5
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Figure 2.5) CRISPR knock out of some STING-TBK1-IRF3 and NF-B pathway components
stimulates MCPyV replication in HDFs. A) qPCR-measured abundance of MCPyV genome
equivalents in cell lysates and supernatants of HDF CRISPR knockout cell lines targeted by the
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indicated sgRNAs. Shown are the MCPyV DNA levels in MCPyV-infected HDF CRISPR knockout
cells relative to the same cells treated with heat-inactivated MCPyV at 168 h.p.i. Error bars
represent the standard error of the mean. B) Representative images from IF co-staining for LT and
VP1 in MCPyV infected CRISPR knockout HDF cell lines fixed around 160 h.p.i. Number values in
lower right corner indicate the percent of intact, positive nuclei in that condition for that antigen.
Final row is a magnification of the insert outlined by the white box in the second row.
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Figure 2.6

Figure 2.6) Schematic working model of cellular responses to MCPyV infection. Solid black
arrows represent functional findings in the present paper and expected relationships based on
established canonical pathways. Dotted line arrows indicate suspected mechanism based on
indirect evidence and literature. Light gray items represent possible alternative localizations of that
factor. MCPyV undergoes attachment, entry, and trafficking to the nucleus without eliciting ISG or
inflammatory cytokine induction. Naked MCPyV DNA in the nucleus enables viral gene transcription
and replication. cGAS likely detects MCPyV DNA either in the cytoplasm or nucleus to stimulate
signaling through the STING-TBK1-IRF3 axis. Upregulation of cytokines are suspected to then
function in an autocrine and paracrine fashion to turn on other innate immune pathways such as
NF-κB. ISGs and inflammatory cytokines are ultimately upregulated as a result of MCPyV activity.
IFI16 contributes to the induction of cytokines, but not ISGs, independently of cGAS-STING in a
manner that is yet to be determined. (Inf. cytokines = inflammatory cytokines: IL-1β, TNF-α, IL-6).
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CHAPTER 3: Combining DNA damage induction by a natural
product and BCL-2 inhibition effectively kills MCPyV-positive
Merkel cell carcinoma cells

Chapter 3 Accreditation
The research presented in this chapter was accomplished in collaboration with Dr. Wei Liu in
equal contribution. We collaborated closely to develop the experiment design and study direction,
while the project was initially conceptualized by Dr. Jianxin You. I performed the screens of
natural products in fibroblasts and MKL-1 cells that identified glaucarubin as a lead candidate
compound. Dr. Liu executed the western blots and cell viability assays that detailed the molecular
function of glaucarubin in different MCC cell lines. Dr. Liu harvested total protein samples for
RPPA assay carried out by the staff members of the MD Anderson Cancer Center core facility. I
analyzed the results of the RPPA assay and wrote the manuscript for the article published in
Biology with critique and improvements from Drs. Jianxin You and Wei Liu.

This research was previously published by Molecular Diversity Preservation International (MDPI)
in Biology. The full citation is provided below:

Liu W, Krump NA, Herlyn M, You J. Combining DNA Damage Induction with BCL-2 Inhibition to
Enhance Merkel Cell Carcinoma Cytotoxicity. Biology (Basel). 2020 Feb 19;9(2):35. doi:
10.3390/biology9020035. PMID: 32093022; PMCID: PMC7168258.

55

3:1 – Abstract
Merkel cell carcinoma (MCC) is a highly lethal form of neuroendocrine skin cancer.
Although MCC tumors are responsive to chemotherapy in the short term, the duration of the
response is often short-lived and many tumors develop resistance to chemotherapy. While the
recently developed PD-1/PD-L1 immune checkpoint blockade therapies have had successes in
MCC treatment in clinical trials, a significant portion of MCC patients do not respond to the
treatment. Therefore, a pressing need for effective chemotherapies for MCC remains. To identify
compounds with activity against MCC tumors, we were particularly interested in those with proven
safety in human subjects in order to avoid the practical barriers faced when developing a drug
from novel chemical compounds. We screened compounds originating from natural products that
are regularly consumed by humans and have been pooled by the National Cancer Institute. We
found that one compound, glaucarubin, potently reduced the viability of the Merkel cell
polyomavirus (MCPyV)-positive MCC cell line MKL-1 while remaining nontoxic to primary human
fibroblasts and most MCPyV-negative MCC cell lines tested. Protein array and western blot
analyses revealed that glaucarubin activates DNA damage-induced p53-dependent apoptosis
specifically in MKL-1 cells. We also found that high basal expression of the antiapoptotic factor
BCL-2, which was further induced upon glaucarubin treatment, allowed a small population of
MKL-1 cells to survive glaucarubin-induced cell death. Glaucarubin treatment, when combined
with that of an FDA-approved BCL-2 inhibitor, leads to nearly complete killing of MCPyV-positive
MCC cells expressing wild-type p53 and high levels of BCL-2. Our study identifies this dual
treatment of low-dose DNA damage induced by glaucarubin and chemical BCL-2 inhibition as a
novel therapeutic strategy for MCPyV-positive MCCs. This strategy may also have potential for
treating other p53 wild-type human cancers with robust BCL-2 expression. Health care providers
may also consider the use of BCL-2 inhibitors for the treatment of primary MCC tumors in
combination with standard care radiation with the goal of preventing therapy-resistant MCC
recurrence.
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3.2 – Introduction
Merkel cell carcinoma (MCC) is a neuroendocrine carcinoma associated with Merkel cell
polyomavirus (MCPyV)(Feng et al., 2008; Gjoerup and Chang, 2010). MCC metastasizes rapidly
and is one of the most aggressive skin cancers(Feng et al., 2008; Gjoerup and Chang, 2010) with
a disease-associated mortality of 46% (which exceeds the mortality rate of melanoma) (Lemos et
al., 2010) and a five-year survival rate less than 45% (Agelli and Clegg, 2003). The incidence of
MCC has tripled over the past 20 years(Hodgson, 2005). With the prevalence of MCPyV infection
in ~80% of the general population (Foulongne et al., 2012; Schowalter et al., 2010; Tolstov et al.,
2009a) and increasing number of MCC diagnoses(Paulson et al., 2017b), it is important to
develop better treatment strategies for this highly aggressive skin cancer.
Despite increasing prevalence and poor patient outcomes, there are no effective
chemotherapeutic treatments available for the metastatic MCC (Colunga et al., 2017). Clinical
trials exploring the use of PD-1/PD-L1 immune checkpoint inhibitors in combating metastatic
MCC have yielded promising results, but the responses are short-lived (Cassler et al., 2016;
Nghiem et al., 2016; Terheyden and Becker, 2017; Winkler et al., 2017). A substantial portion of
MCC patient population is unresponsive to these immunotherapies(Becker et al., 2017a;
D'Angelo et al., 2018; Nghiem et al., 2019; Nghiem et al., 2016; Terheyden and Becker, 2017;
Winkler et al., 2017). Furthermore, patients with immunosuppression or autoimmune disease are
not eligible for immune-based therapy. Therefore, alternative therapies are needed for patients
with advanced MCC.
MCPyV has a circular, double-stranded DNA genome of ~5kb(Feng et al., 2008; Gjoerup
and Chang, 2010). A non-coding regulatory region containing the viral origin of replication and
bidirectional promoters divides the genome into early and late regions(Gjoerup and Chang, 2010;
Harrison et al., 2011a; Kwun et al., 2009b). The early region encodes large T (LT), small T (sT),
the 57kT antigen, and ALTO(Carter et al., 2013; Gjoerup and Chang, 2010; Shuda et al., 2008).
The late region encodes the capsid proteins, VP1 and VP2 (Schowalter and Buck, 2013;
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Schowalter et al., 2011; Schowalter et al., 2012). Expression of the early and late genes is driven
by the early and late promoters, respectively.
In more than 80% of MCCs, MCPyV genome is clonally integrated into the tumor cell
genome(Feng et al., 2008; Harms et al., 2018). That MCPyV-positive MCC tumors exhibit
monoclonal integrations conserved between primary and metastatic tumors suggests that viral
integration initiates MCC oncogenic progression (Feng et al., 2008). MCPyV integration typically
results in tumor-specific truncation mutations that preserve expression of sT and the N-terminal
half of LT (LTT)(Feng et al., 2008; Shuda et al., 2008). Tumor-associated LTT retains the wildtype RB inhibiting motif, which sequestrates and inactivates this tumor suppressor, and loses its
C-terminal helicase domain that can induce DNA damage responses including p53
activation(Borchert et al., 2014; Houben et al., 2012; Li et al., 2013; Sastre-Garau et al., 2009;
Shuda et al., 2008).
Compared to MCPyV-negative tumors, MCPyV-positive MCCs harbor very few somatic
mutations(Goh et al., 2016; Harms et al., 2015), suggesting that the viral oncogenes play critical
roles in driving tumor development. Indeed, MCPyV-positive MCC cells are addicted to sT/LTT
oncogenes and require their continued expression from the integrated viral genome to survive
(Grundhoff and Fischer, 2015; Houben et al., 2010; Shuda et al., 2014; Shuda et al., 2011;
Spurgeon and Lambert, 2013; Verhaegen et al., 2014a; Wendzicki et al., 2015). Knockdown of
sT/LTT induces growth arrest and cell death in all MCPyV-positive MCC cell lines tested (Houben
et al., 2010; Shuda et al., 2014), and leads to tumor regression in xeno-transplantation models
(Houben et al., 2012). These findings suggest that MCPyV-positive and MCPyV-negative MCCs
are supported by distinct oncogenic mechanisms and may require different treatment strategies.
Also, compared to MCPyV-negative MCCs and other cancers that have high mutational burdens,
MCPyV-positive MCCs likely have a narrower range of specific therapeutic targets. Therefore,
identifying the correct combination of oncogenic factors to target could be a viable strategy to
combat these virus-driven cancers.
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In this study, we screened the compounds in the National Cancer Institute (NCI) Nature
Products Set IV library and discovered that a natural product, glaucarubin, could specifically
reduce viability of MCPyV-positive MCC cells with wild type p53 status, but spare most of the
MCPyV-negative MCC cells and healthy human skin cells. We also found that highly expressed
antiapoptotic BCL-2 allows a small percentage of MCPyV-positive MCC to survive glaucarubin
treatment. Combined treatment of these cells with glaucarubin and the FDA-approved BCL-2
inhibitor ABT-199 completely inhibits the proliferation of this subpopulation of cancer cells. The
results discussed herein support a novel therapeutic strategy for MCPyV-positive MCCs and may
also have potential for treating other human cancers with wild type p53 status and robust BCL-2
expression.
3.3 – Results
3.3.1 – Identification of a natural product—glaucarubin—that can specifically inhibit the growth of
MCPyV-positive MCC MKL-1 cells
To identify candidate molecules with the potential to kill MCC cells, we performed cell
cytotoxicity screening of the chemical compounds in the Natural Product Set IV provided by the
Developmental Therapeutics Program (DTP) of National Cancer Institute. This library contains
419 compounds isolated from natural products frequently consumed by humans. We used the
MCPyV-positive MCC cell line called MKL-1 as the archetype for the screen. Primary human
dermal fibroblasts (HDFs) isolated from neonatal foreskins served as a measure for potential
toxicity to normally dividing cells.
From this screen, we discovered that one of the natural product-derived compounds,
glaucarubin, could effectively kill MKL-1 with an EC50 of 149 nM (Fig. 3.1). Glaucarubin has a
much lower efficacy in killing MCPyV-negative MCC cells. The EC50 of glaucarubin for MCPyVnegative MCC cell lines, including UISO, MCC13, and MCC26, are about 30-, 83-, and 70-fold
higher, respectively, compared to MKL-1 cells (Fig. 3.1B and 3.1C). When HDFs were treated
with glaucarubin, we detected more than 1000-fold higher EC50 compared to the value obtained
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from MKL-1 cells (Fig. 3.1B and 3.1C). This result suggests that glaucarubin can kill MCPyVpositive MCC cells in concentration ranges that are non-toxic to healthy HDFs. Interestingly, the
deleterious effect of glaucarubin appeared to be specific for MCPyV-positive MCC cells as all of
the MCPyV-negative MCC cells were nearly as resistant to glaucarubin as healthy HDFs (Fig.
3.1B and 3.1C). The fact that both non-viral MCCs and HDFs required much higher
concentrations of glaucarubin to achieve the same loss of viability as MKL-1 cells suggests that
glaucarubin activates a cell death pathway that is only present in MCPyV-positive MKL-1 cells.
Notably, ~20% of MKL-1 cells remained viable, even at the highest glaucarubin concentration
tested (Fig. 3.1B), implying that this subpopulation was or became resistant.
3.3.2 – Analysis of glaucarubin derivatives for the potency in inhibiting the growth of MCPyVpositive MCC cells
To explore the mechanism of action for the glaucarubin cytotoxic effect on MCPyVpositive MKL-1 cells, we sought to determine whether several glaucarubin-related compounds
were also toxic to MKL-1 cells (Fig. 3.2). We compared the capacity of these compounds to inhibit
the growth of MCPyV-positive MKL-1 cells and normal HDFs. We also collated the proliferation
data with the respective chemical structures of these compounds in order to identify the chemical
moieties essential for the activity in killing MKL-1 cells. Two of the compounds tested, Chaparrin
and Glaucarubol, showed 978- and 1230-fold higher EC50 value on MKL-1 cells, respectively (Fig.
3.2). Since these compounds lack the ester-linked moiety featured on the lactone of glaucarubin,
we reasoned that this side-chain is important for the deleterious function of glaucarubin observed
in MKL-1 cells (Fig. 3.2B). In support of this hypothesis, glaucarubinone, which contains the same
ester-linked domain as glaucarubin, showed the strongest potency in killing MKL-1 cells with an
EC50 of 4 nM, which is 40-fold lower than the EC50 of Glaucarubin on MKL-1 cells (Fig. 3.2).
However, compared to glaucarubin, glaucarubinone also has a much lower EC50 (166 nM) for
HDFs, suggesting that it is too toxic to be a good candidate for drug development. Since
glaucarubin was the only compound that greatly hampered MKL-1 viability, but not HDFs, we
proceeded with this original candidate for functional analysis.
60

3.3.3 – Protein array characterization of cellular genes targeted by glaucarubin
To explore possible explanations for the discrepancy between MKL-1 and HDF sensitivity
to glaucarubin, and to identify targetable cellular factors underlying its mechanism of action, we
sought a curatable proteomics approach. Reverse phase protein microarray (RPPA) enabled us
to probe glaucarubin-induced changes in abundance of antigens with documented functions in
cancer development and progression (Fig. 3.3, Appendix: Supplementary Table 1). We treated
MKL-1 and HDFs with 1 µM or 10 µM of glaucarubin dissolved in DMSO or DMSO alone in
duplicate. We harvested lysates from these samples at 24 hours post treatment; prior to the onset
of significant cell death in MKL-1 cells at the concentrations tested. RPPA plates were probed
with stringently validated antibodies to over 300 cancer-related protein targets (Appendix:
Supplementary Table 1). Antigens abundant in MKL-1 cells that experienced the greatest shift
upon glaucarubin-treatment relative to that in HDFs included key factors in DNA damage
responses and apoptosis (Fig. 3.3). H2A.X, a marker of DNA double strand breaks and repair, is
significantly elevated in MKL-1 cells, but not in HDFs, after treatment with glaucarubin, (Fig. 3.3).
Two anti-apoptotic BCL-2 family proteins, BCL-2 and MCL-1(Kale et al., 2018), are also
differentially expressed in MKL-1 cells in presence of glaucarubin, but are maintained at a low
level in HDFs in each condition tested (Fig. 3.3). While both genes have relatively high basal
expression in MKL-1 cells, increasing glaucarubin concentration further increases BCL-2 level
while reducing MCL-1 level (Fig. 3.3). Previous studies have shown that pro-survival BCL-2 and
MCL-1 are highly expressed in up to 85% and 88% of MCCs, respectively(Brunner et al., 2008;
Feinmesser et al., 1999; Kennedy et al., 1996; Sahi et al., 2012). Between these two genes, BCL2 plays a particularly important role in oncogenesis by inhibiting apoptosis(Kennedy et al., 1996).
High BCL-2 expression has been shown to support better growth and survival of MCC
(Schlagbauer-Wadl et al., 2000; Verhaegen et al., 2014b). In the context of these previous
studies, our findings suggest that glaucarubin may trigger DNA damage-induced apoptosis in
MKL-1 cells, yet further stimulation of BCL-2 levels by glaucarubin may contribute to the
resistance observed in ~20% of the cells surviving the treatment (Fig. 3.1B).
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3.3.4 – Glaucarubin induces cell death in MCPyV-positive MCC via activation of the p53 pathway
To test the hypothesis that glaucarubin kills MCPyV-positive MCC cells by stimulating
DNA damage-induced cell death response, we first validated our RPPA results in MKL-1 cells
treated with glaucarubin via western blot (Fig. 3.4A). Indeed, H2A.X level was elevated in MKL-1
cells 24 hours after treatment with either 1 µM or 10 µM glaucarubin and remained elevated 72
hours post treatment, indicating that DNA damage is induced in these cells. Glaucarubin
treatment does not increase the H2A.X level in HDFs, which also corroborated our protein array
data (Fig. 3.4B). The lack of H2A.X accumulation in glaucarubin-treated HDFs may be because
these cells are able to quickly repair any DNA insults induced by the compound.
Next, we determined whether glaucarubin treatment induces DNA damage in other
MCPyV-positive cell types. Glaucarubin treatment resulted in accumulation of H2A.X in MCPyVpositive MCC MKL-2 cells, but failed to do so in another MCPyV-positive MCC cell line, MS-1,
over the course of the 48-hour treatment (Fig. 3.4B). MS-1 cells do not accumulate H2A.X after
glaucarubin treatment, likely because they overexpress inactive p53(Park et al., 2019), which in
the presence of low-level, persistent DNA damage, could prevent cell cycle arrest and eventual
H2A.X accumulation via caspase-mediated chromosomal degradation. MCPyV-negative MCC
cell lines MCC13, MCC26, and UISO also do not accumulate H2A.X in the presence of
glaucarubin (Fig. 3.4B). That the presence or absence of H2A.X accumulation with glaucarubin
treatment correlated with susceptibility or resistance to the drug toxicity with respect to different
MCC cell lines (Fig. 3.1C) suggests that glaucarubin induces cell death in MKL-1 cells by
inducing DNA damage and downstream signaling pathways.
To examine whether canonical events downstream of DNA damage occurred specifically
in MKL-1 cells, we analyzed the p53 activation status and poly (ADP-ribose) polymerase (PARP1) cleavage in each cell type in the presence of glaucarubin. Western blotting analysis showed
that p53 serine 15 phosphorylation, a marker for activated p53, is dramatically induced in
glaucarubin-treated MKL-1 cells where robust H2A.X accumulation is observed (Fig. 3.4A).
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Significant PARP-1 cleavage, representing late-stage apoptotic progression, also became evident
48 hours post-treatment. The MCC cell lines that were resistant to glaucarubin toxicity did not
exhibit PARP-1 cleavage, nor phosphorylation of p53 at serine 15 with the exception of MS-1,
which overexpresses inactive p53 (Fig. 3.4B-3.4C). Compared to MKL-1, glaucarubin-treated
MKL-2 cells had a lower degree of PARP-1 cleavage, which could potentially be attributed to an
undetectable level of activated p53 present in these cells. These results suggest that the
mechanism of action of glaucarubin in MKL-1 cells involves stimulation of DNA damage, p53
activation, and apoptosis (Fig. 3.4D).
3.3.5 – BCL-2 function supports the resistance of MCPyV-positive MCC cells to glaucarubin
killing
In MKL-1 cells treated with glaucarubin, we consistently observed that nearly 20% of the
cells remained alive even after treatment with very high concentration of glaucarubin (Fig. 3.1B,
and data not shown). From the protein array analysis, we discovered that antiapoptotic proteins
BCL-2 and MCL-1 are highly expressed in MKL-1 cells compared to HDFs (Fig. 3.3). After
glaucarubin treatment, MCL1 level was dramatically reduced in MKL-1 cells, but BCL-2 level was
further elevated (Fig. 3.3). These observations suggest that robust BCL-2 expression may allow
some of the MKL-1 cells to escape glaucarubin killing (Fig. 3.1B). To examine this possibility and
validate the protein array observations, we performed western blotting analysis of BCL-2 and
MCL-1 in MKL-1 cells treated with increasing doses of glaucarubin. Confirming the finding from
the protein array, MCL-1 diminished after glaucarubin treatment, while BCL-2 level remained
elevated (Fig. 3.5A). Both MCL-1 and BCL-2 expression in the other MCPyV-positive MCC cell
lines, MKL-2 and MS-1, remained unaltered by glaucarubin treatment, further implying that they
are resistant to the same cell death mechanism exhibited in MKL-1 cells (Fig. 3.5B). HDFs and
the MCPyV-negative MCC cell lines, MCC13, MCC26, do not express a detectable level of BCL2. The only MCPyV-negative MCC cell line that shows robust BCL2 expression is UISO, which
also maintains unchanged BCL-2 levels upon glaucarubin treatment. This result suggested that
downregulation of MCL-1 is an indicator and possible effector of glaucarubin killing in MKL-1
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cells, but high BCL-2 expression in MCPyV-positive cells likely supports survival after glaucarubin
treatment.
3.3.6 – Combined treatment of an FDA-approved BCL-2 inhibitor and glaucarubin leads to
complete killing of MCPyV-positive MCC cells
Given that glaucarubin readily induces DNA damage in p53 wild-type MCPyV-positive
MCCs, but failed to inhibit BCL-2 in any of the cell types tested, we reasoned that BCL-2 activity
in MKL-1 cells could confer resistance to complete loss of viability after glaucarubin treatment.
Thus, we tested whether combination of glaucarubin and the FDA-approved BCL-2 inhibitor,
ABT-199, could circumvent resistance in those MCC cells (Fig. 3.6A). As expected, neither
glaucarubin nor ABT-199 alone was sufficient to kill all MKL-1 or MKL-2 cells. Compared to MKL1 cells, MKL-2 was more resistant to glaucarubin treatment alone, as could be predicted by its
lower levels of PARP-1 cleavage and unaffected MCL-1 levels after glaucarubin treatment. In
combination, however, glaucarubin and ABT-199 efficacy was greatly increased in both cell lines,
with apparent synergism in MKL-2 cells (Fig. 3.6A). MS-1 cells, which lack a DNA damage
phenotype upon glaucarubin treatment (Fig. 3.4-3.5), remained unaffected when only treated with
glaucarubin. BCL-2 inhibition alone or in combination with glaucarubin also had a minor impact on
MS-1 viability, likely because these cells do not express a high level of BCL-2 (Fig. 3.5). Viability
of normal primary HDFs was not impacted by any of the treatments (Fig. 3.6A), which is
consistent with our earlier observations that no H2A.X accumulation is observed in these cells
after glaucarubin treatment and that there is no detectable level of BCL-2 expressed in these cells
(Fig. 3.5B).
3.4 – Discussion
Currently there are no effective chemotherapeutic strategies for combating metastatic
MCCs. The recently developed PD-1/PD-L1 immune checkpoint inhibitors have demonstrated
promising results but, in many cases, the responses are temporary(Baker et al., 2018; Becker et
al., 2017a; Harms et al., 2018; Nghiem et al., 2016; Terheyden and Becker, 2017). Moreover,
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immune-checkpoint therapies are not suitable for organ transplant recipients requiring
immunosuppressants or patients with either immunosuppressive or autoimmune diseases.
Therefore, alternative therapeutics are needed for treating advanced-stage MCCs.
In this study, we performed compound screening and identified the natural product
glaucarubin as a potent inhibitor that can specifically repress the growth of MCPyV-positive MCC
cells MKL-1. Glaucarubin is a crystalline glycoside extracted from the tropical plant Simarouba
glauca(Van Assendelft et al., 1956). We discovered that glaucarubin could specifically inhibit the
growth of MCPyV-positive MKL-1 cells at low concentrations (EC50= 149 nM) without introducing
much toxocity for MCPyV-negative MCC and healty skin cells, even at very high concentrations
(EC50 ranges from 4.48 to 157 µM).
To search for possible molecular mechanisms underlying glaucarubin cytotoxicity
observed in MKL-1 cells, we performed protein array analysis of putative oncogenes, tumor
suppressors, and metastatic factors in normal healthy HDFs and MKL-1 cells after glaucarubin
treatment. We found that H2A.X is one of the most greatly increased antigens in MKL-1 cells
after glaucarubin treatment, but remained unchanged in HDFs in the same conditions (Fig. 3.3
and 3.4). We found that MKL-1-specific H2A.X induction correlates with induction of a wellcharacterized anti-cancer, cell death effector pathway, involving p53 activation and PARP-1
cleavage (Fig. 3.4A).
Analysis of MCPyV-positive and -negative MCC cell lines demonstrated that the
antiproliferative activity of glaucarubin hinges on its ability to induce H2A.X as well as the status
of p53 expressed in the treated cells (Fig. 3.4). For example, MCPyV-positive MKL-1 cells, which
accumulate H2A.X after glaucarubin treatment and also express wild type p53, are highly
responsive to glaucarubin killing. Glaucarubin treatment induces similar amount of H2A.X
accumulation in another MCPyV-positive MCC cell line, MKL-2, but does not kill these cells with
high efficacy (Fig. 3.6A). This is likely because MKL-2 cells do not express detectable level of p53
(Houben et al., 2013) and consequently had a lower degree of PARP-1 cleavage after
glaucarubin treatment (Fig. 3.4B). On the other hand, normal HDFs, MCPyV-positive MCC MS-1
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cells, and MCPyV-negative MCC13, MCC26, and UISO cells, all of which do not show
accumulation of H2A.X upon glaucarubin treatment, are consistently resistant to glaucarubin
(Fig. 3.1C). In these cells, glaucarubin either does not induce DNA damage, or it induces a level
of DNA damage that can be repaired or tolerated.
Although glaucarubin is effective in killing MCPyV-positive MKL-1 cells, nearly 20% of the
cells remain viable even after treatment with as high as 0.1 mM of glaucarubin. RPPA analysis
showed that two antiapoptotic regulators, BCL-2 and MCL-1, are highly expressed in MKL-1 cells
(Fig. 3.3). These two proteins inhibit apoptosis, in part, by blocking p53-induced cell death(Chiou
et al., 1994; Jiang and Milner, 2003; Zhou et al., 1997). Activated p53 can circumvent
antiapoptotic activity by upregulating several proapoptotic genes such as BAX, Noxa, BID, and
PUMA(Miyashita and Reed, 1995; Oda et al., 2000; Sax et al., 2002; Yu et al., 2003), all of which
can directly or indirectly down regulate BCL-2 and MCL-1 function(Croce and Reed, 2016;
Hemann and Lowe, 2006; Huskey et al., 2015; Leu et al., 2004). In addition, p53 can directly
repress transcription of BCL-2 and MCL-1(Hemann and Lowe, 2006; Miyashita et al., 1994a;
Miyashita et al., 1994b; Pietrzak and Puzianowska-Kuznicka, 2008) (Fig. 3.6B). Both RPPA and
western blotting analysis revealed that MCL-1 is one of the antigens most significantly decreased
after glaucarubin treatment of MKL-1 cells (Fig. 3.3 and 3.5), suggesting that glaucarubin-induced
p53 activity could suppress MCL-1 expression, thereby contributing to the cell death phenotype
we observed in MKL-1 cells (Fig. 3.1 and 3.6B). In contrast, the level of BCL-2 remains elevated
after MKL-1 cells were treated with glaucarubin (Fig. 3.3 and 3.5), indicating that activated p53 is
not able to repress BCL-2 level in these cells (Fig. 3.6B). This finding also suggests that
persistent BCL-2 expression in MKL-1 cells might enable escape from p53-mediated apoptosis.
Constitutive BCL-2 expression could then contribute to the residual viability of glaucarubin-treated
MKL-1 cells we observed in Fig. 3.1B and Fig. 3.6A. Previous efforts and our observations
suggest that combination of DNA damage-induced p53 activation and BCL-2 inhibition could
achieve effective killing of BCL-2-high, p53-positive MCC (Fig. 3.6B). Indeed, dual treatment of
glaucarubin and BCL-2 inhibitor ABT-199 resulted in nearly complete killing of MKL-1 cells (Fig.
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3.6A). Another MCPyV-positive MCC cell line, MKL-2, which exhibits high BCL-2 expression as
well as glaucarubin-induced H2A.X, was also effectively killed by glaucarubin and ABT-199 dual
treatment. In contrast, combined treatment was well tolerated in cell types in which these two
molecular signatures are not detected, as in MS-1 and HDFs (Fig. 3.6A).
Notably, MCPyV-positive MCCs usually carry wild-type p53, whereas MCPyV-negative
MCCs tend to contain p53-inactivating mutations(Park et al., 2019). The truncated forms of LT
expressed from MCPyV genome integrated into MCC genome can indirectly activate p53 via RB
inhibition(Park et al., 2019). Wild-type p53 that is constitutively activated by LTT in MCPyVpositive MCCs could underlie their sensitivity to glaucarubin-mediated DNA damage. By
comparison, tight regulation and low basal expression of p53 in normal HDFs, and inactivating
mutations of p53 in MCPyV-negative MCCs might explain their relative resistance to glaucarubin.
These observations, and the fact that the majority of MCCs maintain high BCL-2 expression
suggest that combining p53 activation using DNA damage inducing agent, such as glaucarubin,
with BCL-2 inhibitors is an effective strategy for treating MCPyV-positive MCCs.
Glaucarubin has been used as herbal medicine for treating intestinal amoebiasis for more
than six decades (Cuckler et al., 1958; Del Pozo and Alcaraz, 1956; Van Assendelft et al., 1956).
In addition, ABT-199 is an FDA-approved anti-cancer drug. The clinically documented safety of
glaucarubin and ABT-199 in humans highlight their potential for rapid translation towards clinical
application of the dual treatment for curing other cancers expressing wild type p53 and a high
level of BCL-2.
Current standard of care for initial presentation of MCC is resection of tissue at the
primary site, and irradiation of the resected site as well as draining lymph nodes. Given evidence
of high expression of BCL-2 in many MCCs, and its potential as an escape mechanism from
DNA-damage mediated cell death, it would seem that BCL-2 inhibition may be best applied in
combination with existing radiation treatments at first diagnosis. MCPyV-positivity and p53 status
can also be determined from primary tumor biopsies with relative ease and are likely predictors of
the success of this combination. The great challenge of treating late-stage cancers with diverse
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mutational backgrounds lends credence to an aggressive treatment strategy of the primary tumor.
ABT-199 treatment with radiation of the primary tumor and lymph nodes could prove effective at
eliminating MCPyV-positive MCCs that would otherwise produce chemotherapeutically resistant
metastases.
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3.5 – Chapter 3 Figures

Figure 3.1

A

B

C

Figure 3.1) Natural product Glaucarubin specifically inhibits the growth of MCPyV-positive
MCC MKL-1 cells. A) Chemical structure of glaucarubin, a compound from the NCI Natural
Product Set IV plate of identified to be toxic in MKL-1 MCC cells. (B) Assay of cell viability in the
MCPyV-positive MCC cell line MKL-1; MCPyV-negative MCC cell lines UISO, MCC13, and
MCC26; and primary HDFs subjected to the indicated concentrations for 3 days at 37C in 5% CO2.
Cell viabilities were measured by cellTiter-GLO 3D cell viability assay (Promega). The growth
curves were generated using GraphPad Prism software. (C) EC50 (μM) concentrations of
glaucarubin for MCCs and HDF cells.
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Figure 3.2
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Figure 3.2) Glaucarubin derivatives inhibit the growth of MCC and HDF cells. A) Cell viability
assay of MCPyV-positive MCC cell line MKL-1 (blue) and HDFs (red) treated with the indicated
concentrations of glaucarubin analogs 72 hours post treatment. B) Table highlighting the EC50s of
each compound from (A) in MKL-1 and HDF cells. Molecular structures of each compound are
included for the purpose of relating features of the compounds to phenotypes in cells. For example,
the ester-linked moiety featured on the lactone of glaucarubin (circled with a green dotted line)
appears necessary for the cytotoxicity in MKL-1 cells, while the hydroxyl group (circled with an
orange dotted line) results in less cytotoxicity in HDFs than a carbonyl group at the same position.
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Figure 3.3

Figure 3.3) Protein array identification of glaucarubin-affected genes. HDFs and MKL-1 cells
were treated with DMSO or glaucarubin at the indicated concentrations. Duplicate cell lysates were
harvested at 24 hours post treatment for each condition and subjected to RPPA analysis. The linear
signal of each slide was normalized to actin for that same sample. Antigens that had a linear
expression level greater than 2 for at least one of the conditions in MKL-1 cells were analyzed.
Antigens increased or decreased in abundance after glaucarubin treatment were ranked in order
of their greatest abundance change relative to that in HDFs. The six antigens with the greatest
increase and decrease are visualized in the heat map. Heat map relative abundance scores are a
visualization of actin-normalized, Log 2, median-centered signal for each sample.

71

Figure 3.4
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Figure 3.4) The mechanism for glaucarubin-induced cell death in MCPyV-positive MCC cells.
A) MKL-1 cells were treated with DMSO or glaucarubin dissolved in DMSO for final concentrations
equaling 1 µM or 10µM respectively. At 24, 48 and 72 hours, total cell lysates were harvested and
immunoblotted with the indicated antibodies. ACTIN was used as a loading control. B) Lysates from
MCPyV-positive cell lines MKL-1, MKL-2, and MS-1, as well as HDFs were treated with 1 µM of
glaucarubin dissolved in DMSO or DMSO alone for 48 hours and harvested for immunoblot
analysis. C) Same as in (B) except with MCPyV-negative cell lines MCC-13, MCC-26, and UISO.
D) Proposed working schematic of effects induced by glaucarubin in MKL-1 cells leading to loss of
cell viability.
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Figure 3.5
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Figure 3.5: Glaucarubin does not affect BCL-2 expression. A) MKL-1 cells were treated with
DMSO or glaucarubin dissolved in DMSO for final concentrations of 1 µM or 10 µM respectively.
Total cell lysates were harvested after 24, 48, and 72-hour treatments and analyzed by western
blotting using the indicated antibodies. B) Western blot of total cell lysates from MCPyV-positive
MCC cell lines MKL-1, MKL-2, MS-1, and primary HDFs treated with DMSO or glaucarubin
dissolved in DMSO for a final concentration of 1 µM for 72 hours. C) Similar data as shown in (B)
except with total cell lysates from MCPyV-negative MCC cells MCC13, MCC26, and UISO.
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Figure 3.6
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Figure 3.6) Targeting BCL2 function using an FDA approved inhibitor to achieve better
killing of MCC cells. A) Cell viability assay of MCPyV-positive MCC cell lines MKL-1 (blue), MKL2 (orange), and MS-1 (gray); and primary HDFs (red) treated with DMSO or the indicated
concentrations of glaucarubin, ABT-199, or both for 72 hours at 37C in 5% CO2. Asterix (*) signify
the number of standard deviations from the mean. B) Proposed working schematic of effects
induced by glaucarubin in MCPyV-positive MCC cell lines with wild-type p53 (MKL-1 and MKL-2)
leading to loss of cell viability. The red cross indicates that MCCs can develop resistance to this
cell death pathway by failing to repress BCL-2. Inhibition of BCL-2 by ABT-199 can circumvent this
resistance mechanism.
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CHAPTER 4: Analysis of Mass Spectrometry Datasets to Identify
Research Directions Regarding the Cellular Response to MCPyV
Infection
4:1 – Introduction and Rationale
Prior to the start of my thesis research, the members of the You Laboratory discovered
that HDFs were capable of supporting MCPyV infection and established a model infection system
with which it was possible to observe the impacts of each phase of the viral infection cycle (Liu et
al., 2016b). Using this model system, we aimed to take steps in understanding the cellular
response to MCPyV infection. Initially, we took cues from existing literature and determined
whether some of the best-studied anti-viral cellular programs were activated during MCPyV
infection (Chapter 2). Indeed, MCPyV activity highly induces the expression of ISGs and
inflammatory cytokines. We found that the canonical cGAS-STING pathway was responsible for
detection of MCPyV infection and mediation of the host response, while the amplification of
inflammatory cytokines was helped by NF-κB activity (Krump et al., 2021). This line of
experimentation uncovered important questions regarding what is unique about cellular
responses to MCPyV infection such as the potential roles of IFI16 at replication centers and in
determining cell fate. Looking forward, we aim to explore the biology of MCPyV more deeply, in a
manner that does not originate from existing literature of host responses to other viruses. Since
little is known about MCPyV infection, an unbiased sampling of its impacts has the potential to
reveal aspects of biology that would be completely unexpected based on existing dogma.
High-throughput techniques such as RNAseq provide a number of advantages when
exploring arrays of gene sets between experimental and control conditions. Principal among
these is the ability to derive quantitative data regarding individual genes across experimental and
control conditions in order to perform gene set enrichment analyses. However, such approaches
can still be limited by the size and selection of the cDNA library. Mass spectrometry (mass spec),
though less sensitive and not quantitative, can be used to identify the presence of any known
members of the human proteome. Furthermore, because mass spec probes samples at the level
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of proteins and their post-translational modifications—the state at which most genes perform their
biological function—the results may have more biological relevance than assaying RNA.
Often times, the unbiased approach of mass spec is followed by a gene ontology (GO)
analysis in order to interpret the large datasets of detected gene products. GO analyses involve
annotating the experimentally identified genes with GO terms that describe their molecular
function, biological process, or a cellular component based on previous findings in the literature.
The hits in the experimental condition are then compared to a background library of GO termannotated genes and statistically determined whether GO-term descriptors are enriched in the
condition of interest. GO term libraries used to annotate genes provide a helpful guide to what
would otherwise be an inscrutable amount of data, yet they are subject to bias introduced by
curation. The statistical component of GO analyses themselves are also limited by the information
that they take into account being the frequency and hierarchy of GO terms in the experimental
condition relative to GO terms in the background library. For this reason, GO analyses results do
not necessarily highlight specific genes detected by the mass spec that would be of interest for
future study.
In the present chapter, I describe a method using the R coding language and publicly
available R packages to explore data from a mass spec experiment by combining GO analysis
with raw data from multiple sampling and additional publicly available gene metadata. The goal of
this study is to limit the introduction of bias in our analysis of mass spec data and to link potential
changes in gene expression profiles with associated genes. I visualize these results in a manner
intended to inspire hypotheses for future study. Ideally, the output of these analyses and
visualizations would be used by researchers to perform targeted validation experiments and more
quantitative assays. Herein, I examine changes to HDFs infected with MCPyV. The analysis
revealed sets of enriched GO terms linked to differentially detected genes between MCPyVinfected and control conditions with the potential to guide exploration of the anti-viral response,
cell surface signaling, cell morphology, and cell fate.
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4:2 – Combining GO Analysis Results with Differentially Detected Gene Information
We performed a mass spec analysis of supernatant and cell pellet samples from MCPyV
infection and control conditions (Fig 4.1). In order to interpret the results from the mass spec, I
performed a GO term enrichment analysis using the GOfuncR package developed as part of
Bioconductor. To provide the necessary inputs for the analysis, I first defined the set of candidate
hits as those genes that were present in the MCPyV infected samples. I then designated a
background library of genes to include every gene detected across all replicates of a given
sample type rather than the entirety of the human proteome. In doing so, the results are less
likely to be skewed by cell type and method of protein extraction or isolation. Next, I annotated
the gene accession numbers in each data frame with GO terms from the Gene Ontology
Consortium. By assigning input lists of GO terms belonging to candidate genes and those
encompassing genes detected across each condition, the GOfuncR package is able to calculate
GO term enrichment.
The results from the GOfuncR GO analysis included a list of potentially enriched GO
terms with raw-p-values and family-wise error rates (FWERs) that correct for multiple
comparisons. The FWER correction, however, resulted in very few significant results as it
sacrifices power to detect true-positives in order to prevent the presence of false-positives. Other
approaches that calculate the false discovery rate (FDR) had similar results (data not shown). On
the other hand, the raw p-values for GO term enrichment contain potentially valuable information,
yet if these hits were to be taken at face value without statistical correction, there would be a high
risk of pursuing a false positive. Performing follow-up experimental validation of these false
positives, or committing a type-1 errors, would waste valuable time and resources; defeating the
purpose of this study. As such, I aimed to pull out GO terms with likely biological significance
even though conventional statistical analysis of the GO enrichment revealed few experimentally
tractable terms of significance.
Closer examination of the candidate and background gene sets reveal that while limiting
the background library to detected genes prevents sampling bias, the smaller set of possible hits
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reduces power to detect true positives. For example, more than half of the genes detected in
across both conditions in supernatant were present in the MCPyV-infected condition and are
therefore classified as candidates (Fig. 4.2A). The high proportion of candidate to background
genes make it difficult to achieve sufficient statistical power when correcting for multiple
comparisons. Since selecting GO terms of interest based on raw-p-values alone would result in a
high possibility of type-1 error, I sought to incorporate additional information from the mass spec
that is not taken into account by the GO analysis.
Though an essential tool in proteomics, mass spec is not as sensitive as modern nucleic
acid sequencing techniques, and can require a billion copies of a given protein to achieve
detection (Timp and Timp, 2020). In practice, this means that our experimental and control
samples, run in triplicate, can result in a list of hits that overlap, but differ significantly between
runs. I used the information from multiple sampling to define a subset of gene hits that were
differentially detected in either the MCPyV infection or control condition (Fig. 4.2A-B). To do this, I
set a cutoff of a difference of 2 or greater in the number of times a hit appeared in a condition.
This ad-hoc method provides a measure of certainty that a given hit is relevant to a condition. By
attributing more weight to these hits in my analysis, it may be possible to determine which GO
terms are truly enriched or underrepresented in the MCPyV-infected condition.
I then linked differentially detected gene hits with their associated GO terms and the
significant terms resulting from the GO analysis (Fig. 4.1). This allowed me to visualize and
explore significant GO terms associated with a high number of differentially detected genes (Fig.
4.3-4.9). For example, GO terms with raw p-values less than 0.05 can be filtered out if they are
not associated with genes that are differentially detected in—or unique to—that condition (Fig.
4.3). Highlighting statistically significant GO terms associated with unique candidate genes and
differentially detected genes on bar plots or network graphs can provide researchers with a
direction from the GO analysis where there was none previously (Fig 4.4-4.9). In connecting the
raw GO analysis results with gene hit data from multiple sampling I aim to 1) reduce the likelihood
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of type-1 error and 2) facilitate identification of potentially enriched genes for downstream
validation.
Some differentially detected genes may have relevant information that is missed in GO
analysis. This is because some of these genes lack GO term classifications, and others are
attributed to GO terms that were not significant in the GO analysis. To make it possible to explore
these genes, I made a searchable table of those differentially detected gene hits that were not
linked to significant GO terms (Appendix – R code – package DT). The intention behind this table
is that a user interested in a gene set from the network visualizations can search for additional
related genes.
4:3 – Exploration and Visualization of Mass Spectrometry Results
Statistically significant GO terms (p-value > 0.05) associated with a high number of
differentially detected genes can direct our attention to relevant biological processes and
molecular functions with gene sets that can be validated by quantitative methods (Fig. 4.3-4.9,
Appendix: R Code). Encouragingly, many of the resultant GO term-gene groupings confirm the
experimental design and our existing understanding of MCPyV infection. For example, biological
processes related to viral infection and immune responses were both overrepresented and
underrepresented in the MCPyV infection condition (Fig. 4.4, 4.6, 4.8-4.9). Their significant overand underrepresentation may reflect the antagonistic relationship between MCPyV and the host
cell, as well as, the fact that these factors can have positive or negative regulatory impacts.
Genes attributed to viral processes that were specific in MCPyV infection include bromodomain
protein 4 (BRD4) which interacts with LT and positively regulates MCPyV replication (Wang et al.,
2012), and F-box and WD repeat domain-containing (FBXW7) which has been reported to
interact with MCPyV sT and is the subject of active debate in MCPyV research field (Dye et al.,
2019; Kwun et al., 2017; Nwogu et al., 2020a; Nwogu et al., 2020b) (Fig 4.9A).
Surprisingly, the analysis did not reveal a specific GO term enrichment of interferon
stimulated genes in MCPyV infection. We know from our previous work that ISGs and
inflammatory cytokines are dramatically upregulated by MCPyV infection (Chapter 2, Fig 2.1)
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(Krump et al., 2021). Closer inspection of differentially detected genes that were not attributed to
significant GO terms (Appendix) shows that some ISG-related proteins were detected more
frequently in MCPyV infection such as IFNA13, IFI27, and IFITM10. However, significant
numbers of ISGs would have to have been specifically detected in MCPyV infection for an ISGrelated GO term to be defined as significant. Indeed, this underscores the relatively low sensitivity
of mass spec, and need to find relationships between sets of genes to explore phenomena more
quantitatively.
One of the outstanding questions in my initial exploration of the innate immune response
to MCPyV infection was whether the intrinsic cellular response impacted interactions with innate
immune cells like macrophages. The mass spec analysis revealed that HLA class-I alpha chain
A, B, and E of the MHC receptor were each detected in 2 out of 3 of MCPyV infection supernatant
samples and in none of the control samples (Fig 4.8, 4.9, Appendix: R Code). This result provides
impetus to perform a quantitative analysis of functional MHC complexes in MCPyV infection. If
HDFs form MCPyV-specific MHC tetramers it would signify their ability to coordinate with innate
immune cells and could usher future co-culture experiments.
MCPyV infection made apparent changes to cell division and transcription, which are
consistent with the role of viruses to co-opt cellular machinery to enhance viral production (Fig.
4.8). Among these changes are possible positive regulation of transcription factors related to Bcell differentiation (Fig. 4.9). It is argued that original cell of MCC is that of pro/pre-B cells present
in the dermis based on transcription factors and B-cell markers (Sauer et al., 2017a; Sauer et al.,
2017b; Zur Hausen et al., 2013). Another possibility is that pro-proliferative activities of MCPyV
oncoproteins in the original host cell of MCC elicit transcriptional changes so that the cells gain
characteristics in common with pro/pre-B cells. The latter hypothesis could be supported if
MCPyV infection in fibroblasts drives transcriptional changes that overlap with pro/pre-B cell gene
expression programs.
The mass spec results indicate that some factors related to apoptosis are less frequently
detected in MCPyV infection (Fig. 4.6B, 4.9B). We have found previously that helicase activity of
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MCPyV LT can promote p53 mediated DNA damage responses in a manner that promotes
apoptosis (Li et al., 2015; Li et al., 2013). Exploration of both the positive and negative regulators
of apoptosis that were more frequently detected in control conditions could provide further detail
regarding cell death during MCPyV infection. In particular, I sought to understand whether IFI16 is
mediating a senescence phenotype in MCPyV infected cells. IFI16 localizes to replication MCPyV
replication centers and contributes to inflammatory cytokine induction (Chapter 2, Fig. 2.2).
Moreover, knock out of IFI16 leads to aberrant fragmentation of VP1 positive nuclei (Chapter 2,
Fig. 2.5B). Though not attributed to a GO term, IFI16 was found in 2 out of 3 control cell pellet
samples, and never in MCPyV infection (Appendix: R Code). This was unexpected since we have
found that IFI16 is slightly upregulated in MCPyV infection (Chapter 2, Fig. 2.1C). The greater
frequency of detecting IFI16 in control HDFs underlines to the need for quantitative validation
following exploration of these mass spec results. Elucidating the specific cell death pathways
engaged during MCPyV infection could provide a clearer picture of immune cell responses to
MCPyV-infected cells and the MCPyV mode of egress.
GO terms enriched in MCPyV infection reflect changes to the deposition/remodeling of
extracellular matrix and cell-cell adhesion (Fig. 4.4A, 4.7A). Some of the differentially detected
genes that could be mediating these changes include MMPs (Fig. 4.8A, 4.9A). We have
previously demonstrated that MMP expression is an important factor for enhancing MCPyV
infection (Liu et al., 2016b). Photoaging in skin as a result of years of UV exposure also increases
MMP production and extracellular matrix remodeling in the skin and increases predisposition for
carcinogenesis (Brenneisen et al., 2002; Fisher and Voorhees, 1998; Woenne et al., 2010).
These mass spec results suggest that MCPyV infection could further increase expression of
MMPs including ADAMTS12, ADAMTS8, MMP27, and MMP24 (Fig. 4.9A). In this manner, robust
MCPyV infection in the skin could exacerbate skin cancer risk indirectly of T antigen driven MCC.
4:4 – Impact and Future Implementation
The analysis of the mass spec results described above provides direction for future
research regarding the impacts of MCPyV infection. Some of the processes and factors revealed
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by the study are related to questions that have arisen in our previous research. These include
unexplored biology of MCPyV-infected cells like their interactions with innate immune cells, the
factors designating cell fate, and structural changes to their membranes and extracellular matrix.
Still other GO term-gene set groupings were unexpected and may have wide-ranging effects on
the cell including changes to ubiquitination, GTPase, and signaling receptor activity (Fig. 4.7B,
4.8B, 4.9). Moreover, the differentially detected genes in MCPyV infection or control settings can
direct future investigation to those genes that are most likely to be enriched or underrepresented
at the protein level. The abundance of these gene sets can be validated by more quantitative
methods such as RNAseq or reverse-phase protein array.
The analysis pipeline connecting differentially detected and unique genes with raw
outputs from GO analyses can be applied to address other datasets as well. In particular,
identifying GO terms of interest in this way may be a useful strategy for other small mass spec
datasets for which it can be difficult to achieve statistical power through conventional multiple GO
enrichment analyses. Furthermore, the alternative approach to achieve significance would be to
compare GO terms of candidate genes to those mapping to the entire human proteome, yet this
conflates artifacts of cell type-specific gene expression and sample preparation methods with
genuine gene enrichment. Linking genes that are unique to a condition is also a way in which to
elevate GO enrichment beyond a list of GO terms. By having a process or function of interest tied
to a set of related genes, it is easier to generate testable hypotheses from unexpected
phenomena, and transition to more quantitative and targeted techniques.
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4.5 – Chapter 4 Figures

Figure 4.1

Figure 4.1) Schematic of mass spectrometry analysis pipeline. For GO analysis genes were
defined as candidates if they were present in any of the MCPyV infection samples. All genes
detected for a given sample type were included in a background library. These two sets of candidate
and background genes were annotated with GO terms, which were used to perform GO analysis
with the GOfuncR package. Differentially detected genes were defined as genes appearing two or
more times more in either the MCPyV infected or control samples (e.g. infection to control ratios
≥+2 =[3:0, 3:1, 2:0]). Unique genes only appeared in one of the conditions and never in the other
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condition (e.g. infection to control ratios [3:0, 2:0, 1:0, 2:0]). The association of these genes with
GO terms was used to identify particular GO terms of importance for future study.
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Figure 4.2

A

B
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Figure 4.2) Bar plot proportions of genes of interest for GO analysis and differentially
detected genes. A) Gene set proportions of genes of interest from mass spec of supernatant
samples. Candidate genes were any genes that were present in the MCPyV-condition and
background library of genes consisted of all genes detected across each condition (left).
Differentially detected genes were given weight by the difference between the number of times a
given gene was detected in the MCPyV-infected sample and the number of times it was detected
in the control sample (right). B) Same as in (A) except with cell pellet lysate samples.
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Figure 4.3

Figure 4.3) Bar plot illustrating the ability to highlight raw GO term p-values with the
number of associated genes of interest. Included are GO terms with a raw p-value<0.05
resulting from the GOfuncR enrichment analysis. Bar length is represented by the –log
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transformation of the raw p-values. The number of candidate genes (present in the MCPyVinfected condition) associated with that GO term are overlayed (white circles). The number of
MCPyV-enriched genes (detected 2 or more times more in the MCPyV-infected condition) are
also overlayed (black squares). Inset black outlines highlight some GO terms with higher
numbers of associated candidate genes and MCPyV-enriched genes.
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Figure 4.4

A

B

Figure 4.4) Bar plots of selected over- and under-represented GO terms in MCPyVinfection labeled ‘Biological Process’ in cell pellet lysates. A) Significant (over-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
MCPyV-infection sample and 2 or more differentially detected genes (defined as being detected
2-3 occurrences more often in the MCPyV infection samples). B) Significant (under-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
control sample and 2 or more differentially detected genes (defined as being detected 2-3
occurrences more often in the control samples). (BMP = Bone morphogenetic protein)

92

Figure 4.5

A

B

Figure 4.5) Bar plots of selected over- and under-represented GO terms in MCPyVinfection labeled ‘Molecular Function’ in cell pellet lysates. A) Significant (over-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
MCPyV-infection sample and 2 or more differentially detected genes (defined as being detected
2-3 occurrences more often in the MCPyV infection samples). B) Significant (under-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
control sample and 2 or more differentially detected genes (defined as being detected 2-3
occurrences more often in the control samples).
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Figure 4.6

A

B

Figure 4.6) Bar plots of selected over- and under-represented GO terms in MCPyVinfection labeled ‘Biological Process’ in supernatants. A) Significant (over-represented raw p94

value <0.05) GO terms were included if they were associated with genes present in the MCPyVinfection sample and 2 or more differentially detected genes (defined as being detected 2-3
occurrences more often in the MCPyV infection samples). B) Significant (under-represented raw
p-value <0.05) GO terms were included if they were associated with genes present in the control
sample and 2 or more differentially detected genes (defined as being detected 2-3 occurrences
more often in the control samples).
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Figure 4.7

A

B

Figure 4.7) Bar plots of selected over- and under-represented GO terms in MCPyVinfection labeled ‘Molecular Function’ in supernatants. A) Significant (over-represented raw
p-value <0.05) GO terms were included if they were associated with genes present in the
MCPyV-infection sample and 2 or more differentially detected genes (defined as being detected
2-3 occurrences more often in the MCPyV infection samples). B) Significant (under-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
control sample and 2 or more differentially detected genes (defined as being detected 2-3
occurrences more often in the control samples).
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Figure 4.8

A

B

Figure 4.8. Network graphs of GO terms in MCPyV-infection labeled ‘Biological Process’ or
‘Molecular Function’ in cell pellet lysates. A) Significant (over-represented raw p-value <0.05)
GO terms were included if they were associated with genes present in the MCPyV-infection
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sample and one or more differentially detected genes (defined as being detected 2-3 occurrences
more often in the MCPyV infection samples). B) Significant (under-represented raw p-value
<0.05) GO terms were included if they were associated with genes present in the control sample
and one or more differentially detected genes (defined as being detected 2-3 occurrences more
often in the control samples). Colored labels are provided for GO term nodes discussed in the
text. Black labels are provided for genes discussed in the text.
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Figure 4.9

A

B

Figure 4.9) Network graph of over-represented GO terms in MCPyV-infection labeled
‘Biological Process’ or ‘Molecular Function’ in supernatants. A) Significant (over-represented
raw p-value <0.05) GO terms were included if they were associated with genes present in the
MCPyV-infection sample and one or more differentially detected genes defined as being detected
2-3 occurrences more often in the MCPyV infection samples). B) Significant (under-represented
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raw p-value <0.05) GO terms were included if they were associated with genes present in the
control sample and one or more differentially detected genes defined as being detected 2-3
occurrences more often in the control samples). Colored labels are provided for GO term nodes
discussed in the text. Black labels are provided for genes discussed in the text.
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Chapter 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.1 – Introduction: rationale for future research
The unifying aim of my thesis research has been to reveal core MCPyV biology as it
relates to observations of its impact on human populations. I was principally interested in
providing guiding details as to how MCPyV infects most of the world population asymptomatically,
but leads to cancer in a relatively small population. Excitingly, the information garnered as a result
of the breakthrough discovery that HDFs support MCPyV infection allowed me to formulate
testable hypotheses regarding the host-virus interaction as presented in this dissertation.
The lack of an animal model of MCPyV-infection remains a barrier to progress. Yet we
can make inferences about the normal course of asymptomatic MCPyV by coalescing data from
several sources: 1) epidemiology of MCC and population studies regarding the frequency and
viral load of MCPyV infections, 2) existing research on fibroblast biology and wounding responses
in human skin, and 3) our in vitro findings that establish the prerequisites for MCPyV replication
and gene expression.
In a similar manner, our observations of cellular responses to MCPyV infection can be
combined with decades of skin pathology research to learn about the dysregulated conditions that
might lead to MCPyV-driven MCC (Bernard et al., 2012; Fagot et al., 2002; Heath et al., 2008a)
(Ahmad et al., 2014; Hardie et al., 1980; Walder et al., 1971). Together they suggest that MCPyV
infection and chronic exposure to UV-radiation could exacerbate inflammation, fibroblast
senescence, and loss of ECM integrity.
Novel strategies to treat metastatic MCC are needed. Better still, would be a means to
lower the incidence of MCC altogether. We have found that therapeutic targeting of MCPyV in the
setting of infection or in MCC is possible. Furthermore, I propose that uncovering the mechanistic
connection between photoaging and MCPyV-driven MCC could unlock new strategies to prevent
this deadly disease from occurring in at-risk populations.
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5.2 – A model of asymptomatic MCPyV infection
In most people, MCPyV infects and sheds from the skin with no discernible symptoms
(Pastrana et al., 2009; Schowalter et al., 2010). The evolutionary strategies that allow MCPyV to
infect a large portion of the population, often for prolonged periods of time, remain a mystery
(Chen et al., 2011). To identify the factors that make MCPyV a successful member of the skin
virome, we have dissected the MCPyV infectious cycle and the consequences it poses for the
host cell. By understanding the scenarios in which MCPyV might would fail to strike a balance
with the host immune response, we may be able to infer the events preceding MCPyV integration
and oncogenesis.
First, our group discovered that although many cells support MCPyV entry, only primary
human dermal fibroblasts (HDFs) are able to support MCPyV gene expression and replication
(Liu et al., 2016b). Later, we confirmed that MCPyV tropism was extremely narrow, as only
chimpanzee and human fibroblasts were able to support a high level of MCPyV infection among
fibroblast isolations from closely related mammals (Liu et al., 2018a). Beyond species and cell
type, we found that modifying the media conditions to include growth factors and enzymes found
in the skin enhances the level of MCPyV replication (Liu et al., 2016b).
The factors that maximize MCPyV gene expression and replication closely resemble
tissue-specific changes that demarcate the skin wounding response. Viral entry is enhanced
during the first two days of infection in the absence of serum and in the presence of collagenase.
This is analogous to the inflammatory phase in which MMPs digest collagen fibers and activate
chemokines (Gill and Parks, 2008; Werner and Grose, 2003). Subsequently, the addition of FBS
in the presence of EGF, FGF, and a WNT agonist replicate the proliferative phase, in which these
cytokines and angiogenesis bringing nutrients to the wound site, stimulating the differentiation
and proliferation of resident fibroblasts. Coincident with the activation of fibroblasts, we were able
to establish the kinetics of viral gene expression and replication (Fig. 2.1). I found that in
response to this flurry of viral activity, the cGAS-STING and NF-κB pathways are activated which
upregulate the expression of anti-viral ISGs and inflammatory cytokines (Fig. 2.1B-D). Knocking
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out elements of these immune regulatory pathways enables significantly higher levels of MCPyV
replication per cell (Fig. 2.5A).
Optimizing the in vitro conditions for MCPyV replication and observing the cellular
responses to MCPyV activity has shed light on the possible stages of MCPyV infection in healthy
human skin (Fig. 1.3). If indeed, fibroblasts are uniquely capable of supporting MCPyV infection in
vivo as they are ex vivo and in vitro (Liu et al., 2016b), then a model of the course of MCPyV
infection could begin to take shape. For instance, a low basal rate of MCPyV activity in fibroblasts
likely avoids immune recognition, as early events like viral entry and trafficking in vitro failed to
activate ISGs. In the event that skin is abraded or irradiated with UV light, damaged keratinocytes
release growth factors and WNT agonists to induce MMP expression and expansion of
fibroblasts. Coincident with these changes in the host cells, MCPyV may initiate expression of
early genes and DNA synthesis. In this scenario, MCPyV late gene expression begins and both
ISGs and inflammatory cytokines are induced in response to sensing of MCPyV PAMPs and/or
DAMPs. An adaptive response to MCPyV major capsid protein VP1 is also likely elevated based
on serological evidence (Faust et al., 2011). The mobilization and proliferation of fibroblasts from
the dermis to the wounded tissue or shedding layers of sunburned skin could result in MCPyV
virions being transmitted to new hosts. The antiviral state conferred by ISG induction, innate
cytokine signaling, and likely recruited immune cells at the wound site would restrict and clear
cells with high levels of MCPyV infection. Host cells with low levels of MCPyV might avoid
recognition and persist at low levels of infection in the skin.
The relationship between sun-exposure and MCPyV infection in vivo is an area of active
investigation. Recently, a group found a positive correlation between sun-exposure and DNA
positivity for β-HPVs on skin swabs and eyebrow hairs, but did not see the same association for
MCPyV (Zhao et al., 2021). This finding suggests that sun-exposure may not be the primary
factor in determining MCPyV load shed from the skin. It may be difficult to parse the multitude of
factors impacting MCPyV level in vivo without more sensitive or quantitative assays. Alternatively,
the in vitro model of MCPyV infection could be expanded to isolate variables of interest. For
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example, the important signaling between the epidermal and dermal layers of the skin could be
modeled through co-culture of fibroblast monolayers and keratinocyte rafts. These co-cultures
could be infected with MCPyV and subjected to UV irradiation to more accurately mimic the
impact of the fibroblast wounding response on MCPyV proliferation.
Such a hypothetical model of MCPyV could be of heuristic value in the future. It considers
that MCPyV likely entrains to the proliferation and differentiation of its host cell, similar to the
relationship between HPV and keratinocytes (Hatterschide et al., 2019; Hummel et al., 1992;
Longworth and Laimins, 2004). Migration of MCPyV-infected fibroblasts to wound sites could
explain a mode of transmission from reservoir cells in the deeper layers of the skin. Another
possible mode of egress that we have discussed previously is that MCPyV virions could be
transported from the dermis via hair follicles (Fig. 1.2) (Krump et al., 2018; Liu et al., 2016b).Even
still, MCPyV load could fluctuate around an equilibrium with the host immune response, so that
the virus only risks detection when the opportunity to infect new hosts arises. If indeed MCPyV
activity corresponds to skin damage and repair pathways, cases of chronic wounding,
inflammation, or altered skin architecture could represent the early events that increase the risk
for MCPyV-associated MCC in certain populations.
5.3 – A model of MCPyV dysbiosis leading to MCC development
Over 90% of MCC patients are not immune-compromised by clinical definitions, yet
almost all are over the age of 50 and have low melanin content in their skin (Heath et al., 2008a).
Unraveling the impact of UV-radiation and aging to the skin, then, could reveal key aspects of
early events in MCPyV-associated MCC. My findings pertaining to MCPyV interactions with host
cells hint that repeated MCPyV activation could introduce similar damage to the skin as through
aging and UV irradiation (Chapters 2, 4; Fig. 2.5, 4.6A, 4.7A, 4.9A).
Frequent exposure to UV-radiation is a risk factor for both MCPyV-positive and -negative
MCC (Heath et al., 2008a). This is evidenced by the fact that incidence for both cancer sub-types
is highest in persons with lower melanin concentrations in their skin (Stang et al., 2018), and the
primary tumors of both occur most frequently on sun-exposed areas (Koljonen et al., 2013). The
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link between MCPyV-negative MCCs and UV-damage is direct, in that they exhibit a high UVrelated mutational burden (Starrett et al., 2017). The relationship between sun-exposure and
MCPyV-positive MCCs, however, is indirect and remains elusive. It has been proposed that UV
light could upregulate MCPyV tumor antigen expression (Mogha et al., 2010), and that UV
dampening of adaptive immunity in the skin microenvironment could allow the escape of
nascently transformed cells (Dowlatshahi et al., 2013; Ma and Brewer, 2014). My findings point to
another possibility that does not exclude the aforementioned hypotheses. MCPyV-induced
inflammatory cytokine induction, ECM remodeling, and accelerated fibroblast senescence (Fig.
1.2-1.3) could amplify the same pro-oncogenic phenotype caused by chronic sun damage.
I found that later events in MCPyV infection resulted in the upregulation of TNF-α, IL-1β,
and IL-6 via the cGAS-STING and NF-κB pathways (Fig. 2.3-2.4). Acute activation of these
cytokines could suppress MCPyV propagation through activation of an anti-viral status in dermal
fibroblast host cells and clearance of infected cells by specialized immune cells. Chronic
activation of these cytokines, as might be found in persons with decades of sun damage, could
worsen the effects of UV-damage. UV-damage releases DAMPs like nucleic acids and
phospholipids that result in upregulation of TNF-α, IL-6, IL-1 in the lower epidermis and dermis
(Bernard et al., 2012; Fagot et al., 2002). Long-term activation of these cytokines by “self” signals
is counterbalanced to avoid hypersensitivity and ultimately results in immune dampening via
Treg/Breg activity and immunosuppressive interleukin signaling (Bernard et al., 2019; Schwarz and
Luger, 1989). This immunosuppressive effect is the reasoning behind therapeutic application of
UV-light for patients with inflammatory skin diseases, like psoriasis (Vieyra-Garcia and Wolf,
2018). However, the same immunosuppressive phenotype can increase susceptibility to skin
cancer (Ahmad et al., 2014; Hardie et al., 1980; Walder et al., 1971).
Some evidence is consistent with the hypothesis that the cytokine response to MCPyV
infection could coincide with an immunosuppressive phenotype in human populations. For
example, MCPyV detection and MCPyV DNA load is significantly lower in patients with
inflammatory skin disorders compared to individuals with healthy skin (Hashida et al., 2019). This
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finding was unique to MCPyV among human polyomaviruses in the skin and suggests that
unmitigated inflammation negatively correlates with MCPyV infection.
Common asymptomatic cellular responses to MCPyV infection may share other
similarities with cancer-prone skin in aging populations as well. One of the first observations we
made regarding MCPyV infection is that fibroblast induction of MMPs in response to growth
factors and exogenously added collagenase heightens the level of infection (Liu et al., 2016b).
Subsequently, I found that MCPyV infection upregulates cytokines like IL-1β, IL-6, and TNF-α via
the NF-κB pathway. These same cytokines have been found to upregulate MMP expression in
fibroblasts (Dasu et al., 2003; Han et al., 2001). This suggests that MCPyV activity could further
upregulate MMP expression in host fibroblasts. A recent study showed that MCPyV sT
expression could upregulate MMP-9 expression in a manner that enhances cell migration (Nwogu
et al., 2020b). Moreover, our mass spectrometry analysis revealed enriched gene representation
in genes related to extracellular matrix remodeling, including MMPs, in the MCPyV infected
condition relative to control (Fig 4.6A, 4.7A, 4.9A).
Damages incurred by UV-radiation to the structure of the skin also result in chemokine
expression and MMP upregulation via the transcription factor AP-1 (Almine et al., 2013;
Brenneisen et al., 2002; Fisher and Voorhees, 1998). In a chronic UV-exposure setting,
progressive weakening and improper ECM remodeling after MMP activation, termed photoaging,
makes the skin vulnerable to tumor invasion (Woenne et al., 2010). Pathologic MMP activity in
MCPyV infection and/or photoaged skin could also skew resident cells toward endothelial-tomesenchymal (EMT) transition, conferring them with enhanced proliferative and migratory
capacity (Haensel and Dai, 2018; Vaalamo et al., 1997). Though most MCPyV infections are
thought to be asymptomatic, it may be worth investigating whether persistent MCPyV activity
indirectly predisposes the cellular milieu to oncogenesis.
Another factor that is relevant to MCPyV infection and may influence the resilience of the
skin microenvironment to cancer is IFI16. I found that IFI16 localizes to MCPyV replication
centers (Fig. 2.2). Intriguingly, IFI16 did not participate in induction of the cGAS-STING pathway
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to mediate the ISG response we observed in MCPyV infection (Fig. 2.4C). However, IFI16 is
necessary for induction of IL-1β, TNF-α, and IL-6 (Fig. 2.4D). This suggests that IFI16 is involved
in a separate mechanism driving expression of these inflammatory cytokines in response to
MCPyV infection. It was found previously that IFI16 K.O. in fibroblasts led to a bypass of cellular
senescence, and that IFI16 accumulates in older fibroblast populations (Xin et al., 2004). More
recently, another group found that robust MCPyV replication in a transfection system led to a
senescence-associated secretory phenotype (SASP) (Siebels et al., 2020). Taken together, these
data suggest IFI16 could mediate elevated levels of senescence in MCPyV infection as well as
older skin (Xin et al., 2004). Like the changes to the skin incurred by photoaging, greater
senescence in dermal fibroblasts can promote carcinogenesis (Coppe et al., 2008; Lawrenson et
al., 2010; Malaquin et al., 2013).
In normally aging skin, dermal fibroblasts downregulate collagenase synthesis,
upregulate MMP production, and trend toward senescence (Varani et al., 2006). The
environmental influence of chronic UV-irradiation can accelerate these processes in a manner
that can lead to cancer. Our recent findings regarding the cellular response to MCPyV infection in
vitro are analogous to many of the documented effects of endogenous aging and UV-light in
human populations. Chronic infection and reactivation of MCPyV with wounding events, like
sunburn, could reinforce a cancer-prone phenotype in populations at-risk of developing skin
cancers, especially MCPyV-positive MCC.
5.4 – The promise of MCPyV-targeted therapies and innate immune modulation
Only recently have there been major victories in combatting metastatic MCC with the
application of immune checkpoint therapies (D'Angelo et al., 2018; Nghiem et al., 2019). Still, a
significant portion of the patient population fails to respond to these therapies or have a medical
need to maintain systemic immune-suppression. As such, there is a need for innovation in the
way of stimulating targeted immune responses in a diverse patient population. Modulation of
innate responses in the primary tumor microenvironment could offer a way to train the adaptive
arm of the immune system to root out metastases. For example, we found that STING is silenced
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in MCCs, but that the pathway can be selectively reactivated via AAV delivery of a mutant-STING
combined with treatment mutant-STING-specific agonist (Liu et al., 2020a). Reactivation of
STING signaling in MCCs resulted in potent cell death and recruitment of effector T cells (Liu et
al., 2020a).
Unlike cancers that arise from mutations of endogenous genes, viral cancers in different
patients share relatively few tumor antigens that drive disease progression. For this reason, there
exists the opportunity to develop effective chemotherapies that would hypothetically be welltolerated. We identified a compound isolated from a natural product that induces DNA damage
and cell killing in MCPyV-positive MCCs at nanomolar concentrations but exhibits little to no
toxicity in healthy cells or MCPyV-negative MCCs at much higher concentrations (Liu et al.,
2020b) (Chapter 3). When combined with an FDA-approved BCL-2 inhibitor, killing is nearcomplete across all the MCPyV-positive MCCs tested. We illustrated that MCPyV-positive tumors
share unique sensitivities, likely since they have low mutational burdens and are addicted to the
expression of MCPyV T-antigens.
Prophylactic approaches to MCC and other skin cancers still present the best outcomes
for patients. Aggressive skin cancers like MCC are of particular concern since they are extremely
difficult to treat in metastatic stages. Some could argue that developing preventative measures
beyond protecting people from the sun would seem like an irrational use of resources for such a
rare cancer. Consider, however, that the groups most at-risk of MCC are relatively easy to
identify: elderly Caucasians and immune-compromised persons. It is reasonable to suggest that
preventative measures targeting MCPyV infection or alleviating the dysbiosis caused by
photoaging could significantly reduce the case load of MCC. Furthermore, with a nuanced
understanding of the underpinnings of the MCPyV infectious cycle and the prerequisite conditions
for MCC, it may not be necessary to alter immunity to afford protection. Limiting MCPyV
replication, for example could reduce the likelihood of MCPyV integration or the potential
sensitizing of the skin to carcinogenesis through upregulation of inflammatory cytokines and
MMPs (Liu et al., 2016b). The risk of MCC and other skin cancers could also be reduced by
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taking measures to mitigate the effects of photoaging. There is a great deal of research in the
fields of cosmetic dermatology and inflammatory skin disease, for example, that aims to prevent
the deterioration of the dermal ECM organization and fibroblast senescence. As a result of these
efforts, many candidate molecules have been discovered that inhibit MMP expression resulting
from UV-radiation, NF-κB signaling, and inflammatory cytokine secretion (Bae et al., 2007; Bae et
al., 2015; Hantke et al., 2002; Jung et al., 2008; Kim et al., 2005; Kim et al., 2015; Kim and Kim,
2006; Lee et al., 2009; Philips et al., 2010). As ongoing research clarifies the link between chronic
inflammation, photoaging, and skin cancer, it may be worth exploring whether such compounds
could be protective against carcinogenesis in certain populations.
5.5 – Closing remarks
The bourgeoning of cancer therapies aimed at activating and directing immune
responses to malignancies give much cause for hope for the treatment of MCC and other viral
cancers. Still, gaps in our understanding of the biology driving MCPyV-related oncogenesis and
T-antigen-related MCC immune escape could improve the breadth of patients that respond to
treatments and the durability of those responses. Addressing some of our gaps in knowledge will
require technological advances like improved detection of low-copy number viral DNA genomes
in tissue isolates or accurate animal models of MCPyV infection. Until that time, we can make
strides in our understanding using the wealth of research of human skin and cancer biology, and
by expanding the model of in vitro MCPyV infection. By applying what we infer from these
sources to re-establish asymptomatic equilibrium between host and MCPyV in at-risk individuals,
we have the potential to prevent MCC cases from occurring in the future.
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Chapter 6: MATERIALS AND METHODS
6:1 – Isolation and culture of fibroblasts from human foreskin
Human neonatal foreskins were obtained from the Penn Skin Biology and Diseases
Resource-based Research Center. Fat and subcutaneous tissue was trimmed from the foreskin
sample. The remaining tissue sample was cut into four smaller pieces which were then incubated
in 5 ml of 10 mg/ml Dispase II (Roche, 04942078001) supplemented with Antibiotic-Antimycotic
(Life technologies, 15240-062) at 4°C overnight. After this digestion, the dermal layer was
transferred to a 15 ml tube containing 5 ml 1.5 mg/ml collagenase type IV (Life technologies,
17104-019) supplemented with Antibiotic-Antimycotic. The samples were incubated at 37°C in
5% CO2 for 4-6 hrs with periodic shaking until macroscopic tissue was no longer visible. The
samples were centrifuged at 180 g for 5 min. The dissociated cells were pelleted and plated in
DMEM medium (Life technologies, 11965084) supplemented with 10% FBS (HyClone,
SH30071.03), 1X non-essential amino acids (Gibco), and 1X Glutamine (Gibco). The same media
was used to expand and passage dermal fibroblasts in 10 cm2 dishes for use in subsequent
experiments. With each passage, fibroblasts were allowed to grow to confluence before splitting
them 1 to 4.
6:2 – Recombinant MCPyV virion preparation
pR17b plasmid (MCPyV genome plasmid) was digested with BamHI-HF to remove the
bacterial promoter. The digest was purified over miniprep columns in order to stop the reaction
and to elute pure MCPyV genome product. The plasmid was ligated overnight using a high
volume T4 ligase reaction at 16˚C in order to limit intermolecular ligation. The ligation reaction
was purified over miniprep columns. Re-ligated MCPyV isolate R17b DNA, along with ST
expression plasmid pMtB and LT expression plasmid pADL
(https://home.ccr.cancer.gov/lco/support.htm), were then used to transfect 293TT(Buck et al.,
2004) cells. Transfected 239TT cells were allowed to expand for 5-6 days, subculturing twice
before harvesting for isolation of MCPyV virions. Quality control for the efficiency of transfection
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was verified during cellular expansion by fixing a small fraction of the cells for IF staining for
MCPyV LT (CM2B24) and VP1 (https://home.ccr.cancer.gov/lco/BuckLabAntibodies.htm).
To harvest the virus, transfected 293TT cell pellets were lysed overnight at 37 °C in a DPBS lysis
buffer intended to protect the integrity of virions (DPBS with 9.5 mM MgCl2, 1x antibioticantimycotic, 25 mM ammonium sulfate, 0.5% X-100, 0.1% Benzonase, and 0.1% ATP-dependent
DNAse). The lysis reaction product was incubated on ice, combined with a 5M NaCl solution, and
spun for 10 min at 12,000 x g in a 4 °C centrifuge. Clear supernatants from the lysis products
were loaded on top of iodixanol gradients (consisting of ~0.7 ml 27%, 33%, and 39% layers) in
thin-wall 5 ml polyallomer tubes. Gradient samples were ultracentrifuged at 16 °C for 3.5 hrs at
234,000 x g in an SW55ti rotor. After ultracentrifugation, fractions of the product were collected in
siliconized tubes (each fraction is ~400 µL). We stored MCPyV virion stock at -80°C until thawing
on ice for infection or for qPCR quantification.
MCPyV gradient fractions were quantified for viral genome equivalents using qPCR
analysis and making dilutions with DPBS to the nearest 1x107 genomes/µl
(https://home.ccr.cancer.gov/lco/NativeMCVproduction.htm). All MCPyV preparations used in the
experiments were between 3x108-1x109 genomes/µl. To extract DNA from preparations of
infectious MCPyV particles, 1 µl of a given MCPyV fraction was added to 50 µl of Lucigen DNA
extraction buffer. The extraction steps were as follows: vortex 15 sec, incubate 15 min at 65˚C,
vortex 15 sec, incubate 6 min at 95˚C, and store at -80˚C. The DNA extraction samples were then
subjected to qPCR analysis using Applied Biosystems SYBR green FAST master mix with
NCCR-targeted primers.
6:3 – MCPyV infection of dermal fibroblasts
Primary HDFs were maintained in DMEM with 10% fetal calf serum, 1% non-essential
amino acids and 1% L-Glutamine. Upon reaching confluence, maintained fibroblasts were split
1:4 without spinning down. In order to ensure the highest MCPyV infection efficiency, we used
primary fibroblasts between passages 5 and 12 that are actively dividing at the time of plating.
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Before infecting HDFs, we would make fresh infection media: DMEM/F12 medium
containing 20 ng/ml EGF, 20 ng/ml bFGF, and 3 µM CHIR99021. We washed well-maintained
HDFs with DPBS, released from the plate with 0.05% Trypsin-EDTA, and spun down cells at
180xg for 5 min in infection media. We resuspended the cells in infection media at 2-4 x 104 cells
per ml. We seeded 180 µL of the cell suspension supplemented with 20 µL of 1 mg/ml
collagenase type IV into each well of a 96-well plate.
Once the cells were seeded, we thawed the MCPyV virion stock on ice. The viral
preparation was mixed well by pipetting up-and-down and used for all conditions. We then added
1x108-109 viral genome equivalents of MCPyV virions in 1 µL volume to the cells. If heatinactivated MCPyV was used as a control, we would then seal the MCPyV virion stock tube with a
plastic lock, boil at 100˚C for 10 min, cool on ice, spin down briefly, and mix before adding the 1
µL volume to control wells. After each well was treated, we tapped the side of the plate gently and
placed the plate in the incubator. After 48-72 hrs, we added 20% FBS to each well. The infection
was allowed to proceed until the desired end-point up to 168 h.p.i.

6:4 – qPCR
qPCR reactions were made using Applied Biosystems SYBR Green Fast Mix on an
Applied Biosystems QuantStudio3 quantitative thermal cycler. qPCR primers used for
quantification of MCPyV genome equivalents relative to cellular DNA are listed in Table 1. The
pR17b plasmid (containing the MCPyV genome) and cellular DNA from control conditions were
used as negative controls to check for possible background amplification. Primers used to
quantify gene expression in RT-qPCR experiments are shown in Table 2. RNA was isolated for
RT-qPCR using Takarabio Nucleospin RNAxs Kits and immediately subjected to reverse
transcription for downstream analysis and long-term storage at -80˚C. An identical set of RNA
isolate samples that underwent the same procedure without reverse transcriptase present were
used as control for background nucleic acid contamination. For 96-well plates, lysates harvested
from 3-5 wells of cells were used for a given replicate. Fold-change in expression of cellular
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genes such as ISGs and inflammatory cytokines was calculated by RT-qPCR 2–∆∆Ct as done
previously (Livak and Schmittgen, 2001), where the control gene is GAPDH and the control
condition is treatment with the same MCPyV preparation that has been heat-inactivated. In RTqPCR analysis of CRISPR sgRNA knockout HDFs, the control condition was MCPyV infection of
HDFs stably expressing Cas9 and an sgRNA for the non-mammalian gene luciferase.

Table 1. The following primers were used for qPCR analysis. All oligos were ordered from
Integrated DNA Technologies (IDT).
Primer
Forward Primer Sequence
Reverse Primer Sequence
Target
TAGGCAGCCAAGTTGTGGTTA
CGTCTCCCTCCCAAACAGAAA
MCPyV
NCCR
Genomic
GGCCCTGACAACTCTTTTCATCTT
CAACTGTGAGGAGGGGAGATTC
GAPDH
Table 2. The following primers were used for RT-qPCR analysis. All oligos were ordered from
Integrated DNA Technologies (IDT).
Primer
Forward Primer Sequence
Reverse Primer Sequence (5’→3’)
Target
(5’→3’)
ISG54
GCACTGCAACCATGAGTGAGA
GCTTGCCTCAGAGGGTCAAT
Viperin
TGGGTGCTTACACCTGCTG
TGAAGTGATAGTTGACGCTGGT
OAS1
AGAAGGCAGCTCACGAAACC
CCACCACCCAAGTTTCCTGTA
RIG-I
TTGCCACCTCAGTTGCTGAT
ACTGCTTTGGCTTGGGATGT
Mx1
CAGCCTGCTGACATTGGGTA
CCACATTACTGGGGACCACC
ATGATTTCTCCATCCTGAACGT
Mx2
CCTGAAGCTCTAGCTCGGTG
G
ISG15
GCGCAGATCACCCAGAAGAT
GTTCGTCGCATTTGTCCACC
ISG56
GCTTACACCATTGGCTGCTG
CCATTTGTACTCATGGTTGCTGT
IFI16
cGAS
PKR
GAPDH
IL-8
IL-6
IL-1β
TNF-
IFN-β

AGAGCCATCTTCGGACTCCT
ACGTGCTGTGAAAACAAAGAA
G
AGAGTAACCGTTGGTGACATA
ACCT
GGTGGTCTCCTCTGACTTCAA
CA
CACCGGAAGGAACCATCTCA
AGGAGACTTGCCTGGTGAAA

CAGTCTTGGTTTCAACGTGGT

CTGAGCTCGCCAGTGAAATG
GCTGCACTTTGGAGTGATCG
GCCGCATTGACCATCTATGAG
A

TGTCCATGGCCACAACAACT
TCACTCGGGGTTCGAGAAGA
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GTCCCACTGACTGTCTTGAGG
GCAGCCTCTGCAGCTCTATGTT
GTTGCTGTAGCCAAATTCGTTGT
GGCAAAACTGCACCTTCACA
CAGGGGTGGTTATTGCATCT

GAGATCTTCAGTTTCGGAGGTAAC

Primer
Target
IFN-

Forward Primer Sequence
(5’→3’)
TTTCTCCTGCCTGAAGAACAG

Reverse Primer Sequence (5’→3’)
GCTCATGATTTCTGCTCTGACA

6:5 – Immunofluorescent staining
Cells were fixed with 3% paraformaldehyde in PBS for 10min. Immunofluorescent (IF) staining
was performed as previously described (Liu et al., 2014). The following primary antibodies were
used in 3% BSA, 0.5% Triton X-100: CM2B4 (MCPyV LT) (1:500, sc-136172, Santa Cruz), antiMCPyV VP1 (1:2000, Christopher Buck Laboratory), anti-RPA 70 (1:100, 2267S, Cell Signaling
Technologies), anti-NF-B p65 (1:1500, 8242S, Cell Signaling Technologies), anti-IRF3 (1:200,
sc-33641, Santa Cruz), and anti-IFI16 (1:200, ab55328, Abcam) antibodies. The secondary
antibodies used were Alexa Fluor 594 goat anti-mouse IgG (1:1000, A11032, ThermoFisher
Scientific) and Alexa Fluor 488 goat anti-rabbit IgG (1:500, A11034, ThermoFisher Scientific).
DAPI (4′,6-diamidino-2-phenylindole, D9542, Sigma) staining at 1:8000 was included in the
secondary antibody incubation mixture. All IF images were collected using an inverted
fluorescence microscope (IX81; Olympus) connected to a high-resolution charge-coupled-device
camera (FAST1394; QImaging). Images were analyzed and presented using SlideBook (version
5.0) software (Intelligent Imaging Innovations, Inc.). The scale bars were added using ImageJ
software.
6:6 – Western blot analysis
To prepare whole cell lysates, cells were lysed in lysis buffer (10 mM HEPES, pH 7.9,
500 mM NaCl, 3 mM MgCl2, 1 mM DTT, 1 mM PMSF, 0.5% Triton X-100 supplemented with
protease inhibitors). Phosphatase-inhibitors were added to the lysis buffer when probing for levels
of phosphorylated epitopes. In order to obtain sufficient lysate volume from 96-well plates, cells
collected from 10-15 wells with the same experimental conditions were combined in lysis buffer
for a single replicate. After 30-60 min incubation on ice with vortexing, whole cell lysates were
centrifuged at 15,000 g for 10 min at 4°C to remove debris. Protein concentration of whole cell
lysates was determined using the Bradford assay. The protein samples were resolved on SDS114

PAGE gels, transferred onto PVDF membranes, and immunoblotted with specific primary
antibodies as indicated in the figure legends. The primary antibodies used in this study include:
anti-IFI16 (1:1000, ab55328, Abcam), anti-cGAS (1:1000, D1D3G, Cell Signaling Technology),
anti-STING (1:1000, 13647S, Cell Signaling Technology), anti-TBK1/NAK (1:1000, D1B4, Cell
Signaling Technology), anti-IRF3 (1:250, sc-33641, Santa Cruz Biotechnology), anti-p65 (1:400,
sc-8008, Santa Cruz), anti-IKK (1:1000, 2684S, Cell Signaling Technology), and anti-GAPDH
(1:2000, 5174S, Cell Signaling Technology). Primary antibodies used in this study recognizing
phosphorylated epitopes include: anti-p-TBK1 S172 (1:1000, 5483S, Cell Signaling Technology),
anti-p-IRF3 S396 (1:250, 4947S, Cell Signaling Technology), anti-p-p65 S536 (1:250, 3033S, Cell
Signaling Technology), and anti-p-IKK/ S176/180 (1:250, 2697S, Cell Signaling Technology).
The secondary antibodies used were HRP-linked anti-rabbit IgG (1:3000, 7074S, Cell Signaling
Technology) and HRP-linked anti-mouse IgG (1:3000, 7076S, Cell Signaling Technology).
Western blots were developed using Western Lightning ECL solution (PerkinElmer) and images
were captured using an AmershamTM Imager 600 device (GE/Cytiva).
6:7 – Generation of CRISPR knockout HDF stable cells
sgRNAs were cloned into the LentiCRISPR v2 (pXPR_023) plasmid (Addgene) following
protocols from the Genetic Perturbation Program and the Feng Zhang Lab at the Broad Institute
that have been adapted by the Elizabeth White Laboratory at the University of Pennsylvania.
Oligos for the generation of sgRNA cassettes targeting genes of interest were selected from the
Brunello library from the Broad Institute as well as successful CRISPR knockout exhibited in work
by others (Table 3). Reconstituted oligos were annealed in a BioRad PCR thermal cycler using
T4 ligation buffer and T4 PNK enzyme (New England Biolabs). The pXPR_023 plasmid was cut
and dephosphorylated at 37˚C for 30 min in a reaction containing FastDigest BsmBI (Esp3I)
(Thermo/Fermentas) restriction enzyme, FastDigest Buffer, and 0.1mM DTT. The 12.8 kb
linearized vector was gel purified and ligated to 1:250 diluted sgRNA cassettes. The resulting
constructs were transformed into competent E.coli (DH5), which were then plated on ampicillin-
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LB plates and incubated overnight at 37˚C. Picked colonies were miniprepped and validated by
sequencing using a U6 promoter-targeted primer.
For the production of lentivirus harboring the LentiCRISPRv2 construct stably expressing
desired sgRNA, HEK293T cells were cultured in 10 cm dishes to 90% confluency.
LentiCRISPRv2 plasmids were transfected into HEK 293T cells together with psPAX2 and
pMD.2G using Lipofectamine 2000 (Invitrogen). At 6 h post-transfection, the culture medium was
changed to fresh medium. Twenty-four hours later, lentiviruses were harvested from the
supernatant and filtered through a 0.45 µm filter. Passage 2 HDFs were transduced with the
purified lentiviruses supplemented with polybrene. Starting on day 2 after transduction, cells were
selected using 0.5-2 µg/ml puromycin where the lower range of concentration would be used at
lower cell densities. Throughout selection, non-transduced HDFs were exposed to the same
selection conditions in parallel to ensure complete killing of cells lacking the resistance gene.
HDFs remained under selection with these parameters while being expanded to passage 4, at
which point stocks were frozen. Prior to infection, thawed cells were expanded to confluence
under puromycin selection and re-plated the following day. Knockout efficiency was reconfirmed
by western blotting at the point of MCPyV infection.

Table 3. The following sgRNAs were used to generate cassettes that were cloned into the
LentiCRISPR v2 plasmid. All oligos were ordered from Integrated DNA Technologies (IDT).
sgRNA
Oligo 1
Oligo 2
Source
Target
CACCGGAATGAAGTCTTCCGA
AAACTCACTCGGAAGACTTCA (Gray et
IFI16
al., 2016)
GTGA
TTCC
cGAS

CACCGATGATATCTCCACGGC
GGCG

AAACCGCCGCCGTGGAGATA
TCATC

STING

CACCGCCCGTGTCCCAGGGGT
CACG

AAACCGTGACCCCTGGGACA
CGGGC

TBK1

CACCGAAGGATGTTTGCAAGA
ACAG

AAACCTGTTCTTGCAAACATC
CTTC

IRF3

CACCGGAGGTGACAGCCTTCT
ACCG

AAACCGGTAGAAGGCTGTCA
CCTCC

IKK-

CACCGTCAGCCCCCGGAACCG AAACCTCTCGGTTCCGGGGG
AGAG
CTGAC
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(Doench
et al.,
2016)
(Sali et
al., 2015)
(Goodwin
et al.,
2017)
(Sali et
al., 2015)
(Doench
et al.,
2016)
(Fang et
al., 2017)

sgRNA
Target

Oligo 1

Oligo 2

Source

p65

CACCGGGAAGATCTCATCCCC
ACCG

AAACCGGTGGGGATGAGATC
TTCCC

(Doench
et al.,
2016)

Luciferase

CACCGCTTCGAAATGTCCGTT
CGGT

AAACACCGAACGGACATTTCG
AAGC

(Vysocha
n et al.,
2017)

6.8 – Immunofluorescent-smFISH (single molecule fluorescence in situ hybridization)
HDF cells were fixed with 3.7% formaldehyde in PBS for 10min, and then the
immunofluorescent staining was performed using IFI-16 antibody (Sigma, Cat#HPA002134) with
1:500 dilution as previously described (Liu et al., 2014). After immunofluorescent staining, the
cells were fixed with 3.7% formaldehyde in PBS for 10min, and then wash twice with PBS, once
with Wash Buffer A (Biosearch Technologies) as the manufacturer’s instruction. Hybridization
was performed with the coverslips upside down on a drop of MCPyV LT probes (synthesized by
Biosearch Technologies, 1:50 dilution) in the hybridization buffer. After sealed with rubber
cement, the coverslips (the target virus DNA and probes) were heated/denatured at 94C for 3
minutes, and then incubated at 37C overnight in a humidified hybridization chamber as
previously described (Liu et al., 2016b). Following hybridization, the samples were incubated at
37C for 30 minutes with Wash Buffer A, and then incubated at 37C for 30 minutes with
100ng/ml DAPI in Wash Buffer A. After wash twice with Wash Buffer B (Biosearch Technologies),
cells were mounted and observed using an inverted fluorescence microscope (IX81; Olympus).
6.9 – cGAMP ELISA
ELISA for cyclic-GMP-AMP (cGAMP) was performed using the 2′,3′-Cyclic GAMP ELISA
Kit (Arbor Assays, Cat#K067-H1). Mock-infected and MCPyV-infected HDFs were grown in 6-well
plate format. At 120 h.p.i., cells were washed once with PBS and followed by 150ul of M-per
buffer +1mM EDTA mixture being added to each well. Plate was hand shaken for 5 minutes at
room temperature. Wells were observed with a tissue culture microscope to ensure complete

117

coverage and lysis across the well. A standard curve was made using a stock cGAMP dilution of
0.0328 pmol/ml. All other steps were performed exactly as prescribed in the assay kit manual.
6:10 – Statistical analyses
Statistical analysis for RT-qPCR and qPCR experiments was performed with Prism
software (Version 8.3.0). Fold induction presented on the graphs for each of these experiments
was calculated by the expression 2-(∆-∆), where ∆-∆ is the difference in Ct values of the gene of
interest and a housekeeping gene between the experimental condition from that of the control
condition. Experimental analysis for these data was carried out at the level of ∆-∆. The specific
statistical analyses for each dataset were as follows:
Figure 2.1B: Two-way ANOVA: p < 0.0001; with Sidak’s multiple comparison’s test
Figure 2.1C-D: Multiple t-tests; p-values controlled for multiple comparisons using Holm-Sidak
method
Figure 2.1E: Two-way ANOVA: p < 0.0001; with Dunnett’s multiple comparison’s test
Figure 2.4B-C: Two-way ANOVA: p < 0.0001; with Dunnett’s multiple comparison’s test
Figure 2.5A: Two-way ANOVA: p < 0.0001; with Dunnett’s multiple comparison’s test
6:11 – Compounds
All compounds were obtained from NCI Developmental Therapeutics Program Open
Chemical Repository (http://dtp.cancer.gov). All glaucarubin-derived compounds were obtained
from NCI/DTP Open Chemical Repository. BCL2 inhibitor ABT-199 (Cat. NO. 16233) was
purchased from Cayman Chemical (Ann Arbor, MI, USA).
6:12 – NCI natural compound screen
Two primary HDF cell lines expressing luciferase under the control of the MCPyV early
promoter were treated with 10 µM of each compound or control DMSO for 24 hrs before
qualitative assessment and harvesting for luciferase quantification. After washing twice with PBS,
cell lysates were harvested in Promega Passive Lysis Buffer and frozen at -80˚C overnight. After
thawing, samples in lysis buffer were combined with Promega luciferase substrate buffer at a 1:5
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ratio and detection of luciferase signal was measured using a Thermo Electron Corporation
Luminoskan Ascent apparatus. The compounds that reduced luciferase expression relative to
control and did not induce significant cell toxicity in HDFs were then screened for toxicity in the
MCPyV-positive MCC cell line, MKL-1. Normal HDFs and MKL-1 cells were treated with each of
these compounds at 10 µM and 20 µM for 24 hrs. Cells were visually assessed for toxicity relative
to DMSO control over the course of 72 hrs. The candidate compounds that had low toxicity in
HDFs and evidence of in deleterious effects on MKL-1 cells proliferation and/or survival were then
assessed for toxicity in a more formal assay.
6:13 – Cytotoxicity Screening
Cells were seeded at a density of 5000 cells in 100 µL of medium per well. Cells were
incubated at 37 °C in humidified air containing 5% CO 2 for 72 hrs with drugs. Cell viability was
measured with CellTiter-Glo 3D (Promega, Madison, WI, USA) following the manufacturer’s
instructions. The validity of Cell Titer-Glo results in measuring cell viability was confirmed by WST1 assays (Roche, Basel, Switzerland) in pilot studies.
6:14 – Reverse Phase Protein Lysate Array (RPPA)
HDFs and MKL-1 treated in duplicate with DMSO or glaucarubin dissolved in DMSO for
final concentrations equaling 1 µM or 10 µM, respectively. After 24 hrs, cell lysates were
harvested for each condition. A total of 50 µg protein per sample was subjected to RPPA analysis
using a set of validated antibodies targeting 304 antigens with documented roles in cancer. The
RPPA assay was performed by the staff members of the MD Anderson Cancer Center core
facility. All antibodies used in the RPPA assay were previously validated by Western blotting
(Tibes et al., 2006)
6:15 – Mass spectrometry and sample preparation
HDFs were treated with active or heat-inactivated MCPyV (control). At 120 hours-postinfection, the supernatants and cell pellets consisting of the same number of cells were harvested
from both conditions. Protein content from supernatants and cell pellet lysates were then
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trypsinized and analyzed using the 2D nano-ultra-high-performance liquid chromatography
(UHPLC)-mass spectrometer (Q-Exactive). Mass spec was performed by the Mass Spec Core at
the University of Pennsylvania. The samples were run in three technical replicates. Raw data files
were searched against the current Homo sapiens protein sequence database from UniProt using
Proteome Discoverer TM 2.4 with the SEQUEST database search algorithm.
6:16 – GO analysis
The accession numbers for each sample, condition, and technical replicate from the
mass spec analysis were imported into an R workspace. Accession numbers were used
throughout analysis since not every gene has a gene symbol. Datasets from each sample type,
cell pellet lysates and supernatants, were analyzed separately and in an identical manner. For
each of these parallel analyses, a background library of accession numbers was made consisting
of the union of all control and experimental replicates, so that each gene detected in the mass
spec analysis is represented at least once. In a similar manner, a set of candidate genes was
defined as any gene that was detected in the MCPyV-infected condition. The background and
candidate gene sets were then annotated with associated GO terms using the human proteome
annotation made available online by the Gene Ontology Consortium (http://geneontology.org/).
GO enrichment analysis on sets of candidate and background GO terms was then performed
using the GOfuncR package which calculates the statistical likelihood of GO term enrichment in
the condition of interest relative to the root node GO term. An example of a parent or root node
might be ‘viral process’ in relation to a child node termed, ‘virion trafficking.’ The resultant raw pvalues represent the likelihood of falsely identifying an enriched GO term without corrections for
multiple comparisons. A hypergeometric test was performed with 1000 randomized sets using the
GOfuncR package to calculate the family-wise error rate (FWER). Where occurrences and
parent-child relationships of GO terms remain constant, the hypergeometric test permutates the
likelihood that candidate genes would be assigned to GO terms randomly. The FWER is
represented by a p-value that is the fraction of randomsets were the lowest p-value across all
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GO-categories is lower or equal to the original p-value of the GO category (Grote S
(2020). GOfuncR: Gene ontology enrichment using FUNC. R package version 1.10.0.).
6:17 – Combining genes of interest with GO terms
Because each sample was run via mass spec in triplicate, greater weight could be given
not only to those genes that were unique to a condition, but to those genes that appeared more
often in the condition of interest. To designate differentially detected genes, we identified the
number of times each gene was detected in each condition across three replicates and set a
cutoff differential equal to or greater than 2 (e.g. infection to control ratios of 3:0, 3:1, and 2:0).
Significant GO terms from the GO enrichment analysis (raw p-value <= 0.05) were then
visualized on bar graphs (-log adjusted p-values) overlapping with the number of genes
associated with those GO terms that were designated as differentially detected or unique to the
condition (e.g. infection to control ratios of 3:0, 2:0, and 1:0). Significant GO term nodes were also
visualized on network graphs with linkages between significantly enriched genes using a variety
of R packages (igraph, ggnetwork, intergraph, and visNetwork). By identifying nodes that were
deemed significant by not only GO enrichment, but the number of linkages to enriched genes, it
was possible to recognize gene sets and related cellular processes that can be explored in future
experiments.
6:18 – Data visualization
Bar graphs were made using ggplot2 as part of the tidyverse family of R packages.
Searchable data tables of key genes, GO terms, and gene metadata were made using the
package DT. Interactive network graphs were made using the visNetwork package. Static
network graphs for print figures were made using the packages igraph, intergraph, and
ggnetwork.
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APPENDIX
Supplementary Table 1
Supplementary Table 1 includes the data from the RPPA analysis performed for Chapter 3. The
data represent detection of the given antigen in a log-2 normalized and median-centered format
for each treatment condition in duplicate. Below is a link to the excel file for Supplementary Table
1:

Supplementary
Table 1 Glaucarubin_ReversePhaseProteinArray Raw Data Final.xlsx

For readers of a physical copy of this dissertation, see attached Supplementary Table 1 affixed to
the end of this document.
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R Code
Here I have included links to interactive elements produced in the Chapter 4 analysis.
The link below opens a navigable Rmarkdown document detailing the complete analysis including
packages and versions used, data import and wrangling, GO analysis, as well as, data
exploration and visualization. There are also searchable tables for the interested reader to look
for specific GO terms or potential genes of interest that were not linked to significant GO terms.
MCV_Mass_Spec_Analysis.html

The links below open interactive and searchable versions of the four network plots included in
Chapter 4, Figures 4.8 and 4.9.
4.8A) Cells sample MCPyV enriched GO terms and genes network plot. Network plot of
significant (over-represented raw p-value <0.05) ‘Biological Process’ or ‘Molecular Function’ GO
terms linked to at least one differentially detected (defined as being detected 2-3 occurrences
more often in the MCPyV infection samples).

MCPyV.Cells.Enriched.Interactive.Network.html

4.8B) Cells sample MCPyV underrepresented GO terms and genes network plot. Network
plot of significant (under-represented raw p-value <0.05) ‘Biological Process’ or ‘Molecular
Function’ GO terms linked to at least one differentially detected (defined as being detected 2-3
occurrences more often in the control samples).

MCPyV.Cells.Underrepresented.Interactive.Network.html

4.9A) Supernatant sample MCPyV enriched GO terms and genes network plot. Network plot
of significant (over-represented raw p-value <0.05) ‘Biological Process’ or ‘Molecular Function’
GO terms linked to at least one differentially detected (defined as being detected 2-3 occurrences
more often in the MCPyV infection samples).

MCPyV.Supernatant.Enriched.Interactive.Network.html

4.9B) Supernatant sample MCPyV underrepresented GO terms and genes network plot.
Network plot of significant (under-represented raw p-value <0.05) ‘Biological Process’ or
‘Molecular Function’ GO terms linked to at least one differentially detected (defined as being
detected 2-3 occurrences more often in the control samples).

MCPyV.Supernatant.Underrepresendted.Interactive.Network.html
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For the interested reader of a print version of this dissertation, the R code used for the analysis in
Chapter 4 is included below. It is written in an Rmarkdown syntax meaning that it is easily ‘knit’
from an RStudio environment into an interactive document in Microsoft Word or an .html file. The
code output, including tables and graphs are excluded from this section for space and formatting
considerations. Static graphs are included as figures in Chapter 4. Interactive graphs and
networks plots can be produced from the code below.
--title: "Mass Spectrometry Analysis of MCPyV-infected HDFs"
output:
html_document:
code_folding: hide
toc: yes
word_document:
toc: yes
--```{r setup, include=FALSE}
knitr::opts_chunk$set(echo = TRUE, warnings = FALSE, message = FALSE)
```
# Introduction
The goal of this analysis is to identify potential changes to gene abundance
profiles as a result of MCPyV infection. First, we aim to validate and improve
upon the initial GO ontology analysis performed using the Panther tool. To do
this, we explore different gene ontology tools that allow specification of a
background library of genes, rather than the human proteome. This should
produce a more representative list of GO terms, but may produce fewer results
due to less power. Second, we aim to use raw results from these analyses along
with information in the mass spec raw data that is not used in the GO analyses
to reach a representative set of GO terms and their associated genes. Finally,
we will visualize these relationships between GO terms and genes and make the
analyses interactive and searchable for future research projects.
# Load Packages
Bring installed packages into the R environment to use for our analysis.
```{r, warning=FALSE}
library(tidyverse) #This family of packages enables the capability of
datawrangling, analysis and visualization in a relatively easy to discern
syntax.
library(readxl) # ... allows us to read in the raw data excel file to work
with it in R.
library(readr) # ... reads in rectangular datasets of different file types.
library(gprofiler2) #...Performs GO ontology from a gene list via hyper with
built-in graphics and -ultimately use GOfuncR in my final analysis since it
produces a more accessible data object that can be further analyzed.
library(GOfuncR) #... performs GO enrichment analysis.
library(DT) #... creates interactive datatables for searching genes of
interest.
library(ggplot2) #...flexible graphical plotting package that allows the
plotting of a coordinate plane and layering on different graphical elements.
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library(igraph) #...creates a matrix object from a list of vertices(nodes) and
an edgelist(e.g. interactions between nodes) that can be coerced into a
network object.
library(ggnetwork)#...a static network graphing package that can take igraph
objects if intergraph is present.
library(intergraph)#...helps make the igraph object readable by ggnetwork.
library(visNetwork)# ...makes interactive network graphs from a node dataset
and edgelist.
library(RColorBrewer) #...supplies additional color palettes beyond base R for
graphical visualization.
library(formattable)

# Cite packages
```{r}
citation("tidyverse")
citation("readxl") # ... allows us to read in the raw data excel file to work
with it in R.
citation("readr") # ... reads in rectangular datasets of different file types.
citation("gprofiler2") #...Performs GO ontology from a gene list via hyper
with built-in graphics and -ultimately use GOfuncR in my final analysis since
it produces a more accessible data object that can be further analyzed.
citation("GOfuncR") #... performs GO enrichment analysis.
citation("DT") #... creates interactive datatables for searching genes of
interest.
citation("ggplot2") #...flexible graphical plotting package that allows the
plotting of a coordinate plane and layering on different graphical elements.
citation("igraph") #...creates a matrix object from a list of vertices(nodes)
and an edgelist(e.g. interactions between nodes) that can be coerced into a
network object.
citation("ggnetwork")#...a static network graphing package that can take
igraph objects if intergraph is present.
citation("intergraph")#...helps make the igraph object readable by ggnetwork.
citation("visNetwork")# ...makes interactive network graphs from a node
dataset and edgelist.
citation("RColorBrewer") #...supplies additional color palettes beyond base R
for graphical visualization.
citation("formattable")
```
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# Import Files
Here we read in the files generated from the mass spectrometry analysis.
The different folders contained repeats of the same conditions performed at
different time points. Below is an index linking the experimental conditions
with the sample IDs used.
Mass spec label notes from June Yang:
-------------------126

* Group 1 is from Supernatant ("Sup")
Sam 1 is MCV ("MCV")
Con 1 is heat-inactivated MCV ("Control")
* Group 2 is from Cell Cells ("Cells")
Sam 2 is MCV ("MCV")
Con 2 is heat-inactivated MCV ("Control")
* For each of the above there is test 1 and test 2 data (technical replicates,
"Rep1" or "Rep2")
* Also reanalyzed test 2 data using updated program ("repeat")
-------------------Read in excel files and separate Ensembl Gene ID version from the rest of the
ID
## Import Cells Sample Datasets
```{r}
Cells.Control.Rep1<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_1/Group_2_Pellet/Con2_1.x
lsx") #Reads in excel file using the file path.
Cells.Control.Rep1<-separate(Cells.Control.Rep1, "Ensembl Gene ID", into=
c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE, extra =
"merge") #Separates the Ensembl gene ID version number from the base ID
number and creates a new column for the version.
Cells.Control.Rep1<-select(Cells.Control.Rep1, -c(Master)) #Removes column
that only contains the words Master protein and makes a consistent number of
columns with replicate 2.
Cells.MCV.Rep1<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_1/Group_2_Pellet/Sam2_1.x
lsx")
Cells.MCV.Rep1<-separate(Cells.MCV.Rep1, "Ensembl Gene ID", into= c("Ensembl
Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE, extra = "merge")
Cells.MCV.Rep1<-select(Cells.MCV.Rep1, -c(Master))
Cells.Control.Rep2<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_2/Group_2_Pellet/Con2_2.x
lsx") #Has fewer columns but still has accession numbers
Cells.MCV.Rep2<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_2/Group_2_Pellet/Sam2_2.x
lsx") #Has fewer columns but still has accession numbers
Cells.Control.Rep2.repeat<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Reanalyze_Test_2_data/Repeat_Con2_2.xlsx")
Cells.Control.Rep2.repeat<-separate(Cells.Control.Rep2.repeat, "Ensembl Gene
ID", into= c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove =
FALSE, extra = "merge")
Cells.MCV.Rep2.repeat<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Reanalyze_Test_2_data/Repeat_Sam2_2.xlsx")
Cells.MCV.Rep2.repeat<-separate(Cells.MCV.Rep2.repeat, "Ensembl Gene ID",
into= c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE,
extra = "merge")
```
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<a href="#top">Back to top</a>
## Import Supernatant Sample Datasets
```{r}
Sup.Control.Rep1<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_1/Group_1_Sup/Con1_1.xlsx
") #Reads in excel file using the file path.
Sup.Control.Rep1<-separate(Sup.Control.Rep1, "Ensembl Gene ID", into=
c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE, extra =
"merge") #Separates the Ensembl gene ID version number from the base ID number
and creates a new column for the version.
Sup.Control.Rep1<-select(Sup.Control.Rep1, -c(Master)) #Removes column
that only contains the words Master protein and makes a consistent number of
columns with replicate 2.
Sup.MCV.Rep1<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_1/Group_1_Sup/Sam1_1.xlsx
")
Sup.MCV.Rep1<-separate(Sup.MCV.Rep1, "Ensembl Gene ID", into= c("Ensembl
Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE, extra = "merge")
Sup.MCV.Rep1<-select(Sup.MCV.Rep1, -c(Master))
Sup.Control.Rep2<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_2/Group_1_Sup/Con1_2.xlsx
") #Has fewer columns but still has accession numbers
Sup.MCV.Rep2<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Proteomics_Tests/Test_2/Group_1_Sup/Sam1_2.xlsx
") #Has fewer columns but still has accession numbers
Sup.Control.Rep2.repeat<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Reanalyze_Test_2_data/Repeat_Con1_2.xlsx")
Sup.Control.Rep2.repeat<-separate(Sup.Control.Rep2.repeat, "Ensembl Gene
ID", into= c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove =
FALSE, extra = "merge")
Sup.MCV.Rep2.repeat<-read_excel("D:/You Lab
Datasets/MCV_infection_MS_data/Reanalyze_Test_2_data/Repeat_Sam1_2.xlsx")
Sup.MCV.Rep2.repeat<-separate(Sup.MCV.Rep2.repeat, "Ensembl Gene ID", into=
c("Ensembl Gene ID", "Version"), sep = "[^[:alnum:]]", remove = FALSE, extra =
"merge")
```
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# Dataset Wrangling
Here we are generating a library of background genes for each experiment
(Cells mass spec, and Supernatant mass spec) that will be used as the list of
all possible genes that we were able to detect using mass spec. Then we will
create candidate gene sets from those lists if they were present in the MCV
infection condition. Later when we perform the GO enrichment analysis we will
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see if sets of genes with a particular tag tended to be more present in the
MCV condition from the total library of background genes.
## Cells Dataset Gene Library
Cells background library genes by accession number
```{r}
#This chunk will produce the union of all of the accession numbers for genes
detected in the Cells mass spec experiment. Each accession number will be
present once even if it was detected in multiple samples.
Cells.library<dplyr::bind_rows( #bind_rows will attach rows of separate datasets as long
as their column heading is the same.
dplyr::select(Cells.Control.Rep1, 'Accession'), #pulls the Accession
column from the Cells.Control.Rep1 dataset.
dplyr::select(Cells.Control.Rep2, 'Accession'),
dplyr::select(Cells.Control.Rep2.repeat, 'Accession'),
dplyr::select(Cells.MCV.Rep1, 'Accession'),
dplyr::select(Cells.MCV.Rep2, 'Accession'),
dplyr::select(Cells.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>% #
dplyr::group_by(Accession) %>%
tally() %>% #when grouped by accession, tally() will count the number of
times an accession number is present, eliminate duplicate rows, and create a
new column with the number of times that accession number was present. I do
this so that the dataset has just one of each accession number for the GO
analysis.
mutate(is_candidate = 0) %>% #Add a column for gene of intrerest and denote
all with the values with 0, indicating that these will be background genes in
the combined datatable. In the final table for analysis this number will be a
1 if it was present in the MCV infection.
select(Accession, is_candidate) #If this dataframe was not to be used in a
gene ontology assesment you could keep the 'tally' column to get the 'n'
number of times the accession number was detected across the samples
```
Cells MCV candidate genes by accession number
```{r}
Cells.MCV.candidates<dplyr::bind_rows(dplyr::select(Cells.MCV.Rep1, 'Accession'),
dplyr::select(Cells.MCV.Rep2, 'Accession'),
dplyr::select(Cells.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
mutate(is_candidate = 1) %>% #Add a column for gene of intrerest and denote
all with the values with 0, indicating that these will be background genes in
the combined datatable. In the final table for analysis this number will be a
1 if it was present in the MCV infection.
select(Accession, is_candidate) #If this dataframe was not to be used in a
gene ontology assesment you could keep the 'tally' column to get the 'n'
number of times the accession number was detected across the samples
```
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Joined Cells genesets labeling any accession number present in an MCV sample
with a '1' and any that were not present in an MCV sample with a '0'
```{r}
Cells.GO.library <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.candidates, #This creates a joined datatable
with all of the accession numbers from the MCV conditions and all others
detected in the Cells samples.
Cells.library,
by='Accession') %>% #The resulting product has each
accession number once, with two columns (is_candidate.x = Cells.MCV.candidates
and is.candidate.y = Cells.library) with a 1/0 value or NA.
dplyr::mutate(is_candidate = ifelse(is.na(is_candidate.x), yes = 0, no =
1)) %>% #Makes a new column with the needed label (is_candidate) for each
accession number that returns a 1 if it was present in the
Cells.MCV.candidates dataset and a 0 if it was not. The final 1 values may or
may not have been present in the background sample- those with a 0 were in the
background and were not in the Cells.MCV.candidates.
dplyr::rename(gene_ids=Accession) %>% #renames the Accession column
header to gene_ids, which is neccessary for the candidate genes object in the
GOfuncR function go_enrich.
dplyr::select(gene_ids, is_candidate)) #selects only the needed columns
for the go enrichment analysis and drops the is_candidate.x/y
```

Cells metadata from original files for later exploration of key hits
identified from GO analysis
```{r}
Cells.metadata <- #This dataset will include all of the information that we
might want to reference about our final genes of interest from the MCV
condition. Once we have the enriched GO terms we can use this metadata to
learn more about the associated genes.
dplyr::bind_rows(dplyr::select(Cells.Control.Rep1, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol'),
#dplyr::select(Cells.Control.Rep2, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol', contains('Pathways')), #This replicate lacks
metadata
dplyr::select(Cells.Control.Rep2.repeat, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol'),
dplyr::select(Cells.MCV.Rep1, 'Accession', 'Description',
'Biological Process', 'Cellular Component', 'Molecular Function', 'Gene
Symbol'),
#dplyr::select(Cells.MCV.Rep2, 'Accession', 'Doescription',
'Biological Process', 'Cellular Component', 'Molecular Function', 'Gene
Symbol', contains('Pathways')), #This replicate lacks metadata
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dplyr::select(Cells.MCV.Rep2.repeat, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol')) %>%
dplyr::distinct(.)
```

## Supernatant Dataset Gene Library
Supernatant background library genes by accession number
```{r}
#This chunk will produce the union of all of the accession numbers for genes
detected in the Cells mass spec experiment. Each accession number will be
present once even if it was detected in multiple samples.
Sup.library <dplyr::bind_rows(dplyr::select(Sup.Control.Rep1, 'Accession'),
dplyr::select(Sup.Control.Rep2, 'Accession'),
dplyr::select(Sup.Control.Rep2.repeat, 'Accession'),
dplyr::select(Sup.MCV.Rep1, 'Accession'),
dplyr::select(Sup.MCV.Rep2, 'Accession'),
dplyr::select(Sup.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
mutate(is_candidate = 0) %>% #Add a column for gene of intrerest and denote
all with the values with 0, indicating that these will be background genes in
the combined datatable. In the final table for analysis this number will be a
1 if it was present in the MCV infection.
select(Accession, is_candidate) #If this dataframe was not to be used in a
gene ontology assesment you could keep the 'tally' column to get the 'n'
number of times the accession number was detected across the samples
```
Supernatant candidate genes by accesion number
```{r}
Sup.MCV.candidates<dplyr::bind_rows(dplyr::select(Sup.MCV.Rep1, 'Accession'),
dplyr::select(Sup.MCV.Rep2, 'Accession'),
dplyr::select(Sup.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
mutate(is_candidate = 1) %>% #Add a column for gene of intrerest and denote
all with the values with 0, indicating that these will be background genes in
the combined datatable. In the final table for analysis this number will be a
1 if it was present in the MCV infection.
select(Accession, is_candidate) #If this dataframe was not to be used in a
gene ontology assesment you could keep the 'tally' column to get the 'n'
number of times the accession number was detected across the samples
```
Joined Supernatant genesets labeling any accession number present in an MCV
sample with a '1' and any that were not present in an MCV sample with a '0'
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```{r}
Sup.GO.library <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.candidates, #This creates a joined datatable with
all of the accession numbers from the MCV conditions and all others detected
in the Sup samples.
Sup.library,
by='Accession') %>% #The resulting product has each
accession number once, with two columns (is_candidate.x = Sup.MCV.candidates
and is.candidate.y = Sup.library) with a 1/0 value or NA.
dplyr::mutate(is_candidate = ifelse(is.na(is_candidate.x), yes = 0, no =
1)) %>% #Makes a new column with the needed label (is_candidate) for each
accession number that returns a 1 if it was present in the Sup.MCV.candidates
dataset and a 0 if it was not. The final 1 values may or may not have been
present in the background sample- those with a 0 were in the background and
were not in the Sup.MCV.candidates.
dplyr::rename(gene_ids=Accession) %>% #renames the Accession column
header to gene_ids, which is neccessary for the candidate genes object in the
GOfuncR function go_enrich.
dplyr::select(gene_ids, is_candidate)) #selects only the needed columns
for the go enrichment analysis and drops the is_candidate.x/y
```
Supernatant metadata from orignal gene files
```{r}
Sup.metadata <- #This dataset will include all of the information that we
might want to reference about our final genes of interest from the MCV
condition. Once we have the enriched GO terms we can use this metadata to
learn more about the associated genes.
dplyr::bind_rows(dplyr::select(Sup.Control.Rep1, 'Accession', 'Description',
'Biological Process', 'Cellular Component', 'Molecular Function', 'Gene
Symbol', contains('Pathways')),
#dplyr::select(Sup.Control.Rep2, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol', contains('Pathways')), #This replicate lacks
metadata
dplyr::select(Sup.Control.Rep2.repeat, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol', contains('Pathways')),
dplyr::select(Sup.MCV.Rep1, 'Accession', 'Description',
'Biological Process', 'Cellular Component', 'Molecular Function', 'Gene
Symbol', contains('Pathways')),
#dplyr::select(Sup.MCV.Rep2, 'Accession', 'Description',
'Biological Process', 'Cellular Component', 'Molecular Function', 'Gene
Symbol', contains('Pathways')), #This replicate lacks metadata
dplyr::select(Sup.MCV.Rep2.repeat, 'Accession',
'Description', 'Biological Process', 'Cellular Component', 'Molecular
Function', 'Gene Symbol', contains('Pathways'))) %>%
dplyr::distinct(.)
```
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# GO Ontology
##GOfuncR
Here we generate a custom GO term annotation library from tab-delimited files
downloaded from the Gene Ontology Consortium. The GofuncR::go_enrich function
natively attempts annotation from web-based databases using gene symbol data.
Since not every hit from our mass spec analysis has a gene symbol, we chose to
create this custom library for annotating to accession numbers. The dataset
did not include any accession numbers pertaining to protein complexes or RNA
species so we derived the annotation library from the file containing all
annotations for human proteins.
### GO annotation of datasets
Importing GO annotations for accession numbers of human proteins
```{r warning= FALSE}
human.accession.GO <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
read_tsv("D:/You Lab Datasets/goa_human.gaf", col_names = FALSE) %>%
#reads in tab-delimited file to R workspace
dplyr::rename(gene=X2, #I renamed some of the column headers for which I
immediately recognized the observations. These metadata can also be used later
when interpretting the results
#Symbol=X3,
#interacts_with=X4,
go_id=X5,
#Function_Component_Process=X9,
#Description=X10
) %>%
dplyr::select(gene, go_id) #ensures that the resulting dataframe object only
contains the two columns required by the GOfuncR package.
)
```
GO enrichment analysis for Cells samples
```{r echo=TRUE, results= 'hide', warning=FALSE}
#The go_enrich function is the core function that performs the GO analysis and
generates an object with the statistical and summary results.
GOenrich.Cells <- GOfuncR::go_enrich(
genes = Cells.GO.library, #must be dataframe with first column as gene_ids
and second column as is_candidate
test = "hyper", #hypergeometric test is for testing enrichment when the
genes have a binary value for candidate or not-candidate.
n_randsets = 1000,
annotations = human.accession.GO #must be a dataframe with first column as
gene and the second column as go_id.
)
```
GO enrichment analysis for Supernatant samples
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```{r echo=TRUE, results= 'hide', warning=FALSE}
#The go_enrich function is the core function that performs the
generates an object with the statistical and summary results.
GOenrich.Sup <- GOfuncR::go_enrich(
genes = Sup.GO.library, #must be dataframe with first column
second column as is_candidate
test = "hyper", #hypergeometric test is for
enrichment when the genes have a binary value for candidate or
n_randsets = 1000,
annotations = human.accession.GO #must be a
first column as gene and the second column as go_id.
)
```

GO analysis and

as gene_ids and
testing
not-candidate.
dataframe with
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### Selection of over/under represented GO terms
#### Overrepresented terms
Pull out cell samples with a raw p-value less than 0.05.
```{r}
Overrep.Cells.GOterms <dplyr::filter(
GOenrich.Cells$results,
#ontology != 'cellular_component',
raw_p_overrep <= 0.05
) %>%
mutate(sample_type = "cell pellet")
```
Pull out supernatant samples with a raw p-value less than 0.05.
```{r}
Overrep.Sup.GOterms <dplyr::filter(
GOenrich.Sup$results,
#ontology != 'cellular_component',
raw_p_overrep <= 0.05
) %>%
mutate(sample_type = "supernatant")
```
Combine both GO term sample types into one dataset.
```{r}
Overrep.GOterms <bind_rows(Overrep.Cells.GOterms,
Overrep.Sup.GOterms)
```
#### Underrepresented terms
Pull out cell samples with a raw p-value less than 0.05.
```{r}
Underrep.Cells.GOterms <dplyr::filter(
GOenrich.Cells$results,
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#ontology != 'cellular_component',
raw_p_underrep <= 0.05
) %>%
mutate(sample_type = "cell pellet")
```
Pull out supernatant samples with a raw p-value less than 0.05.
```{r}
Underrep.Sup.GOterms <dplyr::filter(
GOenrich.Sup$results,
#ontology != 'cellular_component',
raw_p_underrep <= 0.05
) %>%
mutate(sample_type = "supernatant")
```
Combine both GO term sample types into one dataset.
```{r}
Underrep.GOterms <bind_rows(Underrep.Cells.GOterms,
Underrep.Sup.GOterms)
```
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### Exploration of GO results with interactive datatabes
Overrepresented GO terms datatable.
```{r}
datatable(Overrep.GOterms,
extensions = c('KeyTable', 'FixedHeader'),
caption = htmltools::tags$caption(
style = 'caption-side: top; text-align: center; color:black; fontsize:200% ;', 'Top GO terms overrepresented in MCPyV infection'),
colnames = c(
'Node Description' = 'node_name',
'Ontology Type' = 'ontology',
'GO term Node ID' = 'node_id',
'Raw p-value for Underrep.' = 'raw_p_underrep',
'Raw p-value for Overrep.' = 'raw_p_overrep',
'Family-wise Error Rate Underrep.' = 'FWER_underrep',
'Family-wise Error Rate Overrep.' = 'FWER_overrep',
'Sample Type' = 'sample_type'
),
filter = 'top', #creates boxes at the top of each column by which
the data can be filtered
options = list(keys = TRUE,
searchHighlight = TRUE, #highlights terms entered in
the search bar
pageLength = 10, #default number of rows shown on the
page
lengthMenu = c("10", "25", "50", "100"), #drop-down
options for the number of rows shown on the page
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autoWidth = TRUE, #necessary call in order to dictate
column width
columnDefs = list(list(width = '100px', targets =
'_all')), #sets column width
initComplete = JS( #forces font to Arial, rather than
default for browser
"function(settings, json) {",
"$('body').css({'font-family': 'Arial'});",
"}")))
```
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Underrepresented GO terms datatable.
```{r}
datatable(Underrep.GOterms,
extensions = c('KeyTable', 'FixedHeader'),
caption = htmltools::tags$caption(
style = 'caption-side: top; text-align: center; color:black; fontsize:200% ;', 'Top GO terms underrepresented in MCPyV infection'),
colnames = c('Ontology Type' = 'ontology',
'GO term Node ID' = 'node_id',
'Node Description' = 'node_name',
'Raw p-value for Underrep.' = 'raw_p_underrep',
'Raw p-value for Overrep.' = 'raw_p_overrep',
'Family-wise Error Rate Underrep.' = 'FWER_underrep',
'Family-wise Error Rate Overrep.' = 'FWER_overrep'),
filter = 'top', #creates boxes at the top of each column by which
the data can be filtered
options = list(keys = TRUE,
searchHighlight = TRUE, #highlights terms entered in
the search bar
pageLength = 10, #default number of rows shown on the
page
autoWidth = TRUE, #necessary call in order to dictate
column width
columnDefs = list(list(width = '100px', targets =
'_all')), #sets column width
lengthMenu = c("10", "25", "50", "100"), #drop-down
options for the number of rows shown on the page
initComplete = JS( #forces font to Arial, rather than
default for browser
"function(settings, json) {",
"$('body').css({'font-family': 'Arial'});",
"}")))
```
<a href="#top">Back to top</a>

# Exploration of alternative means of identifying key genes and GO terms.
Here we identify genes of interest in two ways: 1) by determining genes that
are enriched based on their GO term having a low p-value in our earlier
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analysis, and 2) identifying hits that showed up in multiple replicates in the
condition of interest (MCV infection) but did not show up in the other
condition. This second rudimentary method is useful since our GO enrichment
analysis was blind to the number of times a hit showed up across replicates
and not every gene in the analysis has a GO term ID and some were excluded
from analysis.
## Cells samples
Here we create a dataset of all of the MCV hits with a tally column of the
number of samples in which it was present.
```{r}
Cells.MCV.goi<dplyr::bind_rows(dplyr::select(Cells.MCV.Rep1, 'Accession'),
dplyr::select(Cells.MCV.Rep2, 'Accession'),
dplyr::select(Cells.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
dplyr::rename(MCV_n = n)
```
And here we do the same for the control condition.
```{r}
Cells.Control.goi<dplyr::bind_rows(dplyr::select(Cells.Control.Rep1, 'Accession'),
dplyr::select(Cells.Control.Rep2, 'Accession'),
dplyr::select(Cells.Control.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
dplyr::rename(Control_n = n)
```
Now we combine all the important information that we want to visualize. Each
accession number is given two values to designate its association with the
experimental or control: where "difference" is the difference between the
number of times that gene was detected in the MCPyV condition and the control
condition, and "is_candidate" whether a gene was uniquely found in the MCPyV
condition regardless of the number of times it was detected.
```{r}
Cells.goi.library <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.goi, #This creates a joined datatable with all
of the accession numbers from the MCV conditions and all others detected in
the Cells samples.
Cells.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
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dplyr::mutate(Difference = MCV_n-Control_n) %>% # Create a row calculating
the difference between the number of times a gene was present in the infection
relative to control.
dplyr::mutate(is_candidate = if_else(MCV_n >= 1 & Control_n == 0, true = 1,
false = 0)) %>%
#dplyr::filter(MCV_n-Control_n >= 2) %>% # Based on this and the above lines
of code there should be 394 genes of interest, adding additional metadat
should not add any more rows.
dplyr::left_join(., Cells.metadata, by = 'Accession') %>% #adding some
additional metadata columns keeps the number of rows at 394
#dplyr::left_join(., Overrep.Cells.Annotation, by = 'Accession') %>% #now
there are 549 rows because there are multiple GO terms for some of the hits.
This may be O.K. if I can overlay the bar graph for GO terms with gene hits.
distinct(Accession, .keep_all = TRUE)
```

### Barplot visualization of genes of interest in Cells : GO analysis vs.
multiple MS sampling
Create a barplot that visualizes the makeup of the genes of interest - for the
GO library and for hits across Mass Spec samples.
```{r}
Cells.difference.ms.hits <Cells.goi.library %>%
group_by(Difference) %>%
summarise(diff = n()) %>%
arrange(desc(Difference)) %>%
rename(weight = Difference)
Cells.candidate.ms.hits <Cells.goi.library %>%
group_by(is_candidate) %>%
summarise(cand = n()) %>%
arrange(desc(is_candidate)) %>%
rename(weight = is_candidate)
Cells.diff.cand.ms.hits <left_join(Cells.difference.ms.hits, Cells.candidate.ms.hits, by = "weight")
%>%
pivot_longer(!weight, values_to = "number", names_to = "set")
Cells.ms.hits.plot <Cells.diff.cand.ms.hits %>%
ggplot(aes(x= set,
y = number,
label = number,
fill = forcats::fct_rev(as_factor(weight)))) +
geom_bar(position = "fill",
stat = "identity",
width = 0.5,
) +
scale_fill_brewer(palette = "RdBu") +
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geom_text(size = 3, position = position_fill(vjust = 0.5)) +
scale_x_discrete(limit = c("cand", "diff"),
labels = c("GO Analysis \n Gene Library",
"Difference Between \n Infection and Control"
),
) +
labs(title = "Mass Spec Accession Library \n Cells Samples",
x = "",
y = "Proportion",
fill = "Weight") +
theme_minimal() +
theme(panel.grid.major = element_blank(),
panel.grid.minor = element_blank(),
axis.line = element_line(colour = "black"),
plot.title = element_text(hjust = 0.5),
axis.text.x = element_text(size = 12, vjust= 0.5, face = "bold")) +
geom_hline(yintercept = 0, size = 0.5)

Cells.ms.hits.plot
#png("Cells.ms.hits.plot.png",
#
width = 500,
# height = 500,
# units = "px",
#bg = "white")
#print(Cells.ms.hits.plot)
#dev.off()
```
<a href="#top">Back to top</a>
## Supernatant samples
Here we create a dataset of all of the MCV hits with a tally column of the
number of samples in which it was present.
```{r}
Sup.MCV.goi<dplyr::bind_rows(dplyr::select(Sup.MCV.Rep1, 'Accession'),
dplyr::select(Sup.MCV.Rep2, 'Accession'),
dplyr::select(Sup.MCV.Rep2.repeat, 'Accession'),
.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
dplyr::rename(MCV_n = n)
```
And here we do the same for the control condition.
```{r}
Sup.Control.goi<dplyr::bind_rows(dplyr::select(Sup.Control.Rep1, 'Accession'),
dplyr::select(Sup.Control.Rep2, 'Accession'),
dplyr::select(Sup.Control.Rep2.repeat, 'Accession'),
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.id = NULL) %>%
dplyr::group_by(Accession) %>%
tally() %>%
dplyr::rename(Control_n = n)
```
Now we combine all the important information that we want to visualize. Each
accession number is given two values to designate its association with the
experimental or control: where "difference" is the difference between the
number of times that gene was detected in the MCPyV condition and the control
condition, and "is_candidate" whether a gene was uniquely found in the MCPyV
condition regardless of the number of times it was detected.
```{r}
Sup.goi.library <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.goi, #This creates a joined datatable with all of
the accession numbers from the MCV conditions and all others detected in the
Sup samples.
Sup.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::mutate(Difference = MCV_n-Control_n) %>% # Create a row calculating
the difference between the number of times a gene was present in the infection
relative to control.
dplyr::mutate(is_candidate = if_else(MCV_n >= 1 & Control_n == 0, true = 1,
false = 0)) %>%
dplyr::left_join(., Sup.metadata, by = 'Accession') %>% #adding some
additional metadata columns keeps the number of rows at 394
distinct(Accession, .keep_all = TRUE)
```
### Barplot visualization of genes of interest in Sup : GO analysis vs.
multiple MS sampling
Create a barplot that visualizes the makeup of the genes of interest - for the
GO library and for hits across Mass Spec samples.
```{r}
Sup.difference.ms.hits <Sup.goi.library %>%
group_by(Difference) %>%
summarise(diff = n()) %>%
arrange(desc(Difference)) %>%
rename(weight = Difference)
Sup.candidate.ms.hits <Sup.goi.library %>%
group_by(is_candidate) %>%
summarise(cand = n()) %>%
arrange(desc(is_candidate)) %>%
rename(weight = is_candidate)
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Sup.diff.cand.ms.hits <left_join(Sup.difference.ms.hits, Sup.candidate.ms.hits, by = "weight") %>%
pivot_longer(!weight, values_to = "number", names_to = "set")
Sup.ms.hits.plot <Sup.diff.cand.ms.hits %>%
ggplot(aes(x= set,
y = number,
label = number,
fill = forcats::fct_rev(as_factor(weight)))) +
geom_bar(position = "fill",
stat = "identity",
width = 0.5,
) +
scale_fill_brewer(palette = "RdBu") +
geom_text(size = 3, position = position_fill(vjust = 0.5)) +
scale_x_discrete(limit = c("cand", "diff"),
labels = c("GO Analysis \n Gene Library",
"Difference Between \n Infection and Control"
),
) +
labs(title = "Mass Spec Accession Library \n Supernatant Samples",
x = "",
y = "Proportion",
fill = "Weight") +
theme_minimal() +
theme(panel.grid.major = element_blank(),
panel.grid.minor = element_blank(),
axis.line = element_line(colour = "black"),
plot.title = element_text(hjust = 0.5),
axis.text.x = element_text(size = 12, vjust= 0.5, face = "bold")) +
geom_hline(yintercept = 0, size = 0.5)

Sup.ms.hits.plot
#png("Sup.ms.hits.plot.png",
#
width = 500,
# height = 500,
# units = "px",
#bg = "white")
#print(Sup.ms.hits.plot)
#dev.off()
```
<a href="#top">Back to top</a>

# Create interactive network analyses for visualizing key genes connected to
top GO terms
## Annotate the set of Cells hits with GO terms and select those that we wish
to visualize.
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We are interested in GO terms with 'molecular function' and 'biological
process' labels that have a p-value greater that 0.05. We are interested in
genes that occurred more frequently in the MCPyV condition compared to the
control condition (e.g 3:0, 3:1, and 2:0). Linking these important genes to
matching important GO terms will help us make sense of the GO analysis and can
also reveal its shortcomings in that it does not weight the number of times a
hit occurred.
```{r}
Cells.Annotation =
human.accession.GO %>%
rename(Accession = gene,
node_id = go_id) %>%
right_join(., GOenrich.Cells$results, by = "node_id") %>%
select("Accession", "node_id", "ontology", "node_name", "raw_p_overrep",
"raw_p_underrep") %>%
mutate(., adj_p_overrep = -log(raw_p_overrep)) %>%
mutate(., adj_p_underrep = -log(raw_p_underrep))
Cells.goi.for.network <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.goi, #This creates a joined datatable with all
of the accession numbers from the MCV conditions and all others detected in
the Cells samples.
Cells.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n >= 2) %>% # Based on this and the above lines
of code there should be 394 genes of interest, adding additional metadat
should not add any more rows.
dplyr::left_join(.,Cells.metadata, by = 'Accession') %>% #adding some
additional metadata columns keeps the number of rows at 394
dplyr::left_join(., Cells.Annotation, by = 'Accession') %>% #now there are
549 rows because there are multiple GO terms for some of the hits. This may
be O.K. if I can overlay the bar graph for GO terms with gene hits.
dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
## Create "edges" and "vertices" objects for Cells dataset.
```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Cells =
Cells.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(to ="Accession",
from = "node_id") %>%
dplyr::distinct()
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#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.Cells.accession =
Cells.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(group = "Gene") %>%
dplyr::rename(id = "Accession",
sym_desc = "Gene Symbol") %>%
unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Cells.go =
Cells.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_overrep")) %>%
mutate(GO = "GO") %>%
unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
sym_desc = "node_name") %>%
unite(c("id", "adj_p_overrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Cells <bind_rows(vert.Cells.accession,
vert.Cells.go) %>%
dplyr::distinct()
```
## Use the visNetwork package to make an interactive network for the Cells
dataset.
```{r}
vertices.Cells$label <- vertices.Cells$sym_desc # Node label
vertices.Cells$size
<- (vertices.Cells$adj_p_overrep)*10 # Node size
vertices.Cells$color.highlight.background = "orange"
vertices.Cells$color.highlight.border = "darkred"

visnet.Cells = visNetwork(vertices.Cells, edges.Cells,
width="150%",
height="1000px",
background="#ffffff",
main="MCPyV Cells Mass Spec",
submain="Enriched Molecular Function and Biological
Process Genes",
footer= date()) %>%
143

visLegend() %>%
visGroups(vertices.Cells,
groupname = "GO:molecular_function",
shape = "dot",
color = list(background = "#66C2A5", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Cells,
groupname = "GO:biological_process",
shape = "dot",
color = list(background = "#FC8D62", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Cells,
groupname = "Gene",
shape = "box",
size = 10,
color = list(background = "aliceblue",
border="darkblue")) %>%
visOptions(highlightNearest = list(enabled = TRUE,
degree = 2,
hover = TRUE),
selectedBy = list(variable = "label",
highlight = TRUE)
) %>%
visInteraction(tooltipDelay = 0) #%>%
#visSave(graph= visnet.Cells, file = "D:/You Lab
Datasets/MCV_infection_MS_data/visnet.Cells.html", selfcontained = TRUE,
background = "white")
visnet.Cells
```
## Create "edges" and "vertices" objects for Cells Underrepresented dataset.
Here we aim to discover genes or families of genes that might be downregulated
by MCPyV infection.
```{r}
Cells.goi.for.network.underrep <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.goi, #This creates a joined datatable with all
of the accession numbers from the MCV conditions and all others detected in
the Cells samples.
Cells.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n <= -2) %>% #For underrepresented genes we are
interested in the negatively weighted genes based on our sample hits.
dplyr::left_join(.,Cells.metadata, by = 'Accession') %>%
dplyr::left_join(., Cells.Annotation, by = 'Accession') %>%
dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
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```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Cells.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(to ="Accession",
from = "node_id") %>%
dplyr::distinct()
#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.Cells.accession.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(group = "Gene") %>%
dplyr::rename(id = "Accession",
sym_desc = "Gene Symbol") %>%
unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Cells.go.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_underrep")) %>%
mutate(GO = "GO") %>%
unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
sym_desc = "node_name") %>%
unite(c("id", "adj_p_underrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Cells.underrep <bind_rows(vert.Cells.accession.underrep,
vert.Cells.go.underrep) %>%
dplyr::distinct()
```
## Use the visNetwork package to make an interactive network for the Cells
Underrepresented dataset.
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```{r}
vertices.Cells.underrep$label <- vertices.Cells.underrep$sym_desc # Node
label
vertices.Cells.underrep$size
<- (vertices.Cells.underrep$adj_p_underrep)*10
# Node size
vertices.Cells.underrep$color.highlight.background = "orange"
vertices.Cells.underrep$color.highlight.border = "darkred"

visnet.Cells.underrep = visNetwork(vertices.Cells.underrep,
edges.Cells.underrep,
width="150%",
height="1000px",
background="#ffffff",
main="MCPyV Cells Mass Spec \n (Underrepresented)",
submain="Molecular Function and Biological Process
Genes Enriched in Control Samples",
footer= date()) %>%
visLegend() %>%
visGroups(vertices.Cells.underrep,
groupname = "GO:molecular_function",
shape = "dot",
color = list(background = "#66C2A5", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Cells.underrep,
groupname = "GO:biological_process",
shape = "dot",
color = list(background = "#FC8D62", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Cells.underrep,
groupname = "Gene",
shape = "box",
size = 10,
color = list(background = "aliceblue",
border="darkblue")) %>%
visOptions(highlightNearest = list(enabled = TRUE,
degree = 2,
hover = TRUE),
selectedBy = list(variable = "label",
highlight = TRUE)
) %>%
visInteraction(tooltipDelay = 0) #%>%
#visSave(graph = visnet.Cells.underrep, D:/You Lab
Datasets/MCV_infection_MS_data/visnet.Cells.underrep.html", selfcontained =
TRUE, background = "white")
visnet.Cells.underrep
```
## Annotate the set of Supernatant hits with GO terms and select those that we
wish to visualize.
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We are interested in GO terms with 'molecular function' and 'biological
process' labels that have a p-value greater that 0.05. We are interested in
genes that occurred more frequently in the MCPyV condition compared to the
control condition (e.g 3:0, 3:1, and 2:0). Linking these important genes to
matching important GO terms will help us make sense of the GO analysis and can
also reveal its shortcomings in that it does not weight the number of times a
hit occurred.
```{r}
Sup.Annotation =
human.accession.GO %>%
rename(Accession = gene,
node_id = go_id) %>%
right_join(., GOenrich.Sup$results, by = "node_id") %>%
select("Accession", "node_id", "ontology", "node_name", "raw_p_overrep",
"raw_p_underrep") %>%
mutate(., adj_p_overrep = -log(raw_p_overrep)) %>%
mutate(., adj_p_underrep = -log(raw_p_underrep))
Supernatant.goi.for.network <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.goi, #This creates a joined datatable with all of
the accession numbers from the MCV conditions and all others detected in the
Supernatant samples.
Sup.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n >= 2) %>% # Based on this and the above lines
of code there should be 394 genes of interest, adding additional metadat
should not add any more rows.
dplyr::left_join(.,Sup.metadata, Sup.Annotation, by = 'Accession') %>%
#adding some additional metadata columns keeps the number of rows at 394
left_join(., Sup.Annotation, by = 'Accession') %>% #now there are 549 rows
because there are multiple GO terms for some of the hits. This may be O.K. if
I can overlay the bar graph for GO terms with gene hits.
dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
## Create "edges" and "vertices" objects for Sup dataset.
```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Sup =
Supernatant.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(to ="Accession",
from = "node_id") %>%
dplyr::distinct()
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#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.sup.accession =
Supernatant.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(group = "Gene") %>%
dplyr::rename(id = "Accession",
sym_desc = "Gene Symbol") %>%
unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.sup.go =
Supernatant.goi.for.network %>%
dplyr::filter(.,raw_p_overrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_overrep")) %>%
mutate(GO = "GO") %>%
unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
sym_desc = "node_name") %>%
unite(c("id", "adj_p_overrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Supernatant <bind_rows(vert.sup.accession,
vert.sup.go) %>%
dplyr::distinct()
```
## Use the visNetwork package to make an interactive network for the
Supernatant dataset
```{r}
vertices.Supernatant$label = vertices.Supernatant$sym_desc # Node label
vertices.Supernatant$size = (vertices.Supernatant$adj_p_overrep)*10 # Node
size
vertices.Supernatant$color.highlight.background = "orange"
vertices.Supernatant$color.highlight.border = "darkred"

visnet.Supernatant = visNetwork(vertices.Supernatant, edges.Sup,
width="150%",
height="1000px",
background="#ffffff",
main="MCPyV Supernatant Mass Spec",
submain="Enriched Molecular Function and Biological
Process Genes",
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footer= date()) %>%
visLegend() %>%
visGroups(vertices.Supernatant,
groupname = "GO:molecular_function",
shape = "dot",
color = list(background = "#66C2A5", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Supernatant,
groupname = "GO:biological_process",
shape = "dot",
color = list(background = "#FC8D62", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Supernatant,
groupname = "Gene",
shape = "box",
size = 10,
color = list(background = "aliceblue",
border="darkblue")) %>%
visOptions(highlightNearest = list(enabled = TRUE,
degree = 2,
hover = TRUE),
selectedBy = list(variable = "label",
highlight = TRUE)
) %>%
visInteraction(tooltipDelay = 0)
#visSave(graph = visnet.Supernatant, "D:/You Lab
Datasets/MCV_infection_MS_data/visnet.Supernatant.html", selfcontained = TRUE,
background = "white")
visnet.Supernatant
```
<a href="#top">Back to top</a>
## Create "edges" and "vertices" objects for Supernatant Underrepresented
dataset.
Here we aim to discover genes or families of genes that might be downregulated
by MCPyV infection.
```{r}
Supernatant.goi.for.network.underrep <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.goi, #This creates a joined datatable with all of
the accession numbers from the MCV conditions and all others detected in the
Supernatant samples.
Sup.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n <= -2) %>% #For underrepresented genes we are
interested in the negatively weighted genes based on our sample hits.
dplyr::left_join(.,Sup.metadata, by = 'Accession') %>%
dplyr::left_join(., Sup.Annotation, by = 'Accession') %>%
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dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Supernatant.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(to ="Accession",
from = "node_id") %>%
dplyr::distinct()
#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.Supernatant.accession.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(group = "Gene") %>%
dplyr::rename(id = "Accession",
sym_desc = "Gene Symbol") %>%
unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Supernatant.go.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_underrep")) %>%
mutate(GO = "GO") %>%
unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
sym_desc = "node_name") %>%
unite(c("id", "adj_p_underrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Supernatant.underrep <bind_rows(vert.Supernatant.accession.underrep,
vert.Supernatant.go.underrep) %>%
dplyr::distinct()
```
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## Use the visNetwork package to make an interactive network for the
Supernatant Underrepresented dataset.
```{r}
vertices.Supernatant.underrep$label <- vertices.Supernatant.underrep$sym_desc
# Node label
vertices.Supernatant.underrep$size
<(vertices.Supernatant.underrep$adj_p_underrep)*10 # Node size
vertices.Supernatant.underrep$color.highlight.background = "orange"
vertices.Supernatant.underrep$color.highlight.border = "darkred"

visnet.Supernatant.underrep = visNetwork(vertices.Supernatant.underrep,
edges.Supernatant.underrep,
width="150%",
height="1000px",
background="#ffffff",
main="MCPyV Supernatant Mass Spec \n
(Underrepresented)",
submain="Molecular Function and Biological Process
Genes Enriched in Control Samples",
footer= date()) %>%
visLegend() %>%
visGroups(vertices.Supernatant.underrep,
groupname = "GO:molecular_function",
shape = "dot",
color = list(background = "#66C2A5", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Supernatant.underrep,
groupname = "GO:biological_process",
shape = "dot",
color = list(background = "#FC8D62", border="black"),
font = list(background = "#FFFFFF", size = 24)) %>%
visGroups(vertices.Supernatant.underrep,
groupname = "Gene",
shape = "box",
size = 10,
color = list(background = "aliceblue",
border="darkblue")) %>%
visOptions(highlightNearest = list(enabled = TRUE,
degree = 2,
hover = TRUE),
selectedBy = list(variable = "label",
highlight = TRUE)
) %>%
visInteraction(tooltipDelay = 0) #%>%
visSave(graph = visnet.Supernatant.underrep, "D:/You Lab
Datasets/MCV_infection_MS_data/visnet.Supernatant.underrep.html",
selfcontained = TRUE, background = "white")

visnet.Supernatant.underrep
```
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# Produce static network figures highlighting key findings.
Need to make an igraph network object from dataframes. Two dataframes will be
used: 1) will contain the information about the "edges" or lines connecting
the nodes in the first two columns with metadata in the remaining columns-this is called "d" in igraph; and 2) which contains information on the
"vertices" or nodes that are connected by the lines - in which the first
column are the node IDs and the remaining columns are node attributes (this
dataframe is called "vertices").
I will be using the function "graph_from_data_frame()" to produce an igraph
network object that can then be plotted various ways.
The igraph object will have a 4-letter symbol: D/U for directed/undirected
(whether the edges have arrow-directionality), N for a named graph (where
nodes have "name" attribute), W for weighted graph (where edges have
"weight"), and B for when the graph is bipartite (two-mode) where nodes have a
"type" attribute - as is the case here where GOs and accessions lead to each
other but accessions never lead to accessions and GOs never lead to GOs. The
two numbers following refer to the number of nodes and edges in the graph
respectively.
```{r}
edges.Cells =
Cells.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(id ="Accession",
source = "node_id") %>%
dplyr::distinct()
vert.Cells.accession.static =
Cells.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(type = "0") %>% #this line will gives the final network an edgetype
even though we do not need to visualize it. 0 refers to a gene
dplyr::rename(id = "Accession",
vertex.name = "Gene Symbol") #%>% #requires a column named
vertex.name to plot, here I am using the gene symbols
#unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Cells.go.static =
152

Cells.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_overrep")) %>%
mutate(type = "1") %>%
#unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
vertex.name = "node_name") #%>% #requires vertex.name to plot,
here I am using the names of the GO nodes
#unite(c("id", "adj_p_overrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Cells.static =
bind_rows(vert.Cells.accession.static,
vert.Cells.go.static) %>%
dplyr::distinct()

MCV.Cells.static.network <graph_from_data_frame(
d = edges.Cells,
vertices = vertices.Cells.static,
directed = FALSE)
class(MCV.Cells.static.network)
```
```{r}
MCV.Cells.static.network <ggnetwork(MCV.Cells.static.network)
head(MCV.Cells.static.network)
```
```{r}
MCV.Cells.static.network %>%
ggplot(.,
aes(x, y, xend= xend, yend = yend,
vertex.name = vertex.name,
Description = Description)) +
geom_edges(aes(linetype = as.factor(type)),
color = "grey50",
show.legend = FALSE) +
geom_nodes(aes(size = adj_p_overrep,
color = ontology)) +
geom_nodes(aes(shape = M_H),
size = 4) +
scale_shape_manual(values= c(2,0,7)) +
scale_shape_discrete(
name = "MCPyV to Control 'Hit' Ratio",
c("3:0", "2:0", "3:1")) +
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scale_size_continuous(
name = "-Log Adjusted p-value \n for GO enrichment") +
scale_color_discrete(
name = "Ontology Type",
c("biological_process",
"molecular_function"),
labels = c("Biological Process",
"Molecular Function")) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "purple",
box.padding = unit(1, "lines"),
segment.size = 1,
data = function(MCV.Cells.network) {
MCV.Cells.network[MCV.Cells.network$vertex.name %in% c("cell adhesion","cell
division"), ]},
segment.colour = "purple"
) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "red",
box.padding = unit(1, "lines"),
segment.size = 1,
data = function(MCV.Cells.network) {
MCV.Cells.network[MCV.Cells.network$vertex.name %in% c("antibacterial humoral
response","cellular response to BMP stimulus"), ]},
segment.colour = "red"
) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "red",
box.padding = unit(1, "lines"),
segment.size = 1,
data = function(MCV.Cells.network) {
MCV.Cells.network[MCV.Cells.network$vertex.name %in% c("antibacterial humoral
response","cellular response to BMP stimulus"), ]},
segment.colour = "red"
) +
geom_nodelabel_repel(aes(label = "HLA alpha chain E"),
color = "black",
box.padding = unit(1, "lines"),
segment.size = 1,
data = function(MCV.Cells.network) {
MCV.Cells.network[MCV.Cells.network$name %in% c("P13747"), ]},
segment.colour = "black"
) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "black",
box.padding = unit(1, "lines"),
segment.size = 1,
data = function(MCV.Cells.network) {
MCV.Cells.network[MCV.Cells.network$vertex.name %in% c("ADAMTS12"), ]},
segment.colour = "black"
) +
theme_void()
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#MCV.Cells.static.network.plot
#png("MCV.Cells.static.network.plot.png",
#
width = 750,
# height = 700,
# units = "px",
# bg = "white")
#print(MCV.Cells.static.network.plot)
#dev.off()
```
Make a static plot of the underrepresented cells dataset.
```{r}
Cells.goi.for.network.underrep <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.goi, #This creates a joined datatable with all
of the accession numbers from the MCV conditions and all others detected in
the Cells samples.
Cells.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n <= -2) %>% #For underrepresented genes we are
interested in the negatively weighted genes based on our sample hits.
dplyr::left_join(.,Cells.metadata, by = 'Accession') %>%
dplyr::left_join(., Cells.Annotation, by = 'Accession') %>%
dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Cells.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(id ="Accession",
source = "node_id") %>%
dplyr::distinct()
#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.Cells.accession.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
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"Description",
"Gene Symbol")) %>%
mutate(type = "0") %>%
dplyr::rename(id = "Accession",
vertex.name = "Gene Symbol") #%>%
#unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Cells.go.underrep =
Cells.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_underrep")) %>%
mutate(type = "1") %>%
#unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
vertex.name = "node_name") #%>%
#unite(c("id", "adj_p_underrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Cells.underrep <bind_rows(vert.Cells.accession.underrep,
vert.Cells.go.underrep) %>%
dplyr::distinct()
MCV.Cells.static.network.underrep <graph_from_data_frame(
d = edges.Cells.underrep,
vertices = vertices.Cells.underrep,
directed = FALSE)
class(MCV.Cells.static.network.underrep)
```
```{r}
MCV.Cells.static.network.underrep <ggnetwork(MCV.Cells.static.network.underrep)
head(MCV.Cells.static.network.underrep)
```
```{r}
MCV.Cells.static.network.underrep %>%
ggplot(.,
aes(x, y, xend= xend, yend = yend,
vertex.name = vertex.name,
Description = Description)) +
geom_edges(aes(linetype = as.factor(type)),
color = "grey50",
show.legend = FALSE) +
geom_nodes(aes(size = adj_p_underrep,
color = ontology)) +
geom_nodes(aes(shape = M_H),
size = 2) +
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scale_shape_manual(values= c(2,0,7)) +
scale_shape_discrete(
name = "MCPyV to Control 'Hit' Ratio",
c("3:0", "2:0", "3:1")) +
scale_size_continuous(
name = "-Log Adjusted p-value \n for GO enrichment") +
scale_color_discrete(
name = "Ontology Type",
c("biological_process",
"molecular_function"),
labels = c("Biological Process",
"Molecular Function")) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "red",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "red",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("viral process",
"intracellular transport of virus"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "steelblue",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "steelblue",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("apoptotic process"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "magenta",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "magenta",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("protein
polyubiquitination", "ubiquitin-protein transferase activity"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "goldenrod3",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "goldenrod3",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("sequence-specific DNA
binding"), ]},
)+
theme_void()
```
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Make a static plot of the supernatant dataset.
The igraph package is also useful because it gives you error information when
there is an issue with the edgelist or vertices dataset- whereas the the
visNetwork package simply plots an empty network. In particular, every vertex
name in the edgelist must be represented in the vertex data frame and the
vertex data frame cannot have any duplicates.
```{r}
edges.Sup =
Supernatant.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(id ="Accession",
source = "node_id") %>%
dplyr::distinct()
vert.Sup.accession.static =
Supernatant.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(type = "0") %>% #this line will gives the final network an edgetype
even though we do not need to visualize it. 0 refers to a gene
dplyr::rename(id = "Accession",
vertex.name = "Gene Symbol") #%>% #requires a column named
vertex.name to plot, here I am using the gene symbols
#unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Sup.go.static =
Supernatant.goi.for.network %>%
dplyr::filter(.,
raw_p_overrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_overrep")) %>%
mutate(type = "1") %>%
#unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
vertex.name = "node_name") #%>% #requires vertex.name to plot,
here I am using the names of the GO nodes
#unite(c("id", "adj_p_overrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Supernatant.static =
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bind_rows(vert.Sup.accession.static,
vert.Sup.go.static) %>%
dplyr::distinct()

MCV.Sup.static.network <graph_from_data_frame(
d = edges.Sup,
vertices = vertices.Supernatant.static,
directed = FALSE)
class(MCV.Sup.static.network)
```

```{r}
MCV.Sup.static.network <ggnetwork(MCV.Sup.static.network)
head(MCV.Sup.static.network)
```
```{r}
MCV.Sup.static.network.plot =
ggplot(MCV.Sup.static.network,
aes(x, y, xend= xend, yend = yend,
#sym_desc = sym_desc,
Description = Description)) +
geom_edges(aes(linetype = as.factor(type)),
color = "grey50",
show.legend = FALSE) +
geom_nodes(aes(size = adj_p_overrep,
color = ontology)) +
scale_size_continuous(
name = "-Log Adjusted p-value \n for GO enrichment") +
scale_color_discrete(
name = "Ontology Type",
c("biological_process",
"molecular_function"),
labels = c("Biological Process",
"Molecular Function")) +
geom_nodes(aes(shape = M_H)) +
scale_shape_manual(values= c(2,0,7)) +
scale_shape_discrete(
name = "MCPyV to Control 'Hit' Ratio",
c("3:0", "2:0", "3:1")) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "red",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "red",
data = function(MCV.Sup.network) { MCV.Sup.network[
MCV.Sup.network$vertex.name %in% c("viral process", "immune response"), ]},
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)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "blue",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "blue",
data = function(MCV.Sup.network) { MCV.Sup.network[
MCV.Sup.network$vertex.name %in% c("extracellular matrix organization",
"glycosaminoglycan binding"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "purple",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "purple",
data = function(MCV.Sup.network) { MCV.Sup.network[
MCV.Sup.network$vertex.name %in% c("B cell differentiation", "regulation of
transcription, DNA-templated", "regulation of transcription by RNA polymerase
II"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "orange",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "orange",
data = function(MCV.Sup.network) { MCV.Sup.network[
MCV.Sup.network$vertex.name %in% c("G protein-coupled receptor signaling
pathway", "G protein-coupled receptor activity"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "black",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "black",
data = function(MCV.Sup.network) { MCV.Sup.network[
MCV.Sup.network$vertex.name %in% c("BRD4", "FBXW7", "ADAMTS8", "MMP27",
"MMP24"), ]},
)+
theme_void()
MCV.Sup.static.network.plot
```
Make static network plot of underrepresented supernatant samples.
```{r}
Supernatant.goi.for.network.underrep <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.goi, #This creates a joined datatable with all of
the accession numbers from the MCV conditions and all others detected in the
Supernatant samples.
Sup.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
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dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::filter(MCV_n-Control_n <= -2) %>% #For underrepresented genes we are
interested in the negatively weighted genes based on our sample hits.
dplyr::left_join(.,Sup.metadata, by = 'Accession') %>%
dplyr::left_join(., Sup.Annotation, by = 'Accession') %>%
dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
```{r}
#The edges file is a two column dataframe that dictates the "links" or "edges"
between nodes.
edges.Supernatant.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
dplyr::select(.,
c("Accession",
"node_id")) %>%
dplyr::rename(id ="Accession",
source = "node_id") %>%
dplyr::distinct()
#The vertices file has a single column with every possible node, along with
metadata in the following nodes. The
vert.Supernatant.accession.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
unite(c("MCV_n", "Control_n"), col = "M_H", sep = ":") %>%
select(c("Accession",
"M_H",
"Description",
"Gene Symbol")) %>%
mutate(type = "0") %>%
dplyr::rename(id = "Accession",
vertex.name = "Gene Symbol") #%>%
#unite(c("id", "M_H", "Description"), col = "title", sep = "\n", remove =
FALSE)
vert.Supernatant.go.underrep =
Supernatant.goi.for.network.underrep %>%
dplyr::filter(.,raw_p_underrep <= 0.05) %>%
select(c("node_id",
"ontology",
"node_name",
"adj_p_underrep")) %>%
mutate(type = "1") %>%
#unite(col = "group", c("GO", "ontology"), sep = ":") %>%
dplyr::rename(id = "node_id",
vertex.name = "node_name") #%>%
#unite(c("id", "adj_p_underrep"), col = "title", sep = "\n", remove = FALSE)
vertices.Supernatant.underrep <bind_rows(vert.Supernatant.accession.underrep,
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vert.Supernatant.go.underrep) %>%
dplyr::distinct()
MCV.Supernatant.static.network.underrep <graph_from_data_frame(
d = edges.Supernatant.underrep,
vertices = vertices.Supernatant.underrep,
directed = FALSE)
class(MCV.Supernatant.static.network.underrep)
```
```{r}
MCV.Supernatant.static.network.underrep <ggnetwork(MCV.Supernatant.static.network.underrep)
head(MCV.Supernatant.static.network.underrep)
```
```{r}
MCV.Supernatant.static.network.underrep %>%
ggplot(.,
aes(x, y, xend= xend, yend = yend,
vertex.name = vertex.name,
Description = Description)) +
geom_edges(aes(linetype = as.factor(type)),
color = "grey50",
show.legend = FALSE) +
geom_nodes(aes(size = adj_p_underrep,
color = ontology)) +
geom_nodes(aes(shape = M_H),
size = 2) +
scale_shape_manual(values= c(2,0,7)) +
scale_shape_discrete(
name = "MCPyV to Control 'Hit' Ratio",
c("3:0", "2:0", "3:1")) +
scale_size_continuous(
name = "-Log Adjusted p-value \n for GO enrichment") +
scale_color_discrete(
name = "Ontology Type",
c("biological_process",
"molecular_function"),
labels = c("Biological Process",
"Molecular Function")) +
geom_nodelabel_repel(aes(label = vertex.name),
color = "black",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "black",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("HMGB1"), ]},
)+
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geom_nodelabel_repel(aes(label = vertex.name),
color = "steelblue",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "steelblue",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("apoptotic process",
"positive regulation of apoptotic process"), ]},
)+
geom_nodelabel_repel(aes(label = vertex.name),
color = "darkorange3",
box.padding = unit(1, "lines"),
segment.size = 1,
segment.colour = "darkorange3",
data = function(MCV.Cells.static.network.underrep) {
MCV.Cells.static.network.underrep[
MCV.Cells.static.network.underrep$vertex.name %in% c("positive regulation of
GTPase activity", "regulation of GTPase activity", "guanyl-nucleotide exchange
factor activity"), ]},
)+
theme_void()
```
<a href="#top">Back to top</a>
# Barplots of top GO terms and numbers of enriched gene interactions.
## Generate dataset containing all the information to be used in the
visualizations for the cell samples.
```{r}
Cells.goi.for.barplots <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Cells.MCV.goi, #This creates a joined datatable with all
of the accession numbers from the MCV conditions and all others detected in
the Cells samples.
Cells.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::mutate(Difference = MCV_n-Control_n) %>% # Create a row calculating
the difference between the number of times a gene was present in the infection
relative to control.
dplyr::mutate(is_candidate = if_else(MCV_n >= 1 & Control_n == 0, true = 1,
false = 0)) %>%
#dplyr::filter(MCV_n-Control_n >= 2) %>% # Based on this and the above lines
of code there should be 394 genes of interest, adding additional metadat
should not add any more rows.
dplyr::left_join(.,Cells.metadata,
by = 'Accession') %>% #adding some additional metadata
columns keeps the number of rows at 394
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dplyr::left_join(., Cells.Annotation, by = 'Accession') %>% #now there are
549 rows because there are multiple GO terms for some of the hits. This may
be O.K. if I can overlay the bar graph for GO terms with gene hits.
#dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```
## Filter the results for the overrepresented genes and enriched GO terms in
the MCPyV condition of the cell samples.
```{r}
Cells.GO.genes.intersections =
Cells.goi.for.barplots%>%
dplyr::filter(Difference >= 2, !is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(gene_intersections = n)
Cells.GO.genes.unique =
Cells.goi.for.barplots%>%
dplyr::filter(is_candidate == 1, !is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(unique_gene_count = n)
Cells.int.uniq <Cells.goi.for.barplots %>%
dplyr::filter(raw_p_overrep <= 0.05,
) %>%
left_join(., Cells.GO.genes.intersections, by = "node_name") %>%
left_join(., Cells.GO.genes.unique, by = "node_name") %>%
distinct_at("node_name", .keep_all = TRUE)
```
### Produce barplots of enriched genes/GO terms in MCPyV cells for molecular
function, biological processes, and cellular components.
```{r}
Cells.barplot.over.mf<Cells.int.uniq %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,15,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
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shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n Overrepresented
in MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.over.mf
#png("Cells.barplot.over.mf.png",
#
width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Cells.barplot.over.mf)
#dev.off()
```
```{r}
Cells.barplot.over.mf.interest<Cells.int.uniq %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,15,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
165

shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Molecular Function' GO terms \n Overrepresented in
MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.over.mf.interest
#png("Cells.barplot.over.mf.interest.png",
#width = 750,
# height = 350,
# units = "px",
#
bg = "white")
#print(Cells.barplot.over.mf.interest)
#dev.off()
```

```{r}
Cells.barplot.over.bp<Cells.int.uniq %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *3,
name = "Gene Intersections (Points)",
breaks = seq(0,100,5))) +
geom_point(aes(y = gene_intersections/3, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
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position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/3, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Biological Process' GO terms \n Overrepresented
in MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.over.bp
#png("Cells.barplot.over.bp.png",
#
width = 1000,
#
height = 1500,
#
units = "px",
#
bg = "white")
#print(Cells.barplot.over.bp)
#dev.off()
```
```{r}
Cells.barplot.over.bp.interest<Cells.int.uniq %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count),
gene_intersections >1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *3,
name = "Gene Intersections (Points)",
breaks = seq(0,100,5))) +
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geom_point(aes(y = gene_intersections/3, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/3, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Biological Process' GO terms \n Overrepresented in
MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.over.bp.interest
#png("Cells.barplot.over.bp.interest.png",
#
width = 750,
#
height = 500,
#
units = "px",
#
bg = "white")
#print(Cells.barplot.over.bp.interest)
#dev.off()
```
```{r}
Cells.barplot.over.cc.select<Cells.int.uniq %>%
dplyr::filter(ontology == "cellular_component",
across(node_name, ~ !grepl("extracellular", .)),
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *4,
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name = "Gene Intersections (Points)",
breaks = seq(0,25,1))) +
geom_point(aes(y = gene_intersections/4, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/4, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Cellular Component' GO terms \n (-extracellular)
\n Overrepresented in MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.over.cc.select
#png("Cells.barplot.over.cc.select.png",
#
width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Cells.barplot.over.cc.select)
#dev.off()
```
## Filter the results for the underrepresented GO terms in the MCPyV condition
and genes that are more prevelent in the control cell samples.
```{r}
Cells.GO.genes.intersections.control =
Cells.goi.for.barplots%>%
dplyr::filter(Difference <= -2,
!is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(gene_intersections = n)
Cells.GO.genes.unique.control =
Cells.goi.for.barplots%>%
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dplyr::filter(is_candidate == 0,
!is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(unique_gene_count = n)
Cells.int.uniq.control <Cells.goi.for.barplots %>%
dplyr::filter(raw_p_underrep <= 0.05
) %>%
left_join(., Cells.GO.genes.intersections, by = "node_name") %>%
left_join(., Cells.GO.genes.unique, by = "node_name") %>%
distinct_at("node_name", .keep_all = TRUE)
```
### Produce barplots of enriched genes/GO terms in control samples relative to
MCPyV infection.
```{r}
Cells.barplot.under.mf.interest<Cells.int.uniq.control %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "Differentially Detected
Gene Count \n (MCPyV <=-2)"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Molecular Function' GO terms \n Underrepresented in
MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
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theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.under.mf.interest
#png("Cells.barplot.under.mf.interest.png",
#
width = 750,
#
height = 200,
#
units = "px",
#
bg = "white")
#print(Cells.barplot.under.mf.interest)
#dev.off()
```
```{r}
Cells.barplot.under.bp<Cells.int.uniq.control %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n Underrepresented
in MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
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theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.under.bp
#png("Cells.barplot.under.bp.png",
#
width = 1000,
#
height = 500,
#
units = "px",
#
bg = "white")
#print(Cells.barplot.under.bp)
#dev.off()
```
```{r}
Cells.barplot.under.bp.interest<Cells.int.uniq.control %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Biological Process' GO terms \n Underrepresented in
MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
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theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.under.bp.interest
#png("Cells.barplot.under.bp.interest.png",
#
width = 750,
#
height = 250,
#
units = "px",
#
bg = "white")
#print(Cells.barplot.under.bp.interest)
#dev.off()
```
```{r}
Cells.barplot.under.cc.select<Cells.int.uniq.control %>%
dplyr::filter(ontology == "cellular_component",
across(node_name, ~ !grepl("cytosol", .))#,
#!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n (-cytosol) \n
Underrepresented in MCPyV-infected Cells",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
173

coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Cells.barplot.under.cc.select
#png("Cells.barplot.under.cc.select.png",
#
width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Cells.barplot.under.cc.select)
#dev.off()
```
## Generate dataset containing all the information to be used in the
visualizations for the supernatant samples.
```{r}
Supernatant.goi.for.barplots <as.data.frame( #forces object to be a dataframe, which is required by the
GOfuncR package.
dplyr::full_join(Sup.MCV.goi, #This creates a joined datatable with all of
the accession numbers from the MCV conditions and all others detected in the
Sup samples.
Sup.Control.goi,
by='Accession')) %>%
dplyr::mutate(MCV_n = replace_na(MCV_n, 0)) %>%
dplyr::mutate(Control_n = replace_na(Control_n, 0)) %>%
dplyr::mutate(Difference = MCV_n-Control_n) %>% # Create a row calculating
the difference between the number of times a gene was present in the infection
relative to control.
dplyr::mutate(is_candidate = if_else(MCV_n >= 1 & Control_n == 0, true = 1,
false = 0)) %>%
#dplyr::filter(MCV_n-Control_n >= 2) %>% # Based on this and the above lines
of code there should be 394 genes of interest, adding additional metadat
should not add any more rows.
dplyr::left_join(.,Sup.metadata,
by = 'Accession') %>% #adding some additional metadata
columns keeps the number of rows at 394
dplyr::left_join(., Sup.Annotation, by = 'Accession') %>% #now there are 549
rows because there are multiple GO terms for some of the hits. This may be
O.K. if I can overlay the bar graph for GO terms with gene hits.
#dplyr::filter(ontology != 'cellular_component') %>%
distinct()
```

## Filter the results for the overrepresented genes and enriched GO terms in
the MCPyV condition of the supernatant samples.
174

```{r}
Sup.GO.genes.intersections =
Supernatant.goi.for.barplots%>%
dplyr::filter(Difference >= 2, !is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(gene_intersections = n)
Sup.GO.genes.unique =
Supernatant.goi.for.barplots%>%
dplyr::filter(is_candidate == 1, !is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(unique_gene_count = n)
Sup.int.uniq <Supernatant.goi.for.barplots %>%
dplyr::filter(raw_p_overrep <= 0.05,
) %>%
left_join(., Sup.GO.genes.intersections, by = "node_name") %>%
left_join(., Sup.GO.genes.unique, by = "node_name") %>%
distinct_at("node_name", .keep_all = TRUE)
```
### Produce barplots of enriched genes/GO terms in MCPyV cells for molecular
function, biological processes, and cellular components in supernatant
samples.
```{r}
Sup.barplot.over.mf<Sup.int.uniq %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *15,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/15, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/15, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
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scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n Overrepresented
in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.over.mf
#png("Sup.barplot.over.mf.png",
#
width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Sup.barplot.over.mf)
#dev.off()
```
```{r}
Sup.barplot.over.mf.interest<Sup.int.uniq %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *15,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/15, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/15, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
176

scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Molecular Function' GO terms \n Overrepresented in
MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.over.mf.interest
#png("Sup.barplot.over.mf.interest.png",
#
width = 750,
#
height = 350,
#
units = "px",
#
bg = "white")
#print(Sup.barplot.over.mf.interest)
#dev.off()
```
```{r}
Sup.barplot.over.bp<Sup.int.uniq %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *15,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/15, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/15, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
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"black")) +
labs(title = "Top-Enriched 'Biological Process' GO terms \n Overrepresented
in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.over.bp
#png("Sup.barplot.over.bp.png",
#
width = 1000,
# height = 1500,
# units = "px",
#bg = "white")
#print(Sup.barplot.over.bp)
#dev.off()
```
```{r}
Sup.barplot.over.bp.interest<Sup.int.uniq %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *15,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/15, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/15, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
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scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Biological Process' GO terms \n Overrepresented in
MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.over.bp.interest
#png("Sup.barplot.over.bp.interest.png",
#
width = 750,
#
height = 450,
#
units = "px",
#
bg = "white")
#print(Sup.barplot.over.bp.interest)
#dev.off()
```
```{r}
Sup.barplot.over.cc<Sup.int.uniq %>%
dplyr::filter(ontology == "cellular_component",
#across(node_name, ~ !grepl("extracellular", .)),
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_overrep),
adj_p_overrep,
#group = ontology,
raw_p_overrep = raw_p_overrep,
node_id = node_id)) +
geom_col(aes(), fill = "#D6604D", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *50,
name = "Gene Intersections (Points)",
breaks = seq(0,1000,50))) +
geom_point(aes(y = gene_intersections/50, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/50, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
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size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Cellular Component' GO terms \n (-extracellular)
\n Overrepresented in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.over.cc
#png("Sup.barplot.over.cc.png",
#
width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Sup.barplot.over.cc)
#dev.off()
```
## Filter the results for the underrepresented GO terms in the MCPyV condition
and genes that are more prevelent in the control supernatant samples.
```{r}
Sup.GO.genes.intersections.control =
Supernatant.goi.for.barplots%>%
dplyr::filter(Difference <= -2,
!is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(gene_intersections = n)
Sup.GO.genes.unique.control =
Supernatant.goi.for.barplots%>%
dplyr::filter(is_candidate == 0,
!is.na(node_name)) %>%
dplyr::group_by(node_name) %>%
tally() %>%
dplyr::rename(unique_gene_count = n)
Sup.int.uniq.control <Supernatant.goi.for.barplots %>%
dplyr::filter(raw_p_underrep <= 0.05
) %>%
left_join(., Sup.GO.genes.intersections, by = "node_name") %>%
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left_join(., Sup.GO.genes.unique, by = "node_name") %>%
distinct_at("node_name", .keep_all = TRUE)
```
### Produce barplots of enriched genes/GO terms in control samples relative to
MCPyV infection.
```{r}
Sup.barplot.under.mf<Sup.int.uniq.control %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n Underrepresented
in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.under.mf
#png("Sup.barplot.under.mf.png",
#
width = 1000,
# height = 500,
# units = "px",
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#bg = "white")
#print(Sup.barplot.under.mf)
#dev.off()
```
```{r}
Sup.barplot.under.mf.interest<Sup.int.uniq.control %>%
dplyr::filter(ontology == "molecular_function",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *2,
name = "Gene Intersections (Points)",
breaks = seq(0,20,1))) +
geom_point(aes(y = gene_intersections/2, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/2, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Molecular Function' GO terms \n Underrepresented in
MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.under.mf.interest
#png("Sup.barplot.under.mf.interest.png",
#
width = 750,
#
height = 350,
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#
units = "px",
#
bg = "white")
#print(Sup.barplot.under.mf.interest)
#dev.off()
```
```{r}
Sup.barplot.under.bp<Sup.int.uniq.control %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *10,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/10, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/10, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n Underrepresented
in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.under.bp
#png("Sup.barplot.under.bp.png",
#
width = 1000,
# height = 500,
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# units = "px",
#bg = "white")
#print(Sup.barplot.under.bp)
#dev.off()
```
```{r}
Sup.barplot.under.bp.interest<Sup.int.uniq.control %>%
dplyr::filter(ontology == "biological_process",
!is.na(unique_gene_count),
gene_intersections>1
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *10,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/10, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/10, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Selected 'Biological Process' GO terms \n Underrepresented in
MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.under.bp.interest
#png("Sup.barplot.under.bp.interest.png",
#
width = 750,
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#
height = 350,
#
units = "px",
#
bg = "white")
#print(Sup.barplot.under.bp.interest)
#dev.off()
```
```{r}
Sup.barplot.under.cc.select<Sup.int.uniq.control %>%
dplyr::filter(ontology == "cellular_component",
across(node_name, ~ !grepl("cytosol", .)),
!is.na(unique_gene_count)
) %>%
ggplot(aes(fct_reorder(node_name, adj_p_underrep),
adj_p_underrep,
#group = ontology,
raw_p_underrep = raw_p_underrep,
node_id = node_id)) +
geom_col(aes(), fill = "#4393C3", color = "black") +
scale_y_continuous(sec.axis = sec_axis(trans= ~. *10,
name = "Gene Intersections (Points)",
breaks = seq(0,200,10))) +
geom_point(aes(y = gene_intersections/10, color = "MCVPyV-Enriched (>=2) \n
Gene Count"), fill = "black",
position = "identity",
shape = 15,
size = 4
) +
geom_point(aes(y = unique_gene_count/10, color = "Candidate Gene Count"),
position = "identity",
shape = 16,
size = 3,
) +
scale_color_manual(values = c("white",
"black")) +
labs(title = "Top-Enriched 'Molecular Function' GO terms \n (-cytosol) \n
Underrepresented in MCPyV-infected Supernatants",
x = "GO term node",
y = "-log adjusted P-value (Bars)",
color = "Gene Intersection Type"
) +
coord_flip() +
theme_dark() +
theme(
plot.title = element_text(hjust = 0.5),
strip.background = element_blank(),
strip.text.x = element_blank(),
)
Sup.barplot.under.cc.select
#png("Sup.barplot.under.cc.select.png",
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#

width = 1000,
# height = 500,
# units = "px",
#bg = "white")
#print(Sup.barplot.under.cc.select)
#dev.off()
```
<a href="#top">Back to top</a>
# Create datatable of differential mass spec hits (>= +/-2) without GO terms
or outside of 0.05 p-value threshold.
```{r}
type2.hits.cells <Cells.goi.for.barplots %>%
filter(Difference >= 2 | Difference <= -2) %>%
filter(is.na(node_name)
| raw_p_overrep >= 0.05 & raw_p_underrep >= 0.05
) %>%
mutate(sample_type = "cell pellet") %>%
distinct_at("Accession", .keep_all = TRUE) %>%
dplyr::anti_join(., Cells.goi.for.network, by = "Accession") %>%
dplyr::anti_join(., Cells.goi.for.network.underrep, by = "Accession")
type2.hits.sup <Supernatant.goi.for.barplots %>%
filter(Difference >= 2 | Difference <= -2) %>%
filter(is.na(node_name)
| raw_p_overrep >= 0.05 & raw_p_underrep >= 0.05
) %>%
mutate(sample_type = "supernatant") %>%
distinct_at("Accession", .keep_all = TRUE) %>%
dplyr::anti_join(., Supernatant.goi.for.network, by = "Accession") %>%
dplyr::anti_join(., Supernatant.goi.for.network.underrep, by = "Accession")
type2.hits <bind_rows(type2.hits.cells,
type2.hits.sup)
```
```{r}
datatable(type2.hits,
extensions = c('KeyTable', 'FixedHeader'),
caption = htmltools::tags$caption(
style = 'caption-side: top; text-align: center; color:black; fontsize:200% ;', 'Enriched/Underrepresented Mass Spec Hits \n Without GO terms or
with GO terms or sig. GO terms'),
colnames = c(
'Node Description' = 'node_name',
'Ontology Type' = 'ontology',
'GO term Node ID' = 'node_id',
'MCPyV Condition Hit Count' = 'MCV_n',
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'Unique to MCPyV Condition?' = 'is_candidate',
'Control Condition Hit Count' = 'Control_n',
'Raw p-value for Underrep.' = 'raw_p_underrep',
'Raw p-value for Overrep.' = 'raw_p_overrep',
'Adjusted p-value for Underrep.' = 'adj_p_underrep',
'Adjusted p-value for Overrep.' = 'adj_p_overrep',
'Sample Type' = 'sample_type'
),
filter = 'top', #creates boxes at the top of each column by which
the data can be filtered
options = list(keys = TRUE,
searchHighlight = TRUE, #highlights terms entered in
the search bar
pageLength = 100, #default number of rows shown on
the page
lengthMenu = c("10", "25", "50", "100"), #drop-down
options for the number of rows shown on the page
autoWidth = TRUE, #necessary call in order to dictate
column width
columnDefs = list(list(width = '100px', targets =
'_all')), #sets column width
initComplete = JS( #forces font to Arial, rather than
default for browser
"function(settings, json) {",
"$('body').css({'font-family': 'Arial'});",
"}")))
```
<a href="#top">Back to top</a>
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